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 Herein are documented our efforts in two projects, beginning with studies toward 
elucidating the biosynthesis of prenylated indole alkaloids from two different Aspergillus 
species.  Marine-derived Aspergillus sp. and terrestrial-derived Aspergillus versicolor 
were found to produce antipodal metabolites, in which we have developed several 
putative biosynthetic pathways to determine the enantio-diverging point of these fungal 
cultures.  Through the synthesis of several potential intermediates, both with and without 
isotopic labeling, as well as through bioinformatics analysis of both the (!)- and (+)-
notoamide biosynthetic gene clusters, significant progress has been made toward 
identifying a single biosynthetic precursor that serves as an intermediate to the postulated 
enantio-diverging event, the intramolecular hetero Diels-Alder cycloaddition. 
 In the second project discussed, through collaboration with Dr. James Berenson at 
the University of California, Los Angeles, we have developed a novel tumor specific 
drug delivery system.  Two naphthyridine-drug derivatives were synthesized and 
conjugated to a modified DNA oligonucleotide specifically targeted for multiple 
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myeloma cells.  The oligonucleotide-drug conjugate was successfully delivered and 
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Introduction and Overview 
 
1.1 Reverse Prenylated Indole Secondary Metabolites 
1.1.1 Introduction 
The brevianamides,1-5 paraherquamides,6-14 stephacidins,15-18 and notoamides19-25 
are secondary metabolites produced by various genera of fungi, which include (among 
others) Aspergillus and Penicillium species (Figure 1).  These reverse prenylated indole 
alkaloids exhibit a range of interesting structural features, such as a core 
bicyclo[2.2.2]diazaoctane ring system and a complex amino acid skeleton. A variety of 
bioactivities are also present in these families, including insecticidal, antitumor, 
anthelmintic, and antibacterial properties.  Structurally, these natural products are 
comprised of tryptophan, a cyclic amino acid, and one or two isoprene units.  The 
synthesis and biosynthesis of these natural products have been extensively investigated;26-
29 however, a detailed understanding of the assembly and modification of the advanced 













































































































Figure 1.  Structures of several members of the brevianamide, paraherquamide, 
stephacidin, and notoamide families of reverse prenylated indole alkaloids. 
 
 The biosynthesis of the paraherquamides has been deeply investigated over the 
past 15 years by Williams et al.;26-27,30-32 however, several late-stage biosynthetic 
transformations are still unknown.  Chapters 2 and 3 detail the groundwork that has been 
previously established for the biosynthesis of paraherquamide A via Penicillium 
fellutanum and asperparaline A via Aspergillus japonicus, as well as some of the recent 
advances that have been made toward determining their biosynthetic precursors.  One 
specific area of focus addressed in Chapter 3 is the biosynthetic timing for the installation 
of the dioxepin ring found in many of the paraherquamides, along with the synthesis of 
two potential dioxepin intermediates: 6- and 7-hydroxypreparaherquamide.  In addition, 
effort has been put forth toward determining whether the biosynthetic intermediate, 
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preparaherquamide, also serves as the precursor to asperparaline A in cultures of 
Aspergillus japonicus, which can be achieved through the synthesis of 13C-labeled 
preparaherquamide and subsequent isotope incorporation studies.      
Over the past several years, the number of new prenylated indole alkaloids 
isolated from fungi of both marine and terrestrial origin has greatly increased.  Recently, 
Gloer and co-workers reported the isolation of (+)-versicolamide B, (!)-stephacidin A, 
and (+)-notoamide B from a terrestrial-derived fungus, Aspergillus versicolor.25  In 
separate work, Tsukamoto and co-workers reported the isolation of the same prenylated 
indole alkaloids from a closely related, albeit, marine-derived Aspergillus sp. MF297-
219,23  Surprisingly, the marine-derived fungus and the terrestrial-derived fungus were 
found to produce, in parallel, enantiomeric counterparts of versicolamide B, stephacidin 
A, and notoamide B (Figure 2).  This raised the question as to whether these two fungal 












































































Marine-Derived Aspergillus sp. Terrestrial-Derived Aspergillus versicolor
 
Figure 2. Structures of antipodal natural metabolites isolated from marine-derived 
Aspergillus sp. MF297-2 and terrestrial-derived Aspergillus versicolor. 
 
 As outlined in Chapters 4 and 5, extensive effort has been put forth to elucidate 
the enantio-divergent biosynthetic pathways of marine-derived Aspergillus sp. MF297-2 
and terrestrial-derived Aspergillus versicolor.  Several potential biosynthetic pathways 
that account for the formation of antipodal metabolites have been proposed.  Isotopic 
incorporation studies and the synthesis of potential biosynthetic intermediates have 
enabled these pathways to be substantially explored.  Recent advancements in the area of 
genomics have allowed for the mining of desired gene clusters from fungal species.  This 
technique has been utilized for the isolation and characterization of the notoamide (not) 
gene sequence from both Aspergillus sp. MF297-2 and Aspergillus versicolor, which has 
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provided a more in-depth understanding of the biosynthetic pathway of these two fungal 
species.33   
1.1.2 Overview of Results 
 Considerable effort has been put forth toward the synthesis of 13C-labeled 
preparaherquamide, as delineated in Chapter 3.  Completion of the synthesis of 
isotopically labeled preparaherquamide requires five steps, and once assembled, the 
isotope incorporation experiment of [13C]2-preparaherquamide with Aspergillus japonicus 
can commence.  While the synthesis of the 6-hydroxytryptophan derivative has been 
achieved, completion of the 7-hydroxytryptophan derivative requires further screening of 
reaction conditions in order to synthesize the C-2 reverse prenylated moiety. 
 Three potential pathways for the biosynthesis of the notoamides and stephacidins 
have been proposed and studied.  Both unlabeled and labeled potential precursors have 
been synthesized, and their presence and/or incorporation in the biosynthetic pathway of 
Aspergillus sp. MF297-2 are discussed in Chapter 4.  With a promising biosynthesis of 
the notoamides and stephacidins established via sequencing of the Aspergillus sp. 
MF297-2 and Aspergillus versicolor genome (Chapters 4 and 5), attention was directed 
toward determining whether these antipodal metabolites shared a similar, if not identical, 
biosynthetic pathway.  Through isotope incorporation studies with Aspergillus versicolor, 
a common intermediate to the two enantiomeric pathways has been established and is 





1.2 Multiple Myeloma-Specific Targeted Drug Delivery 
1.2.1 Introduction  
 Multiple myeloma (MM) is a plasma cell malignancy, characterized by the 
accumulation of plasma cells predominantly in the bone marrow, leading to pathologic 
fractures, anemia, hypercalcemia, renal failure, and recurrent bacterial infections.34,35  
MM accounts for 13.4% of all hematologic malignancies diagnosed, 19% of all deaths 
resulting from hematologic malignancies, and 2% of all cancer deaths.36  Epidemiological 
studies have shown that MM is associated with older age, and found to occur more often 
in men than in women.37    
 Currently, MM is incurable with a five year survival rate, and treatment focuses 
on the reduction in tumor growth and management of symptoms.38  Until recently, 
autologous peripheral blood stem cell transplant, cytotoxic drugs, and steroids have 
formed the mainstay of MM treatment.  Traditionally, either a melphalan-prednisone 
regimen or a single high-dose of melphalan is administered to MM patients.  Recent 
advances in targeted therapy have lead to the development of several new MM treatment 
options, such as bortezomib, and the immunomodulatory agents thalidomide and 
lenalidomide.   
Since MM is a malignancy of clonal antibody-secreting plasma cells, the mutated 
cells often contain a specific rearrangement of DNA, which is transcribed into a unique 
mRNA sequence.39,40  Translation of the mRNA sequence results in the formation of a 
tumor specific monoclonal antibody, which is abundant in all of the malignant cells.  
From this tumor specific transcript, a unique complementary determining region (CDR) 
gene sequence can be identified.41  Recently, Berenson and coworkers were able to 
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demonstrate that a tumor specific oligonucleotide could specifically recognize the MM 
tumor cell population.42  As shown in Figure 3, using a quenched fluorescein-labeled 
oligonucleotide probe (designated as MB8226) displaying a sequence complementary to 
the CDR3 gene sequence from the MM cell line RPMI8226, they were able to establish 
that MB8226 could not only recognize the specific cell line, but also differentiate the 
RPMI8226 cell line from other MM cell lines.  This provided additional support that 
MB8226 selectively enters and reacts with cells expressing this explicit mRNA sequence; 
and since the targeted mRNA sequence is found in a specific type of cancer cells, it was 



















A.  MB8226 with quenched 
      fluorophore
B. Binding of MB8226 to mRNA of the MM cell line RPMI8226 CDR3 gene sequence










= quenched fluorophore F = fluorescence
 
 
Figure 3.  A) Closed/quenched molecular beacon (MB8226). B) Open/fluorescent 





1.2.2 Overview of Results 
To convert MB8226 into a drug delivery agent, the first necessary modification 
was the addition of an extra guanine base to the stem of the oligonucleotide.43  By adding 
a naphthyridine ligand to the desired drug, an oligonucleotide-naphthyridine drug 
conjugate can be used for drug delivery. As shown in Figure 4, the addition of an extra 
guanine to the stem of MB8226 could allow for the desired “Trojan Horse” method of 
drug delivery.  By coupling the desired cancer drug to a naphthyridine moiety, the 
naphthyridine-drug complex could be inserted into the G-bulge of the closed MB8226 
and held in place by hydrogen bonding.  Since MB8226 only reacts with the RPMI8226 
cell line, the MM drug would only be released within cancer cells upon the binding of 














= cytotoxic agent + naphthyridine conjugate
GCATGACGCTG CAG   GT
CGTAC
A. Modified-MB8226 with drug conjugate B. Modified-MB8226 binding to mRNA of the MM cell line RPMI8226 CDR3 gene sequence
 
Figure 4.  “Trojan Horse” design  A) Closed conformation of MB8226 with the cytotoxic 
agent contained in the stem at the G-bulge.  B)  Open conformation of MB8226 and 
release of the drug. 
 
The two drugs selected for use in this experiment were vorinostat and melphalan.  
Vorinostat is an FDA-approved histone deacetylase inhibitor that is used for the treatment 
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of cutaneous T-cell lymphoma, and in 2008 a vorinostat-velcade (vorinostat-bortezomib) 
combination drug entered phase I clinical trials for the treatment of MM.44  As mentioned 
previously, melphalan is the mainstay treatment of MM, and is a nitrogen mustard 
alkylating agent.41  In order for either of these two drugs to be used in the therapeutic 
application of MB8226, they had to be converted to the respective naphthyridine-
modified (N) drug derivatives (Scheme 1), the syntheses of which are discussed in detail 

























Cl N-melphalan  
Scheme 1.  Structures of two MM drugs (vorinostat and melphalan) and their 











Reverse Prenylated Indole Secondary Metabolites 
 
 
2.1 Isolation, Structure, and Pharmacology 
2.1.1 The Brevianamides 
 Between 1969 and 1972, Birch and co-workers isolated six novel secondary 
metabolites, brevianamides A-F (1-6, Figure 5), from a fungal culture of Penicillium 
brevicompactum.1-3 Radiolabeled precursor incorporation studies carried out by Birch 
demonstrated that these fungal alkaloids are biogenetically derived from tryptophan, 
proline, and mevalonic acid.  The isolation and biosynthetic elucidation of these natural 
products exemplify a new class of fungal natural products that contain a unique 
bicyclo[2.2.2]diazaoctane core, a now known feature of various families of prenylated 
indole alkaloids.26 Structurally, brevianamides A and B are stereoisomers, while 
brevianamides C and D are artifacts of isolation due to light irradiation.3 During this time, 
Steyn and co-workers reported the isolation of deoxybrevianamide E (7) from Aspergillus 
ustus.4 This simple metabolite, along with brevianamide F, have been established as 
biosynthetic precursors to numerous prenylated indole alkaloids.33  As shown in Table 1, 

































































7, deoxybrevianamide E  
 
Figure 5. Structures of brevianamides and related metabolites. 
 
Table 1.  Fungal origin of the brevianamides. 
 
Compound Fungal Species Reference 
Penicillium brevicompactum 1-3 
Penicillium ochraceum 5 
 
brevianamide A (1) 
Penicillium viridicatum 45 
brevianamide B (2) Penicillium brevicompactum 1-3 
brevianamide C (3) Penicillium brevicompactum 1-3 
brevianamide D (4) Penicillium brevicompactum 1-3 
brevianamide E (5) Penicillium brevicompactum 1-3 
Aspergillus fumigatus 46 
Aspergillus versicolor 25 
Penicillium brevicompactum 1-3 
 
brevianamide F (6) 
Pseudallescheria species 47 
Aspergillus species 19 deoxybrevianamide E (7) 
Aspergillus ustus 4 
 
 
 The brevianamides represent a unique structural class of fungal alkaloids.    
Besides containing the bicyclo[2.2.2]diazaoctane ring system, the anti-relationship (8) of 
the bicyclic core is distinct to the brevianamides, as opposed to the more common syn-
relationship (9) found in the paraherquamides.  The anti and syn relationship is 
determined by the position of the C-H proton (or C-19, brevianamide numbering) at the 
bridgehead of the bicyclic core in relation to the bridging secondary lactam (Figure 6).48   
 12 
Additionally, brevianamides A and B display a spiro-indoxyl moiety, while 
brevianamides E and F both contain a diketopiperazine moiety.  Another structural 


















9, syn-diastereomer  
Figure 6.  Anti- and syn- relationship of the bicyclo[2.2.2]diazaoctane core. 
 
The brevianamides are a class of mycotoxins that display modest biological 
activities.  Brevianamide A has been shown to possess antifeedant and insecticidal 
effects,49 and brevianamide F exhibited mild antibacterial activity against Staphylococcus 
aureus, methicillin-resistant S. aureus, and multidrug-resistant S. aureus.47   
 
2.1.2 The Paraherquamides 
 Ten years after Birch isolated the first family of prenylated indole alkaloids, the 
second group of similar fungal metabolites, the paraherquamides, was isolated. 
Paraherquamide A (10, Figure 7) was the first member of this family to be isolated by 
Yamazaki et al. from Penicillium paraherquei.6  A decade later, paraherquamide A was 
isolated from Penicillium charlesii (P. fellutanum) along with six structurally related 
novel analogues, paraherquamides B-G (11-16).7  In the following years the 
paraherquamide family of prenylated indole alkaloids continued to expand with the 
isolation of paraherquamides H (17) and I (18) and several related compounds, including 
VM55595 (19), VM55596 (20), VM55597 (21), VM55599 (22), SB200437 (23), and 
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SB203105 (24).8-10  The paraherquamides and related metabolites have been isolated 
from various Penicillium and Aspergillus species, as illustrated in Table 2.   More 
recently, Sherman and co-workers reported the existence of pre-paraherquamide (25) in 
cultures of paraherquamide A producing Penicillium fellutanum, as well as in the 
asperparaline A producing fungus, Aspergillus japonicus.14  Furthermore, they were able 
to demonstrate that paraherquamides A and B were also produced by Aspergillus 
japonicus.  The existence of pre-paraherquamide in both Penicillium and Aspergillus sp. 
MF297-2 provides evidence that 25 is a biosynthetic precursor to the paraherquamides 




























































10, (!)-paraherquamide A, R1 = OH, R2 = Me, R3 = H2, X = N
11, (!)-paraherquamide B, R1 = H, R2 = H, R3 = H2, X = N
12, (!)-paraherquamide C, R1 = R2 = CH2, R3 = H2, X = N
13, (!)-paraherquamide D, R1 = O, R2 = CH2, R3 = H2, X = N
17, paraherquamide H, R1 = H, R2 = Me, R3 = O, X = N
20, VM55596, R1 = OH, R2 = Me, R3 = H2, X = N+-O-













15, paraherquamide F,  R1 = H, R2 = Me, R3 = Me
16, paraherquamide G,  R1 = OH, R2 = Me, R3 = Me


























14, paraherquamide E,  R1 = Me, R2 = H
23, SB200437,  R1 = H, R2 = H 
24, SB203105, R1 = Me, R2 = OH
22, VM55599 25, pre-paraherquamide
18, paraherquamide I
 
Figure 7.  Structures of the paraherquamides and related compounds. 
Table 2.  Fungal origin of the paraherquamides. 
Compound Fungal Species Reference 
Penicillium charlesii (fellutanum) 7 
Penicillium cluniae 8 
Penicillium paraherquei 6 
Penicillium species IMI 332995 9 
 
 
paraherquamide A (10) 




Penicillium charlesii (fellutanum) 7, 12 paraherquamide B (11) 
Penicillium cluniae 8 
paraherquamide C (12) Penicillium charlesii (fellutanum) 7, 12 
paraherquamide D (13) Penicillium charlesii (fellutanum) 7, 12 
Aspergillus species IMI 337664 10 
Penicillium charlesii (fellutanum) 7, 12 
Penicillium cluniae 8 
Penicillium species IMI 332995 9 
 
 
paraherquamide E (14) 
Penicillium species (isolated from soil in 
Kemer, Turkey) 
11 
Penicillium charlesii (fellutanum) 7, 12 
Penicillium species IMI 332995 9 
 
paraherquamide F (15) 
Penicillium species (isolated from soil in 
Kemer, Turkey) 
11 
Penicillium charlesii (fellutanum) 7, 12 
Penicillium species IMI 332995 9 
 
paraherquamide G (16) 
Penicillium species (isolated from soil in 
Kemer, Turkey) 
11 
paraherquamide H (17) Penicillium cluniae 8 
paraherquamide I (18) Penicillium cluniae 8 
VM55595 (19) Penicillium species IMI 332995 9 
VM55596 (20) Penicillium cluniae 8 
Penicillium cluniae 8 VM55597 (21) 
Penicillium species IMI 332995 9 
VM55599 (22) Penicillium paneum 13 
 Penicillium species IMI 332995 9 
SB200437 (23) Aspergillus species IMI 337664 10 
SB203105 (24) Aspergillus species IMI 337664 10 
Aspergillus japonicus 14 pre-paraherquamide (25) 
Penicillium charlesii (fellutanum) 14 
 
 Structurally, all of the paraherquamides contain the bicyclo[2.2.2]diazaoctane 
core with the syn-configuration; however, the paraherquamide family displays a plethora 
of skeletal diversity.  For example, the paraherquamides display varying substitution and 
oxygenation on the proline ring and the spiro-oxindole moiety.  Several of the 
paraherquamides contain a unique dioxepin ring, while others contain a pyran moiety.  
Within this family of secondary metabolites, VM55599 and pre-paraherquamide are the 
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only two compounds that do not contain either a spiro-oxindole functionality or an 
oxygenated ring system on the indole ring.   
 The paraherquamides have attracted considerable interest due to their potent 
anthelmintic activity.  Parasitic nematodes cause severe health problems in humans and 
domestic animals, and the severity of this problem is increasing due to the development 
of drug resistant strains of parasites.50  Initial anthelmintic activity was detected in 
Trichostrongylus colubriformis51 and subsequent investigations showed that 
paraherquamide A is effective against strains of parasites that are resistant to broad-
spectrum anthelmintics.52  Unfortunately, the toxicity of paraherquamide A was 
determined to be too great for it to be used as a broad-spectrum anthelmintic.53  To 
decrease the toxicity, but maintain the potency, several paraherquamide derivatives have 
been synthesized and tested for anthelmintic activity.50  Of these derivatives, 2-deoxy-
paraherquamide A (26, Figure 8), later named PNU-141962, displayed excellent activity 
in models of Haemonchus contortus, Trichostrongylus colubriformis, and Ostertagia 
ostertagi, while maintaining a safe level of toxicity, which makes it an attractive potential 














26, PNU-141962  
Figure 8.  Structure of 2-deoxyparaherquamide A (PNU-141962). 
 
2.1.3  The Stephacidins and Notoamides  
 Following the isolation of numerous paraherquamide type compounds isolated in 
the 1990s, the 2000s saw the emersion of another family of closely related prenylated 
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indole alkaloids, the stephacidins and notoamides.  The first member of the stephacidins 
and notoamides, sclerotiamide (27, Figure 9), was first isolated in 1996 from Aspergillus 
sclerotiorum, and was actually classified as a paraherquamide type compound.15  
Structurally similar to the paraherquamides, sclerotiamide contains the core 
bicyclo[2.2.2]diazaoctane moiety, a spiro-oxindole ring system with a pyran group, and 
an unsubstituted proline ring.  However, unlike the paraherquamides, sclerotiamide 
retains an unreduced diketopiperazine unit and also contains a unique C-10 hydroxyl 
group.  At the time, the rare structural skeleton of sclerotiamide made it a possible 
biosynthetic precursor to the paraherquamides.  It was not until 1999 that other 
structurally related prenylated indole alkaloids were isolated, including (+)-stephacidin A 
(28), stephacidin B (29) and avrainvillamide (30).  Stephacidins A and B were both 
isolated from terrestrial-derived Aspergillus ochraceus by a group at Bristol-Myers 
Squibb,16 while avrainvillamide was independently isolated from marine-derived 
Aspergillus sp. MF297-2 CNC358 by Fenical.17  Two years later, Sugie and coworkers 
reported the isolation of avrainvillamide, under the name of CJ-17,665, from Aspergillus 




















































































Figure 9.  Structures of the stephacidins and related compounds. 
 
Upon closer inspection, stephacidin A, stephacidin B, and avrainvillamide 
appeared to be structurally and biogenetically related to each other.  All three compounds 
contain the core bridging bicycle with an unreduced diketopiperazine, similar to 
sclerotiamide; however, they also display an unoxidized indole moiety resembling pre-
paraherquamide and VM55599.  Biogenetically, it was proposed that stephacidin A could 
be oxidized to afford avrainvillamide, an imine oxide with C-8!N-9 and C-20!C-21 
double bonds (Figure 10).16b Stephacidin B could then result from the dimerization of 
avrainvillamide.  To test these theories, Myers and co-workers were the first to synthesize 
avrainvillamide and effect the dimerization to afford stephacidin B under mild basic 
conditions.55  Baran and Williams have separately carried out the biomimetic conversion 




















































Figure 10.  Proposed biosynthetic pathway from stephacidin A to stephacidin B. 
    
In 2007, Tsukamoto and co-workers reported the isolation of notoamides A-D 
(31-34, Figure 11) from a marine-derived Aspergillus sp. MF297-2 found growing on the 
mussel, Mytilus edulis, collected off the Noto Peninsula in the Sea of Japan.19  Along 
with the notoamides, the known compounds, sclerotiamide, (+)-stephacidin A, and 
deoxybrevianamide E (7), were also isolated.  Notoamides A-D contain the pyranoindole 
ring system common in the stephacidins and some of the paraherquamides.  Notoamides 
A and B both contain the core bridging bicycle with C-12 oxidation, as well as the spiro-
oxindole ring system.  In 2005, a group of structurally similar indole alkaloids, named the 
norgeamides (34, 35-37) were isolated by the Hans-Knöll institute from a cold water 
Aspergillus sp. MF297-220  Norgeamides A (35), B (36), and D (37) appear to be closely 
related in their biogenesis to notoamides C (33) and D (34, also named norgeamide D), 
and are potential metabolites along the pathway to the more complex prenylated indoles 
(+)-stephacidin A (28) and notoamides A (31) and B (32).  Minor metabolites of the 
notoamides continue to be isolated from marine-derived Aspergillus sp. MF297-2; 
notoamides E-R (38-51) are known natural products while notoamides S and T (52 and 














31, notoamide A, R1 = OH, R2 = H, R3 = H
32, (!)-notoamide B, R1 = R2 = R3 = H
41, notoamide H, R1 = OH, R2 = H, R3 = OH













33, notoamide C, R = H
35, norgeamide A, R = OMe







































39, notoamide F, R1 = Me, R2 = H
40, notoamide G, R1 = Me, R2 = OH




















































44, notoamide K, R = H
















46, notoamide M, R = H













































Figure 11. Structures of the notoamides and related compounds. 
 
Stephacidin A and notoamide B were also recently isolated from terrestrial-
derived Aspergillus versicolor, along with a new fungal metabolite, versicolamide B 
(54).25  This new secondary metabolite displays a structural feature unique to the 
stephacidins and notoamides.  Versicolamide B represents the first member outside of the 
brevianamide family to contain the anti-relative configuration at C-19 in the 
bicyclo[2.2.2]diazaoctane ring system.  Following the isolation of versicolamide B from 
Aspergillus versicolor, it was found that this metabolite is also produced by marine-
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derived Aspergillus sp. MF297-2.23  Further investigation of the metabolites isolated from 
Aspergillus versicolor and Aspergillus sp. MF297-2 led to the discovery of another 
unique trait within this family.  (!)-Stephacidin A (55), (+)-notoamide B (56), and (+)-
versicolamide B (54) from Aspergillus versicolor are antipodal to (+)-stephacidin A (28), 
(!)-notoamide B (32), and (!)-versicolamide B (1.57) produced by marine-derived 
Aspergillus sp. MF297-2 (Figure 12).  Additionally, (!)-stephacidin A is the antipode to 
(+)-stephacidin A isolated from Aspergillus ochraceus.  The discovery of these 
enantiomeric metabolites produced by two different Aspergillus species represents the 










































































Marine-Derived Aspergillus sp. Terrestrial-Derived Aspergillus versicolor
 
Figure 1.7.  Structures of the antipodal metabolites produced by Aspergillus sp. MF297-2 
and Aspergillus versicolor.  
 
 21 
As shown in Table 3, numerous prenylated indole alkaloids belonging to the 
stephacidin and notoamide family have been isolated from varying Aspergillus fungal 
cultures.  The structural diversity of the notoamides isolated from Aspergillus sp. MF297-
2 represents one of the most extensive co-metabolite profiles within the numerous 
families of prenylated indole alkaloids.  This profile suggests that there exists a possible 
biosynthetic relationship between members of the stephacidin and notoamide family of 
secondary metabolites, which will be discussed further in Chapter 4.19 
 
Table 3. Fungal origin of the stephacidins and notoamides. 
Compound Fungal Species Reference 
Aspergillus sclerotiorum 15 sclerotiamide (27) 
Aspergillus sp. MF297-2 19 
Aspergillus ochraceus WC76466 16 (+)-stephacidin A (28) 
Aspergillus sp. MF297-2 19 
(!)-stephacidin A (55) Aspergillus versicolor 25 
stephacidin B (29) Aspergillus ochraceus WC76466 16 
Aspergillus ochraceus CL41582 18 avrainvillamide (30) 
Aspergillus species CNC358 17 
notoamide A (31) Aspergillus sp. MF297-2 19 
(!)-notoamide B (32) Aspergillus sp. MF297-2 19 
(+)-notoamide B (56) Aspergillus versicolor 25 
notoamide C (33) Aspergillus sp. MF297 19 
Aspergillus sp. MF297 19 notoamide D (34) 
(norgeamide C) Aspergillus sp. MF297 20 
notoamide E (38) Aspergillus sp. MF297 21 
notoamide F (39) Aspergillus sp. MF297 22 
notoamide G (40) Aspergillus sp. MF297 22 
notoamide H (41) Aspergillus sp. MF297 22 
notoamide I (42) Aspergillus sp. MF297 22 
notoamide J (43) Aspergillus sp. MF297 22 
notoamide K (44) Aspergillus sp. MF297 22 
notoamide L (45) Aspergillus sp. MF297 23 
notoamide M (46) Aspergillus sp. MF297 23 
notoamide N (47) Aspergillus sp. MF297 23 
notoamide O (48) Aspergillus sp. MF297 24 
notoamide P (49) Aspergillus sp. MF297 24 
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notoamide Q (50) Aspergillus sp. MF297 24 
notoamide R (51) Aspergillus sp. MF297 24 
(!)-versicolamide B (57) Aspergillus sp. MF297 23 
(+)-versicolamide B (54) Aspergillus versicolor 25 
norgeamide A (35) Aspergillus sp. MF297 20 
norgeamide B (36) Aspergillus sp. MF297 20 
Aspergillus sp. MF297 20 norgeamide D (37) 
Aspergillus versicolor 25 
 
 Fungi have proven to be a good source of bioactive natural products.  While the 
notoamides appear to have moderate and limited biological activity, the structurally 
related norgeamides have all been shown to inhibit the growth of a variety of cancer cell 
lines with varying efficacies.1.38  Preliminary biological assays reveal that norgeamide A 
is the most cytotoxic against several carcinoma cell lines.  However, sclerotiamide, 
avrainvillamide, and stephacidins A and B appear to be the most bioactive of the 
stephacidins and notoamides.  These secondary metabolites display anti-insecticidal, 
antibacterial, and antitumor properties.16b,15,18 
Sclerotiamide has been shown to exhibit potent activity against first instar larvae 
of the corn earworm Helicoverpa zea.15  When incorporated into standard test diets of 
200 ppm, sclerotiamide resulted in a 46% mortality rate of H. zea.  There was also a 98% 
reduction in growth rate, relative to controls, among the survivors.  Several physiological 
effects, such as shriveling and blackening, were also observed in the larvae.  In a feeding 
assay against adults and larvae of the fungivorous beetle Carpophilus hemipterus, at a 
100-ppm dietary level, sclerotiamide reduced feeding rates by 44% and 40%, 
respectively. 
Avrainvillamide is an antibiotic that inhibits the growth of multi-drug resistant 
Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis with MICs of 
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12.5, 12.5, and 25 µg/ml, respectively.18  When tested against Escherichia coli, at 100 
µg/ml it showed no antibacterial activity.  Avrainvillamide also displays antitumor 
activity against a variety of tumor cell lines, including human colon HCT116 cells, 
melanoma MALME-3M cells, and two breast cancer cells, "T-549 and T-47D.17 
Stephacidins A and B both demonstrate in vitro cytotoxicity against various 
human tumor cell lines (Table 4).  Stephacidin B exhibited more potent and selective 
antitumor activities, especially in the testosterone-dependent LNCaP cells.16  The effects 
of stephacidins A and B indicate a novel mode of action since they are not mediated by 
p53, mdr, or bc12, and they are not tubulin- or topoisomerase II-mediated. 
 
Table 4. In vitro cytotoxicity (µM) of (+)-stephacidin A (28) and stephacidin B (29).16 
Cell Line Histotype Characteristic 28 (IC50) 29 (IC50) 
PC3 prostate testosterone-independent 2.10 0.37 
LNCaP prostate testosterone-sensitive 1.00 0.06 
A2780 ovarian parental 4.00 0.33 
A2780/DDP ovarian mutp53/bc12+ 6.80 0.43 
A2780/Tax ovarian taxol-resistant 3.60 0.26 
HCT116 colon parental 2.10 0.46 
HCT116/mdr+ colon overexpress mdr+ 6.70 0.46 
HCT116/topo colon resistant to etoposide 13.10 0.42 
MCF-7 breast estradiol-sensitive 4.20 0.27 
SKBR3 breast estradiol-independent 2.15 0.32 
LX-1 lung sensitive 4.22 0.38 
  
2.1.4 The Asperparalines 
Asperparaline A (58, Figure 13) is an indole alkaloid that was first isolated in 
1997 by Hayashi and coworkers from the fungus Aspergillus japonicus JV-23 in Sakai, 
Japan.60  In 2000, the same group reported the isolation of two new related indole 
alkaloids, asperparalines B (59) and C (60), from the same fungal strain.61  In separate 
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work, Everett et al. reported the isolation of asperparaline A, named aspergillimide, from 
Aspergillus sp. MF297-2 IMI 337664.62  From the same fungal culture, the 16-keto 










































58, asperparaline A 59, asperparaline B
60, asperparaline C 61, SB202327  
Figure 13.  Structures of the asperparalines. 
 
Similar to many of the prenylated indole alkaloids, the asperparalines possess a 
core bicyclo[2.2.2]diazaoctane ring system.  Asperparalines A and B both contain a "-
methyl proline ring, whereas asperparaline C is the C-3!desmethyl analog.  The 
asperparalines also contain a unique 3-spiro-succinimide ring system in place of the 
spiro-oxindole ring system commonly observed in the paraherquamides, stephacidins and 
notoamides, and brevianamides.63   
All members of the asperparaline family have exhibited some form of biological 
activity.  Asperparaline A exhibited paralysis against silkworms at a dose of 10 µg/g of 
diet within one hour and lasted for 7 to 10 hours upon oral administration.60  
Asperparalines B and C displayed almost the same effect on silkworms.61  Separately, 
asperparaline A and SB202327 were tested for anthelmintic activity against adult 
Trichostrongylus colubriformis infections in gerbils.62  Results from this experiment 
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showed that asperparaline A displayed a 44% and 98% reduction in faecal egg count 
when dosed with 10 mg/kg and 20 mg/kg, respectively.  SB202327 exhibited in vitro 
activity against Haemonchus contortus L3 larvae, but did not display in vivo activity 
against T. colubriformis in gerbils.  
 
2.1.5 Related Secondary Metabolites 
 The structural diversity of reverse prenylated indole alkaloids isolated from fungal 
sources is vast.  The austamides (62-65, Figure 14), malbrancheamide (66), and the 
marcfortines (67-70) all contain unique structural features, different from those discussed 
earlier.  Similar to the previously mentioned fungal metabolites, many of these related 
indole alkaloids also exhibit biological activity. As displayed in Table 5, these related 

























































































68, marcfortine B 70, chrysogenamide A69, marcfortine C  
Figure 14.  Structures of related secondary metabolites. 
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Table 5.  Fungal origin of several related secondary metabolites. 
Compound Fungal Species Reference 
austamide (62) Aspergillus ustus 4, 64 
12,13-dihydroaustamide (63) Aspergillus ustus 64a 
12,13-dihydro-12-
hydroxyaustamide (64) 
Aspergillus ustus 64b 
deoxyaustamide (65) Aspergillus ustus 64a 
malbrancheamide (66) Malbranchea aurantiaca 65 
Aspergillus carneus 66 
Penicillium paneum 67 
marcfortine A (67) 
Penicillium roqueforti 68a 
Penicillium paneum 67 marcfortine B (68) 
Penicillium roqueforti 68 
Penicillium paneum 67 marcfortine C (69) 
Penicillium roqueforti 68 
chrysogenamide A (70) Penicillium chrysogenum 69 
 
Austamide (62), 12,13-dihydroaustamide (63), and 12,13-dihydro-12-
hydroxyaustamide (64) all contain a spiro-indoxyl group similar to the brevianamides, 
however these metabolites also contain a unique seven-membered spiro-indoxyl ring.4,64  
Another metabolite isolated from Aspergillus ustus is deoxyaustamide (65), which 
displays an eight membered ring between the indole and diketopiperazine ring, making it 
a potential metabolic precursor to the austamides.   
More recently, Mata and co-workers reported the isolation of malbrancheamide 
(66) from Malbranchea aurantiaca.65  This metabolite is closely related to the 
paraherquamides and stephacidins and contains the core bicyclo[2.2.2]diazaoctane ring 
system; however, malbrancheamide is chlorinated at the C-5 and C-6 positions of the 
indole ring.  Malbrancheamide also possesses moderate inhibition of growth of 
Amaranthus hypochondriacus and inhibits the activation of the calmodulin-dependent 
enzyme PDE1.   
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The marcfortine family of secondary metabolites also contains the bridging 
bicycle, a spiro-oxindole ring, and substitution on the aromatic ring of the tryptophan 
moiety.  Marcfortines A and B (67 and 68) both display the seven-membered dioxepin 
moiety, while marcfortine C (69) exhibits the six-membered pyran ring.68  Unique to the 
marcfortines, as well as all other prenylated indole alkaloids, is the presence of the C-7 
prenyl group in chrysogenamide A (70).69  Unlike the prenylated indole alkaloids 
previously discussed, the marcfortines posses a pipecolic acid moiety instead of a proline 
residue, and with the exception of chrysogenamide A, the six-membered pipecolic acid 
ring is unsubstituted.  Of the marcfortine metabolites, only chrysogenamide A has 
reported bioactivity; specifically it exhibits a neurocyte protection effect against oxidative 
stress-induced cell death in SH-SY5Y human neuroblastoma cells.69 
 
2.2 Precursor Incorporation Studies in Relation to Biosynthesis 
2.2.1 Amino Acid Precursors 
 As previously stated, early radiolabeling and feeding experiments carried out by 
Birch demonstrated that the brevianamides are biogenetically derived from tryptophan, 
proline, and mevalonic acid (Scheme 2).2,3  In 1970, Birch hypothesized that 
brevianamide F and deoxybrevianamide E were biosynthetic precursors to brevianamide 















































Scheme 2.  Biosynthetic study of brevianamide A.72 
 
Based on the results obtained from the precursor incorporation studies of the 
brevianamides, Williams and co-workers postulated that the structurally similar 
paraherquamides follow a comparable biosynthetic pathway.  To determine which amino 
acid residues are incorporated into paraherquamide A, feeding experiments were 
performed on Penicillium fellutanum using [1-13C]-L-tryptophan, [methyl-13C]-L-
methionine, [1-13C]-L-proline, and [1-13C]-L-isoleucine (Scheme 3).27  Through 13C-NMR 
spectroscopy and electrospray mass spectrometry, the position and percentage of 13C 
incorporation was analyzed.  As expected, [1-13C]-L-tryptophan incorporated at the C-12 
position of the oxindole ring with 2.5% incorporation, while only a small amount (0.6%) 
of [methyl-13C]-L-methionine was found to incorporate at the nitrogen methyl of the 
monoketopiperazine ring.  With regard to the "!methyl-"-hydroxyproline ring, 
precedence established by Arigoni and co-workers for the biosynthesis of bottromycin in 
Streptomyces bottropenis revealed incorporation of [methyl-13C]-L-methionine into 
bottromycin at the 3(R)-methyl group of the "!methyl proline ring of bottromycin.27b   
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Unfortunately, results from the precursor incorporation study with Penicillium 
fellustanum showed that neither [methyl-13C]-L-methionine nor [1-13C]-L-proline 
incorporated into paraherquamide A.  It was later found that [1-13C]-L-isoleucine 
exhibited incorporation to the extent of 3.3-3.7%, with the label at the C-18 position.  To 
establish a potential mechanism of incorporation of isoleucine into paraherquamide A, 
[13C]-[2H]3-L-isoleucine was synthesized and fed to cultures of Penicillium fellutanum.  
Results showed that only one deuterium label was retained, thus confirming a 4-electron 
oxidative cyclization pathway to form "!methyl-L-proline (Scheme 3B).  This possibility 
was supported by an additional 13C-labeling study, which revealed a higher percentage of 
13C incorporation in the monoketopiperazine ring when L-isoleucine underwent oxidative 
cyclization to form the "!methyl-L-proline prior to the precursor incorporation study with 
P. fellutanum.  An incorporation of 14.6% was observed in this case, compared to the 













































































Scheme 3.  (A) 13C-labeled amino acid incorporation into paraherquamide A in 
Penicillium fellutanum.  (B) Proposed biosynthetic pathway for the conversion of L-
isoleucine to 3(S)-methyl-L-proline.27   
 
2.2.2 Advanced Intermediate 
As shown in Scheme 4, the most advanced 13C-labeled intermediate to be 
synthesized and incorporated into paraherquamide A was doubly 13C-labeled pre-
paraherquamide (25), with an incorporation of 0.72%.  When fed to P. fellutanum, this 
material was incorporated with the double label intact, suggesting that pre-
paraherquamide is in fact a precursor in the paraherquamide biosynthesis.  This 
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information also indicates that oxidation of the indole ring to form the dioxepin ring and 

























10, (!)-paraherquamide A25, pre-paraherquamide  
Scheme 4.  Incorporation of 13C-labeled pre-paraherquamide into paraherquamide A in 
P. fellutanum. 
 
2.2.3 Isoprene Units 
Initial characterization of the paraherquamides, notoamides, and stephacidins led 
to the conclusion that two isoprene units are present in these alkaloid families (Figure 
15).  One of the two isoprene units is involved in the formation of the bicyclo[2.2.2] 
nucleus (shown in red), while the other isoprene unit contributes to the formation of the 































Figure 15.  Location of the isoprene units in prenylated indole alkaloids. 
 
To determine the biosynthetic pathway from which the isoprene units originate 
[13C2]-acetate was fed to P. fellutanum (Scheme 5).  Specific incorporation of intact C2 
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units, combined with the 13C coupling patterns observed by 13C-NMR spectroscopy 
demonstrated that the isoprene units in paraherquamide A arise from 















































Scheme 5.  The classical mevalonic acid pathway showing the labeling pattern via 1,2-
doubly labeled acetate (note the change in carbon numbering). 
 
Biosynthetic research has also shown that the addition of [13C2]-acetate into the 
above pathway presents distinct coupling patterns.  In this instance, coupling was 
observed between C-1 and C-2, and between C-3 and C-4 of DMAPP; however, no 
coupling was observed between C-3 and C-5 since it has been demonstrated that C-5 of 












Figure 16.  Observed coupling pattern in DMAPP.  
 33 
When [13C2]-acetate was fed to P. fellutanum, it was demonstrated that the 
isoprene units in paraherquamide A were introduced in two distinct manners (Figure 
17).31  Through 13C-NMR spectroscopy, the coupling of intact C2 units revealed that in 
the C5 fragment formed by C19 to C23, C19 was coupled to C-20, while C-21 was 
coupled to C-22 and C-23, but not to both simultaneously. For the second C5 unit in 
paraherquamide A, C-24 to C-28, the coupling constants showed that C-24 was coupled 
to C-25, while C-26 was coupled to C-27, but not to C-28.31  Through the observed 
coupling patterns, it was concluded that the introduction of the C-24 to C-28 isoprene 
unit must proceed through a direct prenyl transferase in which nucleophilic displacement 
at the pyrophosphate-bearing methylene carbon occurs while the hydrophobic tail of 



























10, (!)-paraherquamide A  
Figure 17.  Relevant coupling patterns observed in the 13C NMR spectrum of 
paraherquamide A.  Thick lines represent intact acetate units. 
 
The mechanistic formation of the C-19 to C-23 fragment was further complicated 
by the observed scrambling of the 13C labels of the geminal methyl groups at C-22 and C-
23, thus indicating a loss of stereochemical integrity during the biosynthetic construction 
of the quaternary center.31,32 These unexpected results pointed to a reverse prenyl 
transferase.  In this case, the olefinic # system of DMAPP is presented in such a manner 
 34 
that both faces are susceptible to attack by the 2-position of the indole moiety.  As shown 
in Scheme 6, one possible explanation is that the pyrophosphate group is anchored in the 
enzyme active site with the hydrophobic isopropenyl moiety being presented in a 




































































9, (!)-paraherquamide A 9, (!)-paraherquamide A  
Scheme 6:  A possible biosynthetic sequence that may explain the scrambling of the 
geminal methyl 13C labels.  
 
2.2.4 Additional Studies 
Following the informative results obtained on the biosynthesis of the 
paraherquamides, similar biosynthetic studies were performed on Aspergillus japonicus.  
To determine the primary amino acid building blocks of asperparaline A [1,2-13C2]-
acetate, [methyl-13C]-L-methionine, [1-13C]- L-isoleucine, [1-13C]- L-tryptophan, and 
[indole-2-13C]- L-tryptophan were employed in precursor incorporation studies.73  The 
position of the 13C enrichment in asperparaline A was determined by 13C-NMR and the 
percentage of labeled amino acid enrichment was determined by 13C-NMR and 
electrospray mass spectrometry.  Results showed that [1,2-13C2]-acetate incorporates into 
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asperparaline A in an analogous manner to that of paraherquamide A, indicating that the 
isoprene units in asperparaline A also arise from the mevalonic acid pathway.  A 
significant amount of incorporation from [methyl-13C]-L-methionine was observed at the 
C-29 (25.2%) and C-30 (26.9%) positions of asperparaline A, but no incorporation was 
observed in any part of the "-methyl proline ring.  However, as expected, [1-13C]- L-
isoleucine exhibited a 5.8% incorporation at the C-18 position of the "-methyl proline 
ring.  While the asperparalines appear at first glance to be the only prenylated indole 
alkaloids not derived from tryptophan, the precursor incorporation studies show 
otherwise.  Both [1-13C]- L-tryptophan and [indole-2-13C]- L-tryptophan showed 
incorporation at the C-12 (6.4-7.2%) and C-2 (12.2%) positions of asperparaline A, 
respectively.  This indicates that tryptophan is responsible for the construction of the 
spiro-succinimide ring found in the asperparalines.  Furthermore, these results suggest 
that asperparaline A and paraherquamide A share a common biosynthetic pathway. 
Further establishing a unified biosynthetic pathway between the families of 
prenylated indole alkaloids, Kuo and co-workers have demonstrated that marcfortine A is 
biogenetically derived from tryptophan, methionine, lysine, and two isoprene units.74  
Precursor incorporation studies revealed that lysine, via $-ketoglutarate, is responsible 
for the formation of the pipecolic acid moiety present in the marcfortines.  This study also 
showed that methionine is the precursor to the C-29 N-methyl group and that both 





2.3 Formation of the Bicyclo[2.2.2]diazaoctane Ring 
 A majority of the prenylated indole alkaloids contain the unique core 
bicyclo[2.2.2]diazaoctane ring, and as such, the synthetic formation of this ring system 
has become a vastly studied area.  Two important synthetic approaches that have been 
developed are the biomimetic Diels-Alder cycloaddition and the intramolecular SN2´ 
cyclization.  These two synthetic strategies, largely utilized by Williams and co-workers, 
have resulted in the total synthesis of brevianamide B, paraherquamide B, stephacidin A, 
avrainvillamide, stephacidin B, VM55599, marcfortine C, malbrancheamide B, and (+)- 
and (!)-versicolamide B.75  Select synthetic examples of these two approaches are 
discussed below.   
 
2.3.1 Biomimetic Diels-Alder Cycloaddition 
 Shortly following the isolation of the brevianamides, Porter and Sammes 
proposed that the core bicyclo[2.2.2]diazaoctane moiety was the result of an 
intramolecular hetero Diels-Alder cycloaddition (IMDA) of a 5-hydroxy-pyrazine-2(1H)-
one (Scheme 7).76  Since then, extensive research has been carried out to synthetically 
support a biosynthetic Diels-Alder reaction via biomimetic routes.  Concurrently, 
considerable effort has been put forth to isolate and characterize the putative Diels-
Alderase enzyme responsible for this biosynthetic transformation, but to date, no such 





















1, (+)-brevianamide A71  
Scheme 7.  Proposed biosynthetic Diels-Alder reaction. 
 
 The first application of the biomimetic Diels-Alder reaction for the formation of 
the bicyclo[2.2.2]diazaoctane ring system in the prenylated indole alkaloids was in the 
biomimetic total synthesis of brevianamide B (Scheme 8).77  Starting with epi-
deoxybrevianamide E (72), formation of the lactim ether 73 with methyl Meerwein’s salt 
was followed by oxidation to give the Diels-Alder precursor 74.  Tautomerization (75) 
was achieved upon treatment with aqueous KOH, which subsequently underwent an 
intramolecular Diels-Alder reaction to afford a 2:1 mixture of syn- and anti- 
diastereomers (76 and 77).  The minor anti-diastereomer (77) underwent oxidation, 
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      65%
 
Scheme 8.  Biomimetic Diels-Alder formation of racemic brevianamide B. 
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 Williams et al. recently developed two different biomimetic Diels-Alder strategies 
for the total synthesis of stephacidin A.  The first route (Scheme 9) relies on the 
formation of the lactim ether version of the key azadiene precursor, similar to that of the 
total synthesis of racemic brevianamide B.78  The reverse prenylated tryptophan 
derivative 79 was first coupled to cis-3-hydroxyproline ethyl ester hydrochloride 80 to 
afford the amide 81, which was subsequently deprotected and cyclized to provide 
dioxopiperazine 82.  A Mitsunobu-type elimination yielded the enamide, which was 
further converted to the desired lactim ether 83.  The bicyclo[2.2.2]diazaoctane ring was 
formed following tautomerization of 83 to the intermediate azadiene 84, which 
underwent a spontaneous intramolecular Diels-Alder reaction to afford the cycloadducts 
85 and 86.  The predominant syn-isomer (85) was deprotected under acidic conditions to 








































1. PBu3, DEAD, 91%


























































Scheme 9.  Biomimetic total synthesis of stephacidin A utilizing the lactim ether. 
 
The second approach by Williams utilizes the originally proposed biosynthetic 
precursor, 5-hydroxy-pyrazine-2(1H)-one (71) as the intermediate to the Diels-Alder 
reaction (Scheme 10).79  From diketopiperazine 82, treatment with PBu3 and DEAD in 
CH2Cl2 at 40 ºC for 20 hours directly afforded stephacidin A, along with the anti-isomer 
in a 2.4:1 ratio, respectively. This biomimetic route to stephacidin A represents the first 
successful example wherein the putative biosynthetic 5-hydroxy-pyrazine-2(1H)-one 
intermediate serves as the substrate for the Diels-Alder cycloaddition,80 thus providing 
 40 



























(±)-stephacidin A  
Scheme 10.  Improved biomimetic total synthesis of stephacidin A. 
 
 Following the isolation of both antipodes of versicolamide B, interest was sparked 
in developing a biomimetic total synthesis of both (+)- and (!)-versicolamide B utilizing 
the IMDA approach (Scheme 11).81  Starting from the cis-diastereomer of 82, the same 
intermediate used in the stephacidin synthesis, oxidative rearrangement using the Davis 
oxaziridine reagent (87) gave a 3:1 mixture of oxindoles 88 and 89.  Each oxindole 
underwent Mitsunobu conditions to afford the corresponding enamides 90 and 91 (only 
the pathway leading from enamide 90 to (+)-versicolamide is shown in Scheme 11).  (+)-
Versicolamide B (54) and a minor diastereomer 92 were formed exclusively as the anti-
cycloadducts via the IMDA under basic conditions. Ab initio calculations reveal that the 
lack of formation of the syn-isomer is explained by the particularly stable transition state 
leading to the anti-cycloadduct when an oxindolic azadiene is used.82  When an indolic 
azadiene is present, such as in the synthesis of stephacidin A, both syn- and anti-


































































































































Scheme 11.  Biomimetic total synthesis of (+)-versicolamide B. 
 
2.3.2 Intramolecular SN2´ Cyclization 
 Another synthetic strategy for the formation of the core bicyclo[2.2.2]diazaoctane 
ring system developed by the Williams research group is the intramolecular SN2´ 
cyclization reaction.  This method was first employed in 1988 in the total synthesis of 
brevianamide B (Scheme 12).83  Starting with the known prenylated proline derivative 
93, nucleophilic ring opening provided the PMB-protected amide 94.  Following 
acylation and cyclization of 94 to form the diketopiperazine 95, ozonolysis afforded the 
aldehyde, which underwent a Wittig olefination and reduction to afford 96.  The primary 
alcohol was subsequently protected as the silyl ether and deprotonation of the 
diketopiperazine, followed by quenching with methyl chloroformate, provided the methyl 
ester intermediate 97.  A Somei-Kamatani coupling of 97 with gramine 98 afforded 99, 
 42 
which then underwent removal of the methyl ester and conversion of the TBS-protected 
primary alcohol to the primary chloride 100, the key intermediate in the SN2´ cyclization.  
Treatment of 100 with NaH and 18-crown-6 provided the core bicyclo[2.2.2]diazaoctane 
ring system (101) predominantly as the anti-isomer, which was followed by deprotection 
of the indole and olefin-cation cyclization to yield the hexacyclic indole substrate 102.  
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2, brevianamide B  
Scheme 12.  Total synthesis of brevianamide B utilizing an intramolecular SN2´ 
cyclization. 
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 Williams and co-workers later utilized the intramolecular SN2´ cyclization 
strategy for the total synthesis of stephacidin A (Scheme 13); however, unlike the above 
synthesis of brevianamide B, the installation of the allylic chloride came about via a 
cross-metathesis reaction.57  To start, tryptophan derivative 104 underwent a traditional 
coupling reaction with allyl proline 105, followed by microwave heating to afford the 
dioxopiperazine 106.  Lactim ether formation and protection of the indole as the Boc-
carbamate provided the key precursor (107) for the cross-metathesis.  Utilizing 
methacrolein and 5 mol% of the Hoveyda-Grubbs 2nd generation catalyst with 107, the 
desired aldehyde 108 was obtained.  Reduction of the aldehyde and conversion to the 
allylic chloride afforded 109, which underwent a syn-selective intramolecular SN2´ 
cyclization to give the core bridging bicycle 110.  Palladium-mediated cyclization of 111 
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55, stephacidin A  
Scheme 13.  Intramolecular SN2´ cyclization approach to the total synthesis of 
stephacidin A. 
 
The contrast in selectivity of the intramolecular SN2´ cyclization between the 
brevianamides and stephacidins is believed to be a result of an open versus closed 
transition state, respectively.83  The anti-diastereoselectivity observed in the 
brevianamide synthesis could be the result of 18-crown-6 weakly coordinating to the 
enolate counterion, resulting in an open transition state where cyclization occurs from the 
alternate rotamer of the allylic halide.  Alternatively, the use of benzene allows for a 




2.4 Research Objectives 
 The original intent of my research was to further explore the biosynthetic pathway 
of the paraherquamides and asperparalines (Chapter 3).  During this time, Tsukamoto and 
co-workers reported the isolation of the notoamides, which resulted in my focus being 
shifted toward determining the biosynthetic pathway of the stephacidins and notoamides 
in marine-derived Aspergillus sp. MF297-2 (Chapter 4) and terrestrial-derived 








Efforts to Further Elucidate the Biosynthesis of Paraherquamide A and 
Asperparaline A 
 
3.1 Pre-paraherquamide as a Biosynthetic Precursor 
 In 1993, Everett and co-workers isolated eight secondary metabolites from 
Penicillium sp. IMI 332995 (Figure 18). Along with (!)-paraherquamides A (10), E (14), 
F (15), and G (16), four novel secondary metabolites were also isolated (19-22).  More 
importantly, the isolation of VM55599 (22) represented the first documented example of 
the hexacyclic indole species that had long been proposed as a potential precursor within 
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Figure 18.  Secondary metabolites isolated from Penicillium sp. IMI 332995.  
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With the isolation of VM55599, it was thought that this metabolite could be a 
biosynthetic intermediate to paraherquamide A; however, one disadvantage to VM55599 
serving as a precursor to any of these metabolites is the stereochemistry of the methyl 
group of the "-methyl proline ring.  In the case of VM55599, the methyl group is 
disposed syn to the bridging isoprene residue, whereas in each of the other metabolites, 
the methyl group is anti to the bridged bicycle.  In order for VM55599 to be a precursor 
to paraherquamide A, oxidation of the "-methyl proline ring would have to occur with 
inversion of stereochemistry at the C-14 position.  To determine whether VM55599 
serves a precursor to paraherquamide A, the Williams group synthesized doubly 13C-
labeled VM55599.30    Through a series of feeding experiments with P. fellutanum it was 
determined that VM55599 did not incorporate into paraherquamide A, which suggests 
that VM55599 is not a precursor within the biosynthetic pathway.   
As mentioned in Chapter 1, 13C-labeled pre-paraherquamide (25), which displays 
the correct stereochemistry at C-14, was synthesized by the Williams group and fed to 
Penicillium fellutanum.33  Results from the precursor incorporation study showed 
significant incorporation of pre-paraherquamide into paraherquamide A, establishing that 
25 is a biosynthetic precursor to paraherquamide A.  Given that the core skeletal 
arrangement found in pre-paraherquamide is displayed in several of the reverse 
prenylated indole metabolites, pre-paraherquamide could serve as a precursor to 
numerous indole natural products.  If this is the case, pre-paraherquamide may have, at 
best, a fleeting existence, making its isolation a daunting and difficult task.  However, 
Sherman and co-workers recently obtained evidence for the existence of pre-
paraherquamide in cultures of Penicillium fellutanum and Aspergillus japonicus by 
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matching the MS/MS fragmentation patterns of synthetic pre-paraherquamide to natural 
pre-paraherquamide.14   
The above work done by Sherman establishes the presence of pre-paraherquamide 
in cultures of Aspergillus japonicus, as well as the presence of paraherquamide A and 
paraherquamide B.  These results provide indirect support that: (a) pre-paraherquamide is 
a precursor to asperparaline A; and (b) paraherquamide A and asperparaline A share a 
unified biosynthetic scheme.  To address both of these hypotheses a unified biogenetic 
pathway starting from pre-paraherquamide has been proposed.  As illustrated in Scheme 
14, the biosynthesis of paraherquamide A could arise via oxidation of the aromatic ring 
of pre-paraherquamide to the catechol derivative (111), followed by prenylation, dioxepin 
formation, and oxidation to the spiro-oxindole (10).  Along this same pathway, formation 
of the spiro-succinimide ring of asperparaline A (58), would occur via interruption of the 
paraherquamide A biosynthesis just before the prenylation step of the catechol derivative.  




























































Scheme 14. Proposed unified biosynthetic pathway of the paraherquamides and 
asperparalines. 
 
Unfortunately, substantial evidence is still lacking to definitively confirm either 
hypothesis.  The incorporation of 13C-labeled pre-paraherquamide into asperparaline A 
through a feeding study with Aspergillus japonicus would not only show that pre-
paraherquamide is an intermediate, but also provide additional support for a unified 
biosynthetic pathway.  
 
3.1.1 Progress Toward the Synthesis of Pre-paraherquamide 
Before synthesizing 13C-labeled pre-paraherquamide for feeding experiments, the 
synthesis was first carried out on unlabeled material through the Diels-Alder pathway 
described in Scheme 15.84  First, the reverse prenylated indole 112 can be converted to 
the tryptophan derivative 113, which could be subsequently coupled with "-methyl-"-
hydroxyproline (114) and cyclized to yield the diketopiperazine 115.  Formation of the 
azadiene 116 followed by tautomerization 117 sets the stage for the Diels-Alder 
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cycloaddition.  Pre-paraherquamide (25) is provided following cleavage of the lactim 

























































Scheme 15.  Key steps towards pre-paraherquamide using the Diels-Alder approach.  
 
Formation of the reverse prenylated indole 112 followed the excellent procedure 
established by Danishefsky and co-workers,85 which began by reacting commercially 
available indole 118 with N-chlorosuccinimide to yield C-3 chloro-indole 119 (Scheme 
16).  Treatment of 119 with prenyl-9-BBN and allene 120 furnished the C-2 reverse 






















Scheme 16. Synthesis of the reverse prenylated indole. 
 With the reverse prenylated indole in hand, gramine 121 was obtained from 112, 
and subsequently coupled with 122 in a microwave assisted Somei-Kametani86 coupling 
to afford 123 in high yield (Scheme 17).  As shown in Scheme 18, 122 was synthesized 
from commercially available benzophenone imine 124 and glycine ethyl ester 125 in high 
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yield.  At this point, instead of proceeding with the originally planned deprotection-
reprotection, saponification of the ethyl ester was attempted.  Product formation was 
observed, albeit in poor yield.  For this reason, the originally planned synthesis was 
continued from 123.  Deprotection of the benzophenone imine was followed by Boc 















































































Scheme 18.  Synthesis of benzophenone imine of glycine ethyl ester. 
 
The formation of the "-methyl-"-hydroxyproline (Scheme 19) started by first 
reacting glycine ethyl ester (124) with ethyl acrylate (129) to yield the secondary amine 
130.  This was followed by N-Boc protection of the amine and a subsequent cyclization 
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of 131 with LiHMDS to afford the "-ketoproline 132. Conversion of 132 to 114 was 
accomplished in one step with AlMe3.  This reaction proceeded in 63% conversion with 






































Scheme 19. Formation of the "-methyl-"-hydroxyproline. 
 With 113 and 114 in hand, first deprotection of 114 with TFA provided the free 
amine 133, which was subsequently coupled with 113 using HATU and 
diisopropylethylamine to afford 134 in excellent yield (Scheme 20).84  TFA provided the 
free amine 135, which was subsequently cyclized to furnish 115.  Treatment of 115 with 
SOCl2 and pyridine, yielded the unsaturated compound 136.  Treatment of the enamide 
with methyl Meerwein’s salt afforded the lactim ether 116, which was subsequently 
reacted with aqueous KOH in methanol to effect tautomerization and the consequent 
IMDA cycloaddition to furnish the diastereomers 137-140.  Based on previous 
calculation, the mixture of syn- and anti- diastereomers should form in a 2.4:1 ratio, in 
favor of the syn-isomer.  Likewise, the stereochemistry of the methyl group in the "-








































































































Scheme 20.  Formation of the Diels-Alder cycloadduct. 
 
3.1.2 Progress Toward the Synthesis of 13C-Pre-paraherquamide 
With the reaction conditions leading to the synthesis of 137 laid out, 13C-labeled 
material was taken through the synthesis. As shown in Scheme 21, the labeled protected 
glycine 138 was synthesized from benzophenone imine 125 and 13C-labeled glycine ethyl 
ester 139.  Coupling 138 with gramine 112 formed the tryptophan derivative 140. 
Removal of the benzophenone imine protecting group afforded the free amine, which was 
subsequently Boc protected to furnish 141.  Saponification yielded the acid 142, which 
was coupled with the 13C-labeled "-methyl-"-hydroxyproline 143.  The Boc protecting 
group was removed and the crude free amine 145 was cyclized to provide the 
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Scheme 21.  Formation of double 13C-labeled diketopiperazine 146. 
 
3.1.3 Future Directions 
 Doubly 13C-labeled pre-paraherquamide can be easily accessed from 146 in five 
steps (Scheme 22).  Once the final steps have been optimized on unlabeled material, the 
doubly 13C-labeled substrate will be converted to pre-paraherquamide following the same 
route.  From 146, the Diels-Alder cycloadduct 149 can be obtained in three steps.  
Removal of the lactim ether followed by selective reduction of 150 will yield pre-
paraherquamide.  Once 25 is obtained, it will be fed to Aspergillus japonicus to check for 

















































































Scheme 22.  Future work towards the synthesis of pre-paraherquamide. 
 
3.2 Biosynthetic Formation of the Dioxepin Ring System 
 The dioxepin ring system, commonly found in the paraherquamides, is a seven-
membered oxygenated heterocycle located at the C-6 and C-7 positions of the trytophyl 
moiety.  Precursor incorporation studies previously established that dimethylallyl 
pyrophosphate (DMAPP) was responsible for the biosynthetic formation of the C5 
fragment, and specifically demonstrated in paraherquamide A, the introduction of the C-
24 to C-28 isoprene unit to form the dioxepin ring proceeds through a direct prenyl 
transferase.31  Additionally, the incorporation of 13C-labeled pre-paraherquamide into 
paraherquamide A provides support that formation of the dioxepin ring occurs after the 
IMDA cycloaddition.   
While the exact biosynthetic mechanism for the formation of the dioxepin moiety 
from pre-paraherquamide is largely unknown, a potential biosynthesis has been proposed 
(Scheme 23).32  Starting from the biosynthetic intermediate pre-paraherquamide (25), 
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oxidation at the C-6 and C-7 positions affords the hypothetical intermediate 11. The 
bishydroxyindole (111) is then alkylated with DMAPP to form 151.  From this 
intermediate, one of two routes is possible for the formation of the dioxepin ring.  A face-
selective epoxidation of olefin 151 followed by a completely stereospecific ring-opening 
of epoxide 152, and subsequent dehydration would yield the final dioxepin ring of the 
paraherquamides (10).  Alternatively, face-selective complexation of a transition metallo-
protein to the olefinic #  system of 151 affording 154, followed by stereospecific 
intramolecular nucleophilic addition and " hydride elimination of 155 to the enol ether 
would also furnish 10.  Of these two pathways, the face-selective epoxidation is the most 





































































Scheme 23.  Proposed biosynthetic formation of the dioxepin ring. 
 
As previously stated, pre-paraherquamide incorporates into paraherquamide A 
when fed to P. fellutanum; therefore, catechol derivative 111 should also incorporate 
during a feeding experiment.  Incorporation of 111 would also provide another advanced 
precursor along the biosynthetic pathway to paraherquamide A; however, when 111 was 
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synthesized in the laboratory, it underwent oxidation to form the more stable quinone 

















































Scheme 24.  Quinone formation from the catechol derivative of pre-paraherquamide.  
 
Since the bishydroxyindole cannot be synthesized and tested as an intermediate 
along the biosynthetic pathway, two alternate approaches have been developed (Scheme 
25).  Based on the coupling patterns observed from the dioxepin ring, it is known that 
addition of this isoprene unit occurs via direct prenylation; therefore, one possibility is 
that the 7-position of the tryptophan core is first oxidized to 157, followed by prenylation 
to provide 158 and subsequent oxidation at the 6-position to yield 151.  From the 
originally proposed intermediate 151, one of the two possibilities previously discussed 























































Scheme 25.  Possible biosynthetic route for formation of the dioxepin ring. 
 
 Since 111 is not a synthetic option, another viable approach involves the synthesis 
of the 6-hydroxy tryptophan core 159, which could undergo oxidation in vivo to furnish 
the catechol intermediate 111 (Scheme 26).  From here, the bishydroxyindole could 




















































10, (!)-paraherquamide A  





3.2.1 Efforts Toward the Synthesis of Potential Precursors via SN2´ cyclization 
In order to determine if 157 or 159 are potential precursors to paraherquamide A, 
plans were constructed to synthesize both compounds with double 13C-labels, and 
through precursor incorporation studies with Penicillium fellutanum, check for their 
incorporation into the known secondary metabolite, paraherquamide A.  Both 157 and 
159 can be synthesized along a common route, with 157 originating from 7-
benzyloxyindole (160) and 159 originating from 6-benzyloxyindole (161).  One currently 
established strategy for the synthesis of 157 and 159 centers around the intramolecular 
SN2´ approach for the preparation of the core bicyclic ring system.57  As shown in 
Scheme 27, 161 and 161 are converted to the corresponding tryptophan derivatives 162 
and 163, subsequently coupled to the proline 164, and cyclized to furnish 165 and 166, 
respectively. Upon conversion of the terminal olefin to the allylic chloride 2.68 and 2.69, 
the bridged bicycle is accessible through an SN2´ reaction.  The final two compounds are 
obtained following closure of the cyclohexyl ring and removal of the benzyl protecting 


































































160:  R1=OBn, R2=H
161: R1=H, R2=OBn 165:  R1=OBn, R2=H
166: R1=H, R2=OBn
167:  R1=OBn, R2=H
168: R1=H, R2=OBn




Scheme 27.  Key steps towards 157 and 159 using an SN2’ approach. 
 
The synthesis of the 6- and 7-benzyloxy tryptophan derivatives, as shown in 
Scheme 28, was attained from the respective commercially available 7- and 6-
benzyloxyindole (160 and 161).  Conversion of 160 and 161 to the gramine 171 and 172 
was achieved with formaldehyde and dimethylamine in glacial acetic acid in high yield.  
Gramines 171 and 172 then underwent a microwave assisted Somei-Kametani reaction 
with 122.  Subsequent treatment with acid afforded the crude amines 175 and 176, which 
were Boc protected to furnish 177 and 178.  The crude N-Boc protected amines were 
saponified with LiOH in THF/H2O to form the final respective tryptophan derivatives 























175:  79%, two steps












162:  87%, two steps
































Scheme 2.15.  Synthesis of 6- and 7-benzyloxy tryptophan derivatives. 
 
The synthesis of the "!methyl proline derivative (Scheme 29) started from 
commercially available (R)-$-methyl benzyl amine 179, which was alkylated with 4-
bromo-1-butene 180 to give the corresponding secondary amine 181.89  Subsequent 
alkylation with ethyl bromoacetate afforded 182 in 58% yield.  Formation of the N-
protected-"!methyl proline derivative 183 was accomplished via deprotonation of 182 
with LDA. The lithium enolate was then transmetalated with a 1M solution of ZnBr2 in 
diethyl ether. Work up with an aqueous solution of ammonium chloride afforded 183.90  
In a protecting group swap, hydrogenation of 183 was followed by Boc protection to 
yield 185.  The first attempt at the allylation of 185 with allyl bromide and NaHMDS in 
THF afforded 186 in 5% yield.  Further optimization was attempted (Table 6); however, 
when using allyl bromide, only starting material was recovered.  The yield was increased 














































Scheme 29.  Synthesis of proline derivative 186. 
Table 6.  Select reaction condition for the formation of 186. 
Entry X Conditions Results 
a Br NaHMDS, THF, -78oC !RT, 24 h 5% 
b Br LiHMDS, THF, -78oC !RT, 3 d NR 
c Br LDA, THF, -78oC !RT, 24 h NR 
d Br NaH, TBAI, THF, 0oC !40oC, 24 h NR 
e Br KHMDS, TBAI, THF, 0oC!RT, 24 h NR 
f I KHMDS, THF, -78oC !RT, 24 h NR 
g I NaHMDS, THF, -78oC !RT, 24 h 25% 
h I NaHMDS, DMF, 0oC !RT, 24 h 18% 
 
Along this route, there are several low yielding steps.  The allylation and 
cyclization (181 to 183) both provide less than 50% product, while the first two steps 
each yield roughly 60%.  These difficulties so early on in the synthesis prompted 





3.2.2 Progress Toward the Synthesis of the 6-Hydroxy and 7-Hydroxy Precursors 
(Diels-Alder Route) 
Another well-established route utilizes a biomimetic intramolecular Diels-Alder 
reaction to form the core bridged bicycle ring system (Scheme 30).78,79 To start, the 6- 
and 7-hydroxy indoles (187 and 188) are first protected and converted to the 
corresponding tryptophan derivative (189 and 190) with the reverse prenyl group located 
at the C-2 position of the indole.  The reverse prenylated indole is then coupled to "-
methyl-"-hydroxyproline 114 to form the respective diketopiperazine 191 and 192.  The 
enamide is formed from the diketopiperazine, followed by conversion to the lactim ether 
193 and 194.  The Diels-Alder cycloadduct is accessible from a base-induced 
tautomerization to form the azadiene followed by a [4+2] cycloaddition to furnish 157 

















































































Scheme 30.  Key steps towards 157 and 159 using the Diels-Alder approach. 
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 Several approaches were attempted toward the synthesis of the 6-hydroxyindole 
188, with each route derived from the known Leimgruber-Batcho indole synthesis.91  For 
the synthesis of the 6-hydroxyindole (Scheme 31), commercially available nitrophenol 
197 was protected as either the Boc- or benzyl-oxynitrotoluene (198 and 199).  
Conversion of 198 and 199 to enamines 200 and 201 with DMF-DMA and pyrrolidine 
were successful, however the Boc-protected nitrotoluene was low yielding.  
Unfortunately, a one step cyclization and deprotection of 200 proved unsuccessful.  
Several cyclization reactions were attempted on 201.  The use of catalytic Rh/C, H2, and 
Fe(OAc)2 resulted in decomposition, however, trace amounts of product were detected 
when using dry Rh/C and H2 without Fe(OAc)2.92  Reacting 201 with Zn and AcOH 
yielded 202 albeit in low yield.  The desired product was obtained in good yield by 
reacting 201 with hydrazine monohydrate and Ni2B (prepared from Ni(OAc)2) in 
ethanol.93  Formation of the desired unprotected 6-hydroxyindole 188 was formed in a 



























































201 188  
Scheme 31.  Synthesis of the 6-benzyloxyindole 202. 
 
With the 6-benzyloxyindole in hand, completion of the reverse prenylated indole 
was underway (Scheme 32).  First, 202 was deprotected and reprotected to afford the 6-
OBoc indole 203, which was followed by formation of the C-2 reverse prenylated indole  
using the excellent procedure established by Danishefsky and co-workers.85 The C-3 
indole position of 203 was chlorinated using NCS in DMF to afford 204, which was 
treated with prenyl-9-BBN in the presence of NEt3 to yield the reverse prenylated indole 
205. With the reverse prenylated indole in hand, the gramine 206 was formed in good 
yield, which was subsequently reacted with the 122 in a Somei-Kamatani microwave 
reaction. Imine hydrolysis afforded the tryptophan derivative 207, which was readily 
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converted to the corresponding N-Boc carbamate 208.  Following standard saponification 
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Scheme 32.  Formation of the reverse prenylated 6-benzyloxyindole. 
 
To form the 7-hydroxyindole, two different protecting groups of the hydroxy 
group were attempted while employing Leimgruber-Batcho indole synthesis.  The first 
approach was to form the Boc-protected nitrotoluene 210 and subsequent formation of 
the enamine derivative 211 (Scheme 33).  The synthesis of 210 proved to be successful, 













209 210 211  
Scheme 33.  First synthetic approach to form 7-hydroxyindole. 
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The second strategy (Scheme 34) began by benzyl protecting commercially 
available nitrophenol 209.  The enamine was formed by reacting the nitrotoluene 212 
with DMF-DMA and pyrrolidine, which was subsequently converted to the 
semicarbazide 213 in decent yield.94  The 7-hydroxyindole was formed in a 
hydrogenation reaction in which the benzyl-protecting group was also removed.  The 
alcohol was immediately Boc protected to afford the desired 7-OBoc indole 214.  
Chlorination of 214 with NCS in methanol afforded the C-3 chloro-indole 215, which 
was then reacted with prenyl-9-BBN.  Unfortunately after numerous attempts, only 
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Scheme 34. Attempt to form the 7-OBoc reverse prenylated indole 216. 
 
3.2.3 Future Directions 
 Completion of the 6-hydroxy derivative 159 requires coupling of the tryptophan 
derivative with "-methyl-"-hydroxyproline and subsequent formation of the 
diketopiperazine.  The Diels-Alder cycloadduct can be attained from the lactim ether, and 
following several functional group manipulations the desired 6-hydroxy precursor can be 
obtained.  Once the reaction conditions have been optimized on unlabeled material, the 
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synthesis of doubly 13C-labeled 159 can begin.  Synthesis of the 7-hydroxy precursor will 









The Biosynthesis of the Stephacidins and Notoamides in Cultures of Marine-
Derived Aspergillus sp. MF297-2  
 
4.1 Marine-Derived Aspergillus sp. MF297-2 
4.1.1 Isolation of Secondary Metabolites 
 In 2007, Tsukamoto and coworkers reported the isolation of four new secondary 
metabolites, notoamides A-D (31-34, Figure 19) from a marine-derived fungus 
Aspergillus sp. MF297-2.  The fungus was found growing on the mussel Mytilus edulis, 
which was collected off the Noto Peninsula in the Sea of Japan.19  In addition to 
notoamides A-D, three known prenylated indole metabolites; sclerotiamide (27), (+)-
stephacidin A (28), and deoxybrevianamide E (7), were also isolated from the fungal 



















































































7, deoxybrevianamide E  
Figure 19.  Structures of metabolites isolated from marine-derived Aspergillus sp. 
MF297-2. 
Similar to other known prenylated indole metabolites, each of these compounds 
are derived from tryptophan, a cyclic amino acid, and one or two mevalonate-derived 
isoprene units.26  Structural analysis revealed that notoamides A-D all contain the 
pyranoindole ring system common in the stephacidins, and that notoamides A and B 
contain the core bicyclo[2.2.2]diazaoctane ring system as well as a spiro-oxindole 
moiety.  Notoamides C and D were found to display the diketopiperazine moiety in place 
of the bridging bicycle.  Additionally, notoamide C contains an oxindole moiety, whereas 
notoamide D is a hexacyclic metabolite with a carbon skeleton closely related to 
brevianamide E.19 
 Shortly after the isolation of notoamides A-D from marine-derived Aspergillus sp. 
MF297-2, Tsukamoto reported the isolation of a fleeting potential precursor, notoamide E 
(38).  As observed in many of the stephacidins and notoamides, notoamide E is a 2,3-
disubstituted indole alkaloid that contains a pyranoindole and a diketopiperazine ring 
system (Figure 20).  Through isolation experiments, it was established that notoamide E 
only exists in the fungal culture on day 5 of incubation, and that by day 6 the metabolite 
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has been completely converted to other downstream metabolites.  These results clearly 
indicate that notoamide E is produced by the fungus as an early biosynthetic intermediate 













38, notoamide E  
Figure 20.  Structure of notoamide E. 
 
 Between 2008 and 2010, notoamides F-R (39-51) and (!)-versicolamide B (57) 
were also isolated by Tsukamoto from marine-derived Aspergillus sp. MF297-2.22-24  
These metabolites vary greatly in their structural arrangement, as shown in Figure 21.  
With the exception of notoamide J, all of these natural products contain a pyranoindole 
ring system.  A small number of these metabolites contain the core 
bicyclo[2.2.2]diazaoctane ring, while others either possess an oxindole moiety or the 
hexacyclic skeleton.  A structurally unprecedented prenylated indole metabolite in this 
grouping is notoamide O, which contains a hitherto unknown hemiacetal/hemiaminal 
ether functionality.21  This family of secondary metabolites includes versicolamide B, 
which displays the unique anti-relative configuration common to the brevianamides.23 
The isolation of these new notoamide metabolites shows the vast variety of prenylated 
indole natural products produced by this fungal culture and provides further insight into 













39, notoamide F, R1 = Me, R2 = H
40, notoamide G, R1 = Me, R2 = OH



















































44, notoamide K, R = H
















46, notoamide M, R = H






















41, notoamide H, R1 = OH, R2 = H, R3 = OH
















Figure 21.  Structures of notoamides F-R and versicolamide B. 
 
4.1.2 Total Synthesis of Marine-Derived Metabolite Notoamide J95 
With the aim to elucidate the entire notoamide/stephacidin biosynthetic pathway, 
a synthesis of notoamide J that was readily amenable to the incorporation of stable 
isotopes from which probe substrates could be interrogated was desired. Herein is the 
first total synthesis of notoamide J, which also serves to corroborate the structural 
assignment published by Tsukamoto and co-workers.95 
As Scheme 35 shows, the synthesis of notoamide J (43) commenced with the 
coupling of tryptophan derivative 190 with proline-ethyl ester 217 using HATU and 
iPr2NEt.  Peptide 218 was globally deprotected with TFA, and subsequently cyclized with 
2-hydroxypyridine to furnish a 1:1 mixture of 6-hydroxydeoxybrevianamide E 220 and 
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diastereomer 221.  Treatment of 220 with Davis oxaziridine afforded the known natural 








































































































Scheme 4.13.  Synthesis of 6-hydroxy-deoxybrevianamide E and notoamide J. 
 
 As desired, the total synthesis of notoamide J allows for easy access to 
isotopomers of notoamide J, as described in detail in Section 4.3.1.  Through isotopic 
labeling of notoamide J, investigation of this species as a potential biosynthetic precursor 
to more complex natural congeners is feasible and is discussed further in Section 4.3.2.  
Additionally, this route provides a potential biosynthetic intermediate, 6-
hydroxydeoxybrevianamide E, which may act as a precursor not only to notoamide J, but 
to other secondary metabolites as well. 
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4.2 Stereochemical Comparison to Metabolites Produced by Aspergillus versicolor: 
Biosynthetic Implications 
 As mentioned in Chapter 2 (Section 2.1.3), metabolites displaying the opposite 
absolute stereochemistry to those isolated from Aspergillus sp. MF297-2 were isolated by 
Gloer and co-workers from terrestrial-derived Aspergillus versicolor.  (For extended 
discussion on metabolites from Aspergillus versicolor, please refer to Chapter 5).  As 
shown in Figure 4.4, (+)-stephacidin A (28), (!)-notoamide B (32), and (!)-versicolamide 
B (57) were isolated from Aspergillus sp. MF297-2, while (!)-stephacidin A (55), (+)-
notoamide B (56), and (+)-versicolamide B (55) were produced by Aspergillus 
versicolor.23,25 These enantiomeric natural metabolites represent the first set of known 
antipodal metabolites isolated from the notoamide, paraherquamide, and stephacidin 
families.  This information sparked further interest in elucidating the biosynthetic 
pathway for the formation of the bicyclo[2.2.2]diazaoctane ring system, which has been 
strongly implicated as being responsible for the enantio-diverging event.96  Focus was 
immediately placed on identifying a single species that could serve as a biosynthetic 











































































Marine-Derived Aspergillus sp. Terrestrial-Derived Aspergillus versicolor
 
Figure 22.  Structures of antipodal natural metabolites isolated from marine-derived 
Aspergillus sp. MF297-2 and terrestrial-derived Aspergillus versicolor.  
 
4.3 First Generation Biosynthetic Pathway—Williams et al. 
4.3.1 Notoamide E as the Diels-Alder Precursor 
The extensive co-metabolite profile produced by Aspergillus sp. MF297-2 suggest 
a possible biosynthetic sequence of deoxybrevianamide E (7) leading to stephacidin A 
(28), and preceding to notoamide B (32), after which the pathway would branch to give 
either notoamide A (31) or sclerotiamide (27).19  However, following the isolation of 
notoamide E from marine-derived Aspergillus sp. MF297-2, it was postulated by 
Williams and coworkers that notoamide E could serve as the biosynthetic precursor to the 
intramolecular Diels-Alder reaction (IMDA).21  As shown in Scheme 36, notoamide E 
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(38) could arise from deoxybrevianamide E (7) following pyran formation.  Subsequent 
oxidation and tautomerization of the diketopiperazine to form achiral azadiene 223 could 
then undergo a [4+2] cycloaddition.  This sequence would give two stereoisomers per 
fungal strain: (+)-stephacidin A (28) and the C6-epi-stephacidin A (224) in Aspergillus 
sp. MF297-2 and the corresponding enantiomers (55 and 225) in Aspergillus versicolor.  
As shown in Scheme 36A, oxidation of the 2,3!disubstituted indole of (+)-stephacidin A 
to the corresponding spiro-oxindole would furnish (!)-notoamide B (32), while oxidation 
of C6-epi-stephacidin A (224) would give (!)-versicolamide B (57).  Likewise, 
notoamide E could serve as a biosynthetic precursor to antipodal metabolites 54-56 and 












































































































































A)  Marine-Derived Aspergillus sp. B)  Terrestrial-Derived Aspergillus versicolor
223, achiral azadiene
 
 Scheme 36.  A) Proposed biosynthetic pathway of notoamide E to (!)-notoamide B in 
Aspergillus sp. MF297-2. B)  Similar pathway of notoamide E to (+)-notoamide B.  
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4.3.2 13C-Notoamide E Incorporation Study 
To establish the role notoamide E plays in the biosynthetic pathway of these 
prenylated indole metabolites, 13C-labeled notoamide E (229) was synthesized and fed to 
cultures of marine-derived Aspergillus sp. MF297-2  As shown in Scheme 37, readily 
accessible 13C-labeled tryptophan derivative 226, was first coupled to 13C-proline ethyl 
ester 227 under standard coupling conditions to yield peptide 228.21  Subjecting 228 to 
morpholine in THF removed the Fmoc protecting group and afforded cyclization to give 


























































Scheme 37.  Synthesis of [13C]2-notoamide E.21 
 The labeled potential precursor 229 was introduced to marine-derived Aspergillus 
sp. MF297-2 in an incorporation feeding study performed by Tsukamoto.21  It was 
anticipated that the conversion of [13C]2-notoamide E into labeled (+)-stephacidin A, (!)-
notoamide B, and (!)-versicolamide B would occur.  While notoamide C (33) and D (34) 
were isolated and shown to display 13C-enrichment at the expected C-12 and C-17 
positions, 28, 32, 57, and all other bridged bicyclo[2.2.2]diazaoctane-containing 
metabolites were absent.  This is particularly notable as these are typically the major 
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metabolites produced by Aspergillus sp. MF297-2 (Scheme 38).  Additionally, 3-epi-
notoamide C (231), a diastereomer to 33 that is not produced by the culture under normal 
growth conditions, was isolated in nearly four times the yield of the natural diastereomer 
33.  Three new structurally unique minor metabolites displaying 13C-enrichment were 
also isolated.  The new alkaloids, notoamides E2 (232), E3 (233), and E4 (234) are not 
present in the normal culture of Aspergillus sp. MF297-2 when cultivated on the standard 








































































































Scheme 38.  Results of the [13C]2-notoamide E incorporation study. 
 
 The absence of  (+)-stephacidin A, (!)-notoamide B, and (!)-versicolamide B in 
conjunction with the formation of “unnatural” metabolites 231-234, suggest that the 
presence of excess notoamide E in the growth medium alters the metabolite profile of this 
fungal culture.  Additionally, the conversion of [13C]2-notoamide E into notoamides C 
and D suggests the possibility of a branching biosynthetic pathway, albeit one that does 
not include notoamide E as a biosynthetic precursor to the Diels-Alder cycloaddition.96 




4.4 Second Generation Biosynthetic Pathway—Tsukamoto et al. 
Since the bicyclo[2.2.2]diazaoctane ring system is not biosynthetically derived 
from notoamide E, a second potential pathway was postulated by Tsukamoto and co-
workers.  This proposal also provides for the biosynthesis of both sets of antipodal 
metabolites. In regard to the generation of the antipodal stereoisomers of notoamide B 
and versicolamide B from Aspergillus sp. MF297-2 and Aspergillus versicolor, the 
enantio-divergence could arise as a consequence of an R- or S-selective indole oxidase, 
instead of the opposite facial selectivity of the IMDA reaction.23  Starting from the same 
precursor proposed in the previously discussed biosynthetic pathway, deoxybrevianamide 
E could first undergo an oxidative rearrangement to furnish two oxindole diastereomers, 
with the R-oxindole leading to metabolites produced by marine-derived Aspergillus sp. 
MF297-2  In this biogenetic pathway, the S-selective indole oxidase would provide the 
correct stereochemistry necessary to furnish (+)-notoamide B and (+)-versicolamide B in 
terrestrial-derived Aspergillus versicolor.  As illustrated in Scheme 39, 
deoxybrevianamide E (7) could undergo oxidation and pinacol-type rearrangement to 
yield 235 and 236.  Oxidation and tautomerization of 235 would provide azadiene 
intermediate 237, which would subsequently undergo a [4+2] cycloaddition to furnish 
four potential stereoisomers (two are shown).  Oxidation and prenylation of 238 and 239 
would construct the pyran ring, leading to the desired products 32 and 57, respectively.  
Following the same biogenesis, (+)-notoamide B and (+)-versicolamide B could arise 


































































































Terrestrial-derived Aspergillus versicolor  
Scheme 39.  Second generation biosynthesis of spiro-oxindole containing compounds 
notoamide B and versicolamide B.  Shortened biosynthetic pathway leading to the 
Aspergillus versicolor metabolites is also shown. 
 
An additional modification to the second generation biosynthesis of antipodal 
notoamide B and versicolamide B is the possibility that the C-6 position of 7 is first 
hydroxylated, thereby resulting in 6-hydroxydeoxybrevianamide E (220).  This would 
then serve as the biogenetic precursor to the enantio-divergence point of the two 
biosyntheses (Scheme 40).  6-Hydroxydeoxybrevianamide E could undergo oxidative 
rearrangement to form 222 and the known natural product notoamide J.  Cycloaddition of 
222 via azadiene 240 would give 241 and 242, in which prenylation and ring closure 











































































































Scheme 40.  Alternative biosynthetic pathway for the formation of spiro-oxindole 
compounds.  
 
Additional support for this pathway is provided by the isolation of notoamide J, as 
well as the biomimetic conversion of 6-hydroxydeoxybrevianamide E to notoamide J.  In 
marine-derived Aspergillus sp. MF297-2, notoamide J may be an artifact of the oxidative 
rearrangement of 6-hydroxydeoxybrevianamide E to the R-stereoisomer 222, which could 
serve as a precursor to other downstream metabolites.  This potential pathway would 
therefore render notoamide J a shunt metabolite in Aspergillus sp. MF297-2, but a 
precursor to notoamide B and versicolamide B in terrestrial-derived Aspergillus 
versicolor. 
 
4.4.1 Synthesis of Potential Biosynthetic Intermediates  
  In order to determine the validity of both second generation biosynthetic 
pathways, unlabeled and isotopically labeled intermediates were synthesized.  The 
unlabeled intermediates were used to detect the presence of these compounds in the 
normal culture of Aspergillus sp. MF297-2, while the isotopically labeled compounds 
were used in feeding studies with the marine fungal culture to check for incorporation 
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into advanced metabolites.  Deoxybrevianamide E (7), 6-hydroxy-deoxybrevianamide E 
(220), and epi-notoamide J (222) were synthesized with and without isotopic labels, 
while oxindoles 235 and 236, as well as the advanced metabolites 238 and 239, were 
synthesized without any isotopic labeling. 
 As shown in Scheme 41, the synthesis of unlabeled deoxybrevianamide E started 
with the coupling of tryptophan derivative 113 to proline-ethyl ester 217 under standard 
conditions to afford peptide 243.  Removal of the Boc protecting group using TFA 
furnished free amine 244, which was subsequently cyclized to give the diketopiperazine 
in a 1:1 ratio of the target molecule 7 and diastereomer 245.  Formation of R- and S-
oxindole compounds 235 and 236 in a 1:2 ratio was obtained upon treatment of 7 with 



































































































Scheme 41.  Synthesis of deoxybrevianamide E and oxindoles 235 and 236.  
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The synthesis of [13C]2-[15N]-deoxybrevianamide E 246 started by coupling [13C]-
tryptophan derivative 142 with [13C]-[15N]-proline-ethyl-ester 247 in the presence of 
HATU, iPr2NEt, and acetonitrile to afford triply-labeled peptide 248 (Scheme 42).  
Removal of the Boc group and cyclization afforded a 1:1 ratio of [13C]2-[15N]-
deoxybrevianamide E 246 and diastereomer 250, which were readily separated via 



































































Scheme 42.  Synthesis of [13C]2-[15N]-deoxybrevianamide E. 
  
Due to the difference in stereochemistry at the C-19 position of (!)-notoamide B 
and (!)-versicolamide B, two different routes were initially employed in the synthesis of 
the Diels-Alder cycloadducts 238 and 239.  As described in the biomimetic total 
synthesis of stephacidin A (Chapter 2), the desired syn- stereochemistry is preferentially 
formed in a 2.4:1 ratio when the C-2 reverse prenylated indole moiety is subjected to the 
IMDA reaction.  Therefore, the synthesis of 238 was proposed following a similar route.  
For the synthesis of 239, the anti-diastereomer is exclusively formed when the oxindole 
derivative undergoes a Diels-Alder cycloaddition reaction, as demonstrated in the 
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biomimetic synthesis of (+)- and (!)-versicolamide B (Chapter 2).  Therefore, the most 
efficient synthesis of 239 would involve forming the oxindole moiety first.     
 Both syntheses began by Boc protecting cis-"-hydroxyproline 80 using standard 
conditions (Scheme 43).  The N-Boc-cis-"-hydroxyproline 251 was then coupled to 
tryptophan derivative 252 to yield peptide 253.  Deprotection and cyclization furnished 
the desired diketopiperazine as a mixture of diastereomers (254).  From this intermediate, 
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Scheme 43.  Synthesis of diketopiperazine intermediate 253.  
 
 For the synthesis of 238, alcohol 254 was converted to enamide 255 using 
Mitsunobu conditions.  The enamide was then treated with 20% aqueous KOH in MeOH 
to give a 2.4:1 ratio of syn (257):anti (258) Diels-Alder cycloadducts (Scheme 44).  
Treatment of 257 with Davis oxaziridine gave a 1:1 mixture of the desired spiro-oxindole 
238 and the undesired diastereomer 259.  Stereochemical conformation of the desired 




















































































Scheme 44.  Formation of spiro-oxindole 238.   
 
Synthesis of the anti-diastereomer followed the route established for the synthesis 
of (+)- and (!)-versicolamide B.  Diketopiperazine 254 was converted to a 2:1 
diastereomeric mixture of oxindoles 260 and 261 using Davis oxaziridine (Scheme 45).  
Elimination of the alcohol under Mitsunobu conditions provided 262, which was 
subsequently treated to 20% KOH in MeOH to effect tautomerization and Diels-Alder 
cycloaddition.  Unfortunately, after numerous attempts with both the R- and S-oxindole 
moieties, formation of the cycloadduct could not be achieved due to a competing retro-


















































































263 264  
Scheme 45. Primary attempt to form (!)-versicolamide B precursor 239. 
 
Since 239 could not be synthesized as originally planned, an alternative synthesis 
was proposed.  Following the same procedure established for the synthesis of 238, the 
anti-diastereomer (258) underwent oxidation and a pinacol-type rearrangement using 
Davis oxaziridine to furnish 239 and 265 in a 1:1 ratio (Scheme 46).  Unfortunately, one 
bottleneck in this route is the low yield of the anti-diastereomer formed from the IMDA 









































Scheme 46.  Second attempt to synthesize 239. 
 
The unlabeled synthesis of 6-hydroxydeoxybrevianamide E and notoamide J is 
shown in detail in Section 4.1.2.  Isotopically labeled 6-hydroxydeoxybrevianamide E 
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266 was readily synthesized from 13C-labeled tryptophan derivative 267 (Scheme 47).  
Coupling of 267 with labeled [13C]-[15N]-Boc-L-proline (268) in the presence of HATU 
and iPr2NEt provided 269.  Double Boc deprotection with TFA, followed by cyclization 
with 2-hydroxypyridine in refluxing toluene gave a 1:1 mixture of triply labeled 
diketopiperazines 266 and 271.  Conversion of 266 to labeled epi-notoamide J (272) was 



















































































































4.4.2 Biosynthetic Results with Aspergillus sp. MF297-2 
 Through collaboration with Tsukamoto, a series of experiments were performed 
with the proposed biosynthetic intermediates to determine whether the proposed second 
generation biogenetic pathway is correct.  Tsukamoto and coworkers compared the 
unlabeled potential precursors (7, 235, 238, 239, and 220; Figure 23) to metabolites 
isolated from the normal culture of marine-derived Aspergillus sp. MF297-2 via HPLC.  
The [13C]2-[15N]-labeled precursors (246, 272, 266) were utilized in precursor 































































































Figure 23.  Potential biosynthetic precursors to metabolites isolated from marine-derived 





Results from the precursor incorporation studies in Aspergillus sp. MF297-2 are 
illustrated in Scheme 48.   It was determined that not only is deoxybrevianamide E a 
secondary metabolite produced by marine-derived Aspergillus sp. MF297-2, but also an 
intermediate along the biosynthetic pathway.  Feeding experiments with [13C]2-[15N]-
deoxybrevianamide E showed incorporation of 246 into a 1:1 ratio of (+)- and (!)-
notoamide B precursors (274 and 275), of which 274 matches the unlabeled metabolite 
235.  Although it was clear from 1H-NMR and 13C-NMR analysis that the metabolites 
isolated from feeding studies with 272 did not contain the core bicyclo[2.2.2]diazaoctane 
ring system, further information was unavailable as the metabolites were produced only 
in trace amounts. Additionally, a majority of the precursor was recovered from this 
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Scheme 48.  Results of the Aspergillus sp. MF297-2 feeding experiment with [13C]2-
[15N]-deoxybrevianamide E. 
 
Results from the comparison study of isolated metabolites with synthetic 
unlabeled metabolites demonstrated that 6-hydroxydeoxybrevianamide E was not 
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detected in the mature fungal culture; however, if this metabolite serves as a precursor to 
the advanced notoamide metabolites, detection of 220 would probably occur prior to day 
5.  Since 220 is a possible precursor to notoamide E, which is only detected on day 5, it is 
likely that 220 would only be present in the fungal culture prior to day 5.  Likewise, the 
spiro-oxindole intermediates were not detected in the mature fungal culture.  Therefore, 
this second generation biosynthetic proposal is unlikely to be the pathway used by the 
fungus. 
 
4.5 Third Generation Biosynthetic Pathway—Sherman et al. 
 In a separate collaboration with Professor David Sherman at the University of 
Michigan, a third biosynthetic pathway was recently proposed that focuses on 
determining the early stage biosynthetic intermediates.33  It is widely known that these 
prenylated indole metabolites are comprised of L-tryptophan and a second cyclic amino 
acid, such as L-proline.  The condensation of these two amino acids leads to a known 
metabolite cyclo-L-tryptophan-L-proline more commonly known as brevianamide F (6).  
As shown in Scheme 49, there are two possibilities to form the proposed intermediate 6-
hydroxydeoxybrevianamide E (220) from 6: (1) brevianamide F could undergo 
hydroxylation at the C-6 position to yield 6-hydroxybrevianamide F (276), followed by 
reverse prenylation at the C-2 position to furnish 6-hydroxydeoxybrevianamide E (220); 
or (2) C-2 reverse prenylation to give deoxybrevianamide E (7) and subsequent C-6 















































7, deoxybrevianamide E  
Scheme 49.  Possible biogenesis of 6-hydroxydeoxybrevianamide E. 
 
 From 220, C-7 prenylation would afford the proposed intermediate notoamide S 
(52), which could undergo cyclization to form the pyran ring to provide notoamide E 
(Scheme 50).  Since notoamide E is not the Diels-Alder precursor, one of the three other 
C-2 reverse prenylated substrates must lend itself to the IMDA cycloaddition to 
ultimately produce (+)-stephacidin A in cultures of Aspergillus sp. MF297-2.  The 
possibility of a stereoselective [4+2] cycloaddition of any of the three C-2 reverse 
prenylated indole alkaloids could account for the formation of the opposite enantiomers 




























































































Scheme 50.  Possible biosynthesis of the bicyclo[2.2.2]diazaoctane ring system found in 
Aspergillus sp. MF297-2 (Aspergillus versicolor not shown). 
 
Continuing with the third generation biogenetic pathway, notoamide A and B 
could be derived biosynthetically from stephacidin A (Scheme 51).  Depending on the 
fungal culture, formation of (+)- and (!)-notoamide B could arise from the face-selective 
oxidation of either (!)- or (+)-stephacidin A, respectively, followed by pinacol-type 














































































Scheme 51.  Possible biosynthetic conversion of antipodal stephacidin A to the 
corresponding enantiomers, notoamide B and A. 
 
4.5.1 (!)-Notoamide Biosynthetic Gene Cluster 
 In 2006, a bimodular nonribosomal peptide synthetase (NRPS) gene (ftmA) was 
mined from an Aspergillus fumigatus genome sequence, and its heterologous expression 
led to the accumulation of brevianamide F.33,97  It was reasoned that an NRPS with a 
function coincident with FtmA would be present in the notoamide biosynthetic pathway, 
leading to the biosynthesis of brevianamide F in Aspergillus sp. MF297-2.  Thus, using 
ftmA to probe for homologous genes, Sherman and coworkers identified an open reading 
frame (orf) named notE that shares 47% amino acid sequence identity with FtmA.  In 
addition to notE, eighteen other genes were identified in a 42456-bp region of the 
























Figure 24.  The notoamide (not) biosynthetic gene cluster derived from complete 
sequencing and bioinformatics mining of Aspergillus sp. MF297-2 genome.33 
 
Additional bioinformatics analysis revealed that NotB and NotI showed high 
similarity to FAD-dependent monooxygenases, while NotD is a presumed flavin-
dependent oxidoreductase.  Furthermore, NotN is predicted to function as a 
dehydrogenase, while NotO could be a short-chain dehydrogenase/reductase.  The notK 
gene encodes a putative efflux pump, which might specify excretion of alkaloid products 
from the cell.  NotL and NotR both share a sequence identity to the AflJ aflatoxin 
pathway, while NotA is a predicted biosynthetic pathway transcriptional repressor.33, 98,99  
Both NotG and NotH show a high sequence similarity to fungal CYP450s, which 
implicates either one in the formation of the isoprene-derived pyran ring.  Upon closer 
comparison to the fumitremorgin biosynthetic gene cluster from Aspergillus fumigatus, 
NotG shows a high similarity to FtmC, which is responsible for C-6 hydroxylation of 
tryprostatin B in the biosynthetic formation of tryprostatin A (Scheme 52).33,100  Based on 
the only other published pathway for isoprenylated alkaloids, it is proposed that in 
marine-derived Aspergillus sp. MF297-2, brevianamide F undergoes C-2 reverse-
prenylation, followed by C-6 hydroxylation via NotG to form the proposed intermediate, 






































Scheme 52.  Biogenetic conversion of tryprostatin B to tryprostatin A via Aspergillus 
fumigatus; proposed conversion of tryprostatin B to 6-hydroxytryprostatin B via the not 
genes from Aspergillus sp. MF297-2. 
 
In addition to the regulators that were identified, two other proteins were noted as 
potential aromatic prenyltransferases.  NotC and NotF are presumed to catalyze the two 
key prenylation reactions, with one protein acting as a reverse prenyltransferase and the 
other as a normal prenyltransferase.  Upon closer analysis, NotC showed a 50% sequence 
identity to FtmH in Aspergillus fumigatus, while NotF shows a 40% identity to a putative 
dimethylallyl tryptophan synthase in Coccidioides posadasii.101  However, the putative 
functions of products encoded by notJ, notM, notP, and notQ remain unknown based on 
bioinformatics analysis.33 
 
4.5.2 Synthesis of Potential Early Stage Biosynthetic Precursors 
To piece together the biosynthetic pathway of the stephacidin and notoamide 
metabolites, proposed biosynthetic intermediates from the third generation biogenetic 
pathway were synthesized and reacted with specific Not enzymes.  Focus was initially 
placed on determining the correct biosynthetic pathway from brevianamide F to 6-
hydroxydeoxybrevianamide E.  Thus, the synthesis of 6-hydroxydeoxybrevianamide F 
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(276) commenced by subjecting 281 to a Mannich reaction to form gramine 282, which 
was subsequently reacted with 122 in a Somei-Kamatani coupling reaction to furnish 283 
(Scheme 53). Hydrolysis of 283 gave the free amine, which was then Boc protected to 
yield 284.  Treatment of 284 under standard saponification conditions afforded the N-Boc 
acid, which was coupled to proline-ethyl ester 217 to provide peptide 285.  Global Boc 
deprotection using TFA and cyclization in the presence of NEt3 yielded the desired 6-
hydroxybrevianamide F and the corresponding trans-diastereomer (not shown) in a 1:1 
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Scheme 53.  Synthesis of potential biosynthetic precursor, 6-hydroxybrevianamide F.   
 
Next, deoxybrevianamide E (7) was synthesized as an authentic standard of the 
reverse prenyltransferase reaction.  Additionally, 6-hydroxydeoxybrevianamide E (220) 
and keto-premalbrancheamide (257) were synthesized to test as substrates for the normal 
prenyltransferase.  As shown in Scheme 54 and previously discussed in Section 4.3.1, 
deoxybrevianamide E was synthesized from the standard coupling of 113 with 217, to 
give 243, which was converted to 7 in two further steps.  6-Hydroxydeoxybrevianamide 
E (220) was synthesized by coupling tryptophan derivative 190 with proline 217.  
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Following a two-step conversion, 220 was obtained.  The synthesis of keto-
premalbrancheamide (257) was accomplished in five steps from tryptophan derivative 

















































































































Scheme 54.  Abbreviated syntheses of 7, 220, and 257. 
 
 In addition to potential notoamide biosynthetic precursors, the known natural 
product tryprostatin B (278) was synthesized in order to determine whether NotG is 
responsible for C-6 hydroxylation of the indole moiety.  Following a route similar to the 
synthesis of deoxybrevianamide E, the synthesis of tryprostatin B began by first forming 
C-2 prenylated indole 287 from 118 (Scheme 55).  The indole nitrogen of 118 was first 
tosyl-protected, and then treated with n-BuLi and prenyl bromide to afford 286.  Removal 
of the tosyl-protecting group gave 287, which was readily converted to gramine 288.  
Somei-Kamatani coupling of 288 with 122 afforded imine 289, and acid hydrolysis 
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provided the free amine, which underwent standard coupling with N-Boc-proline (290) to 
yield peptide 291.  Subsequent treatment with TFA cleaved the Boc-protecting group, 
and formation of the diketopiperazine was achieved upon treatment of the free amine 
with 2-hydroxypyridine to give tryprostatin B (278) and the trans-diastereomer (not 
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Scheme 55.  Synthesis of tryprostatin B.  
 
4.5.3 Results from Biogenetic Testing to Determine the Biosynthetic Pathway in 
Aspergillus sp. MF297-2 
 By over-expressing the isolated not genes from marine-derived Aspergillus sp. 
MF297-2, the synthesized substrates could be reacted with specific genes to check for 
their conversion into downstream metabolites.  NotF was first tested with brevianamide F 
in the presence of dimethylallyl pyrophosphate (DMAPP), and the product exhibited the 
same retention time on HPLC as authentic deoxybrevianamide E (Scheme 56).33  In 
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addition, NotF was tested with unnatural substrates, and no prenylated products were 
detected. These results demonstrate that NotF is the deoxybrevianamide E synthase and 
catalyzes the key reverse prenylation at C-2 of the indole ring leading to the 
bicyclo[2.2.2]diazaoctane core.  Strong evidence was also provided for the early timing 
and high selectivity of the NotF-catalyzed reaction.  However, since NotF has not yet 
been tested with 6-hydroxybrevianamide F, the order of hydroxylation and prenylation to 





















Scheme 56.  Biogenetic conversion of brevianamide F to deoxybrevianamide E via the 
deoxybrevianamide E prenyltransferase from Aspergillus sp. MF297-2 
 
 The role of NotC, the second predicted prenyltransferase, was also investigated.  
There are several different possible substrates that could undergo C-7 normal prenylation 
on the indole ring, and each of these substrates could potentially appear on the pathway 
from deoxybrevianamide E to stephacidin A.33  As Scheme 57 shows, the activity of 
NotC was tested on four structurally related putative substrates, deoxybrevianamide E 
(7), 6-hydroxydeoxybrevianamide E (220), keto-premalbracheamide (257), and 6-
hydroxy-keto-premalbrancheamide (277).  Results demonstrated that NotC showed high 
selectivity toward 6-hydroxydeoxybrevianamide E while the three other substrates failed 
to be converted.  The NotC product was determined to be 6-hydroxy-7-prenyl-
deoxybrevianamide E, later named notoamide S; thus, it was determined that NotC 
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catalyzes a normal prenyltransfer reaction at C-7 of the indole aromatic ring system in 6-
hydroxydeoxybrevianamide E.  These results also suggest that deoxybrevianamide E is 
first hydroxylated at C-6 of the indole ring, and the product 220 is subsequently 
prenylated at C-7 by NotC to generate notoamide S.  However, the exact pathway leading 
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Scheme 57.  Normal prenylation of 220 to notoamide S via NotC from Aspergillus sp. 
MF297-2 
 
Using NADPH as cofactor, it was determined that NotB converts notoamide E 
(38) into notoamide D (34) and either notoamide C (33) or epi-notoamide C (231).  
Results from this study posed an interesting conundrum.  When the products produced by 
the reaction of NotB with notoamide E were compared to synthetic standards, 3-epi-
notoamide C was produced instead of the predicted natural metabolite notoamide C.  The 
production of 3-epi-notoamide C from notoamide E in the presence of NotB could arise 
from a competing mechanistic pathway illustrated in Scheme 58.  Following epoxidation 
of the "-face of notoamide E, the electrons from the indole nitrogen could open the 
epoxide, allowing for nucleophilic attack of the diketopiperazine on the imine and 
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forming notoamide D.  On the other hand, a pinacol-type rearrangement of the "-face 
epoxide would yield 3-epi-notoamide C.  In order for notoamide C to arise from 
notoamide E, epoxidation of the $-face of notoamide E is required, which did not occur 
via NotB.  Therefore, it is proposed that the competing mechanistic pathway must not 
naturally occur in Aspergillus sp. MF297-2 as evident from the lack of formation of 3-
epi-notoamide C in the natural fungal culture.  The natural formation of notoamide C 
must either arise from a currently unknown enzyme, or perhaps the original structural 
assignment of notoamide C was incorrect. The crystallographic study of these metabolites 





























































































































Scheme 58.  Proposed mechanistic formation of notoamide D, notoamide C and 3-epi-
notoamide C from notoamide E.  
 
Based on the results from the biogenetic analysis of the not gene cluster isolated 
from marine-derived Aspergillus sp. MF297-2, as well as results from the notoamide E 
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incorporation study, a proposed biosynthetic pathway has been assembled (Scheme 59).  
It is widely known that brevianamide F (6) is biosynthetically constructed from 
tryptophan and proline, which is proposed to arise via NotE.1-3,26  Brevianamide F could 
then undergo reverse prenylation at C-2 of the indole moiety via NotF in the presence of 
DMAPP to afford deoxybrevianamide E.  Most likely, C-6 hydroxylation of 7 via NotG 
could result in formation of 6-hydroxydeoxybrevianamide E.  NotC then affects 
prenylation in the normal fashion of 220 to provide notoamide S, which is believed to act 
as the branching point between the biosynthetic formation of notoamide E and 
stephacidin A.  To form the desired bicyclo[2.2.2]diazaoctane ring system, oxidation and 
tautomerization of notoamide S (52) would provide the IMDA precursor, which would 
undergo a [4+2] cycloaddition to afford the potential biosynthetic intermediate notoamide 
T (53).  Cyclization to form the pyran ring on the indole moiety would give stephacidin A 
(28).  As previously discussed, pyranoindole formation of notoamide S would yield 
notoamide E, which is readily converted to notoamide D and either notoamide C or 3-epi-



































































































Scheme 59.  Updated third generation biosynthetic pathway of Aspergillus sp. MF297-2 
 
4.6 Future Directions 
 With the third generation biosynthetic pathway showing promise as the biogenetic 
route used by marine-derived Aspergillus sp. MF297-2 to synthesize the core bridging 
bicycle, further investigation of this pathway is necessary.  Additional feeding 
experiments using isotopically labeled proposed intermediates, such as notoamide S 
and/or notoamide T would provide substantial support for this biogenetic pathway.  Extra 
testing of the not genes on putative substrates could also unveil additional information 
about the biosynthetic substrates, as well as the presence of branching pathways used in 









Terrestrial-Derived Aspergillus versicolor: Elucidation of the Stephacidin and 
Notoamide Biosynthesis 
 
5.1 Terrestrial-derived Aspergillus versicolor 
5.1.1 Isolation of Metabolites  
 In 2008, Gloer and coworkers isolated five known prenylated indole metabolites 
from terrestrial-derived Aspergillus versicolor NRRL 35600.25  The isolate of Aspergillus 
versicolor was obtained from a basidioma of Gandoderma australe collected in a 
Hawaiian forest.  From this extract, brevianamide F (6), (!)-stephacidin A (55), 
norgeamide D (37), (+)-notoamide B (56), and (+)-versicolamide B (54) were obtained 
(Figure 25).  Structural determination was obtained through comparison with NMR and 
MS data from literature.  Additionally, through circular dichroism (CD) spectroscopy, 
both versicolamide B and notoamide B were found to display a 3S configuration of the 
spiro-oxindole stereogenic center.  Additionally, versicolamide B (54) represents the first 
member outside of the brevianamide family to possess the rare anti relative configuration 
within the bicyclo[2.2.2]diazaoctane ring system (See Chapter 2 for a more in-depth 


























































56, (+)-notoamide B 54, (+)-versicolamide B  
Figure 25.  Secondary metabolites isolated from Aspergillus versicolor NRRL 35600. 
 
5.1.2 Identification of Antipodal Metabolites 
These five secondary metabolites were nearly identical to metabolites isolated 
from Tsukamoto’s marine-derived Aspergillus sp. MF297-2  Upon further analysis of the 
Aspergillus versicolor metabolites, it was determined that stephacidin A, notoamide B, 
and versicolamide B possess the opposite absolute configurations to the known 
stephacidin A producer Aspergillus ochraceus WC76466 and metabolites previously 
isolated from and marine-derived Aspergillus sp. MF297-2 (Figure 26).25  The 
assignment of (!)-stephacidin A (55), (+)-notoamide B (56), and (+)-versicolamide B 
(54) were determined based on examination and comparison of the CD spectra and 











































































Marine-Derived Aspergillus sp. Terrestrial-Derived Aspergillus versicolor
 
Figure 26. Structures of antipodal natural metabolites isolated from marine-derived 
Aspergillus sp. MF297-2 and terrestrial-derived Aspergillus versicolor. 
 
5.2 Enantio-Divergent Biosynthetic Pathways 
The isolation of these enantiomeric natural metabolites represents the first set of 
antipodal metabolites within the notoamide, paraherquamide, and stephacidin families.  
This sparked further interest in elucidating the biosynthetic pathway for the formation of 
the bicyclo[2.2.2]diazaoctane ring system in Aspergillus sp. MF297-2 and Aspergillus 
versicolor.  It has been strongly implicated that the IMDA reaction forms the core 
bridging bicycle, which is also responsible for the enantio-divergence between the two 
Aspergillus species.96  Devised from the proposed biosynthetic pathway established for 
the biosynthesis of the metabolites isolated from marine-derived Aspergillus sp. MF297-
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2, it is postulated that the biosynthesis of metabolites from Aspergillus versicolor follow 
a similar, if not identical, biosynthetic pathway resulting in the formation of antipodal 
metabolites between the two Aspergillus species. 
As shown in Scheme 60, starting from the common biosynthetic intermediate, 
notoamide S (52), the formation of achiral azadiene 278 allows for a stereospecific [4+2] 
cycloaddition reaction in Aspergillus sp. MF297-2 and Aspergillus versicolor, resulting in 
the formation of the proposed stephacidin A precursor notoamide T (53 and 279).  
Formation of the pyran ring affords either (+)- or (!)-stephacidin A (28 or 55), 
respectively. Likewise, a stereoselective oxidation and pinacol-type rearrangement of 
antipodal stephacidin A could account for the formation of (!)-notoamide B in 
Aspergillus sp. MF297-2, and  (+)-notoamide B in cultures of Aspergillus versicolor 




































































































































































Scheme 61.  Stereoselective formation of (+)- and (!)-notoamide B. 
 
 Another disparity in the biosynthesis of the notoamides and stephacidins not 
understood is the formation of (!)- and (+)-versicolamide B in Aspergillus sp. MF297-2 
and Aspergillus versicolor, respectively.  Since versicolamide B displays an anti-
configuration within the bicyclo[2.2.2]diazaoctane ring system, two potential 
biosynthetic pathways have been proposed.25  First, (+)- and (!)-versicolamide B could 
arise biosynthetically from the C-6 epi-diastereomer of stephacidin A, or secondly, from 
the oxindole of notoamide S (Scheme 62).  At this time, neither proposed precursor has 
































































































Scheme 62.  Potential Biosynthetic Formation of (+)-Versicolamide B in Aspergillus 
versicolor  (Aspergillus sp. MF297-2 not shown). 
 
5.3 Isotope Incorporation Studies and Outcomes 
 To determine if the two sets of antipodal metabolites were biosynthesized along a 
similar, if not identical, biosynthetic pathway, four different isotope incorporation studies 
were performed with terrestrial-derived Aspergillus versicolor (Figure 27).  With a 
potential biosynthetic pathway being set forth by Sherman and co-workers, it seems 
reasonable that Aspergillus versicolor would follow the same biosynthetic formation of 
prenylated indole metabolites.  First, to determine similarities between the two pathways, 
an isotope incorporation experiment was carried out with [13C]2-notoamide E.  Next, 
there exists two different species that could possibly lead to the formation of the bridged 
bicycle, and to determine which one is the pivotal intermediate along the biosynthetic 
pathway, [13C]2-[15N]-6-hydroxydeoxybrevianamide E and [13C]2-[15N]2-notoamide S 
were provided to Aspergillus versicolor.  Finally, the isolation of stephacidin A in the 
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presence of notoamide B within both fungal cultures raised the question as to whether 
stephacidin A is the biosynthetic precursor to notoamide B and if this conversion is 
stereoselective.  Thus, [13C]2-(±)-stephacidin A was introduced to Aspergillus versicolor 

















































286, (±)-stephacidin A  
Figure 27.  Four isotopically enriched compounds utilized in feeding experiments with 
terrestrial-derived Aspergillus versicolor. 
 
5.3.1 Notoamide E  
Although notoamide E has not yet been isolated from the natural Aspergillus 
versicolor culture, it was reasoned that if the biosynthetic pathways were substantially the 
same in both Aspergillus sp. MF297-2 and Aspergillus versicolor, then labeled notoamide 
E would incorporate into notoamide C, notoamide D, and 3-epi-notoamide C in the 
terrestrial-derived fungal culture.   Furthermore, based on Tsukamoto’s results,25 it was 
expected that notoamide E would not incorporate into any compounds containing the 
bridged bicyclo[2.2.2]diazaoctane core, such as (–)-stephacidin A and (+)-notoamide B. 
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[13C]2-Notoamide E was introduced to Aspergillus versicolor in a precursor 
incorporation study, in which significant 13C incorporation was observed by 13C NMR 
spectroscopy at C-12 and C-17 of notoamides C and D (Scheme 63).  From analysis of 
the electrospray mass spectra, incorporation of intact doubly 13C-labeled notoamide E 
into notoamide C was determined to be 6.2%, while incorporation into notoamide D was 
6.0%.102,103  Interestingly, upon closer inspection, trace amounts of doubly 13C-labeled 3-
epi-notoamide C (231), unlabeled (–)-stephacidin A (55), and unlabeled (+)-notoamide B 
(56) were also detected by LC-MS (Table 7). In contrast to the metabolite profile 
observed by Tsukamoto and co-workers, only trace amounts of 3-epi-notoamide C (231) 
were detected and therefore the calculation of the percent of intact incorporation is 
unreliable. As mentioned previously, Tsukamoto observed a complete lack of production 
of any compounds containing the bicyclo[2.2.2]diazaoctane core, and while (–)-
stephacidin A and (+)-notoamide B are usually the major metabolites in the normal 
medium of Aspergillus versicolor, only trace amounts of these unlabeled compounds 

























































trace amount detected  
Scheme 63.  Incorporation of [13C]2-notoamide E into notoamide C and D. 
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Table 7. Intact incorporation of double 13C-labeled Notoamide E (229) into isolated 
metabolites. 
Metabolite % specific 
incorporation 
Notes 
notoamide C 6.2% 8.1 mg 
3-epi-notoamide C NDa trace isolated 
notoamide D 6.0% 11.2 mg 
stephacidin A 0% trace isolated 
notoamide B 0% trace isolated 
                         a) Not enough material to adequately calculate the % incorporation 
 
5.3.2 6-Hydroxydeoxybrevianamide E 
 Based on results obtained by Sherman et al. during the isolation and 
characterization of the not gene sequence, it was expected that an incorporation study of 
[13C]2-[15N]-6-hydroxydeoxybrevianamide E in cultures of Aspergillus versicolor would 
likely furnish labeled notoamide S, as well as labeled bridged bicycle-containing 
compounds.  However, based on results obtained from the notoamide E feeding study, 
there was also the possibility that labeled notoamide J could result from the same 
incorporation experiment.  As scheme 64 shows, 6-hydroxydeoxybreviamide E could 
undergo oxidation and pinacol-type rearrangement to afford notoamide J; or in contrast to 
this proposed route, 6-hydroxydeoxybrevianamide E could react with the NotC enzyme, 
yielding notoamide S.  Either way, both notoamide J and notoamide S could serve as 
viable substrates for the biosynthetic IMDA reaction furnishing (+)-versicolamide B and 
(+)-notoamide B in Aspergillus versicolor.  In order to determine which of the two 
possible routes is utilized in biosynthesis, a feeding experiment with 6-




















































































Scheme 64. Two possible biosynthetic pathway for the formation of (+)-versicolamide B 
and (+)-notoamide B from 7. 
 
 [13C]2-[15N]-6-Hydroxydeoxybrevianamide E (266) was synthesized as outlined in 
Chapter 4, Scheme 47, and introduced to terrestrial-derived Aspergillus versicolor in an 
incorporation study.  Fungal extracts from the precursor incorporation experiment were 
analyzed by 13C-NMR spectroscopy, in which significant 13C-enrichment was detected at 
the C-12 and C-18 positions of notoamide J (43, Scheme 65).    Analysis of the 
electrospray mass spectrum showed 8.4% incorporation of intact triply labeled 6-
hydroxydeoxybrevianamide E (266) into 43.102,103  Further analysis of the fungal extract 
by LC-MS showed the production of several unlabeled advanced metabolites (Table 8), 
such as  (!)-stephacidin A (55), (+)-notoamide B (56), and (+)-versicolamide B (54), as 
well as notoamides C and D (33 and 34).  Unfortunately, only 32% of 266 incorporated 

































Scheme 65.  Incorporation of [13C]2-[15N]-6-Hydroxydeoxybrevianamide E into 
notoamide J in terrestrial-derived Aspergillus versicolor. 
 
Table 8.  Isolated metabolites from Aspergillus versicolor feeding study with 266 and 




notoamide J 8.4% 1.4 mg 
notoamide C 0% 0.6 mg 
notoamide D 0% 0.9 mg 
(!)-stephacidin A 0% 1.1 mg 
(+)-notoamide B 0% 1.2 mg 
(+)-versicolamide B 0% 1.5 mg 
 
 5.3.3 Notoamide S 
 The last logical possibility for a single species that could be produced by both 
Aspergillus sp. MF297-2 and Aspergillus versicolor and lead to the formation of 
antipodal bicyclo[2.2.2]diazaoctane-containing compounds is notoamide S.  Sherman 
established support for the existence of notoamide S within Aspergillus sp. MF297-2 
when the NotC enzyme was reacted with 6-hydroxydeoxybrevianamide E to yield 
notoamide S (52).  To determine whether notoamide S is also a precursor within 
Aspergillus versicolor, [13C]2-[15N]2-notoamide S was synthesized and provided to 
terrestrial-derived  Aspergillus versicolor in a precursor incorporation study.  
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 Upon analysis of the fungal extracts of the [13C]2-[15N]2-notoamide S (285) 
feeding study, the following 13C-incorporation was detected and calculated:  6.4% 
notoamide C, 6.2% notoamide D, 6.2% stephacidin A, 6.4% notoamide B, and 6.5% 
versicolamide B (Scheme 66).  In addition to the above metabolites, through LC-MS 13C 
incorporation was detected in notoamide A, notoamide I, notoamide M, notoamide K, 
and notoamide R, however, only trace amounts of these metabolites were detected, and as 






























































































































































5.3.4 Stephacidin A 
 With the isolation of stephacidin A in the presence of notoamide B, questions 
arose as to whether or not the stephacidins and notoamides share a common biogenesis, 
and if stephacidin A could be a direct precursor to notoamide B. Biosynthetically, face-
selective oxidation of the 2,3-disubstituted indole of (!)- and (+)-stephacidin A would 
yield the corresponding spiro-oxindoles, (+)- and (!)-notoamide B, respectively.  This 
conversion was recently supported synthetically through the efficient biomimetic 
oxidation of stephacidin A to notoamide B by deploying an oxaziridine, which further 
demonstrates that this chemically feasible oxidative transformation was indeed valid in 
Nature.78,79  To specifically investigate the biosynthetic formation of notoamide B, a 
traditional isotopic substrate incorporation technique was employed in Aspergillus 
versicolor NRRL 35600 with [13C]2-(±)-stephacidin A (286). 
As illustrated in Scheme 67, fungal extracts from the feeding study were analyzed 
by LC-MS and 13C-NMR spectroscopy, and further analysis of the electrospray mass 
spectrum showed 2.7% intact incorporation of labeled (–)-286 into (+)-56.102,103 The 
unreacted stereoisomer (+)-286 was also isolated from the fungal extract, which was 
anticipated since it possesses the opposite absolute configuration of the metabolite 
notoamide B produced by A. versicolor. The known minor metabolite versicolamide B 
(54) was also isolated from this precursor incorporation experiment; however, 13C 
enrichment was not observed as expected, due to the diastereomeric relationship at C-19 
































Scheme 67.  Incorporation of [13C]2-(–)-stephacidin A into (+)-notoamide B in 
Aspergillus versicolor.  
 
5.4 Analysis of Results from Feeding Studies 
The results observed from the feeding experiments of double 13C-labeled 
notoamide E with both the Tsukamoto marine-derived Aspergillus sp. MF297-2 and 
Aspergillus versicolor pose some interesting questions about the biosynthetic pathway of 
the major metabolites produced by these organisms.  During the feeding experiment of 
notoamide E with Aspergillus versicolor, it was observed that 3-epi-notoamide C (231) 
was only produced in trace amounts, however, Tsukamoto’s incorporation study with 
Aspergillus sp. MF297-2 showed increased yields of 231.  This could be a distinguishing 
difference between the two Aspergillus species.  Furthermore, when labeled notoamide E 
was introduced to Aspergillus versicolor an inversion in the amounts of the major and 
minor metabolites occurred. When grown on normal media, notoamides C and D are 
produced in trace amounts by Aspergillus versicolor. In contrast, when labeled notoamide 
E was added to the culture media, these substances were isolated as the major 
metabolites. These results suggest that the addition of excess notoamide E does not 
abrogate the oxidative transformations of notoamide E into notoamides C, D and epi-
notoamide C. On the other hand, the suppression of formation of stephacidin A and 
notoamide B observed in the presence of added notoamide E suggests that these 
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compounds inhibit or divert the enzymatic machinery responsible for the production of 
the bicyclo[2.2.2]diazaoctane-containing metabolites, especially stephacidin A and 
notoamide B.   Furthermore, results from both sets of feeding studies establish that 
notoamide E is not a biosynthetic precursor to the proposed biological Diels-Alder 
cycloaddition, as evident by the lack of incorporation of notoamide E into any 
bicyclo[2.2.2]diazaoctane natural products.  Alternatively, these findings suggest the 
presence of a branching biosynthetic pathway, wherein the biosynthesis of notoamide E 
results in the production of notoamides C and D.  
The incorporation of [13C]2-[15N]-6-hydroxydeoxybrevianamide E (266) into 
notoamide J only provides a small glimpse into the biosynthetic pathway of the 
notoamides and stephacidins.  The lack of 13C-incorporation into more advanced 
metabolites may implicate notoamide J as a shunt metabolite.  One possibility for the 
biosynthetic formation of notoamide J is through a pinacol-type rearrangement via a 
promiscuous oxidase, the product of which cannot be further metabolized by the 
organism.  The possibility of an enzyme that oxidizes 2,3-disubstituted indoles is also 
supported by results from the notoamide E incorporation study with Aspergillus sp. 
MF297-2 and Aspergillus versicolor.21,96  The presence of a promiscuous oxidase also 
explains the lack of production of notoamide S by A. versicolor.  Additionally, the 
recovery of 261 from the fungal extract shows that the starting material was taken up by 
the fungus, but did not fully incorporate into the biosynthetic pathway.  Perhaps the 
timing at which 261 is fed and thus incorporated into the biosynthetic pathway is key to 
forming labeled advanced metabolites, such as (+)-notoamide B and (+)-versicolamide B. 
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 The outcome of the notoamide S incorporation study provides great insight into 
the biosynthetic formation of the bicyclo[2.2.2]diazaoctane ring system.  The results 
obtained from the [13C]2-[15N]2-notoamide S incorporation study with Aspergillus 
versicolor demonstrate that notoamide S serves as the pivotal precursor to the IMDA 
reaction, as well as the branching point for the formation of notoamide E, notoamide C, 
and notoamide D.  Further insight about the putative Diels-Alderase has been provided; it 
is highly substrate specific and requires the presence of the 6-hydroxy-7-prenyl-indole 
moiety found on notoamide S, and cannot contain the pyran ring found on notoamide E. 
The results obtained from the stephacidin A precursor incorporation study provide 
experimental validation for the hypothesis that a face-selective oxidative enzyme 
(presumed to be a flavo-enzyme) is present in Aspergillus versicolor NRRL 35600 and 
responsible for the biosynthetic conversion (–)-stephacidin A (55) into (+)-notoamide B 
(56).  Additionally, this enzyme displays high substrate specificity, as evident by the 
conversion of only one enantiomer of stephacidin A.  
 
5.5 (+)-Notoamide Biosynthetic Gene Cluster 
 In 2010, Sherman and co-workers sequenced the Aspergillus versicolor genome 
(Figure 29), and through bioinformatics mining identified similar not genes to those 
previously characterized from Aspergillus sp. MF297-2104  The (+)-notoamide 
biosynthetic gene cluster was found to contain a 70.8% nucleotide identity with the (!)-
notoamide biosynthetic gene cluster from Orf1 + NotA-NotJ.  However, after NotJ, both 
protein similarity and gene organization are highly different from each other, suggesting 
the notoamide gene cluster might end at NotJ.  Further characterization of NotA-NotI 
 120 
revealed that these enzymes share a high amino acid identity/similarity between the two 




















70.8% nucleotide identity/similarity with Aspergillus sp.
 
Figure 29. The notoamide (not) biosynthetic gene cluster from A. versicolor  
Table 9.  Comparison of (+)- and (!)-notoamide biosynthetic gene clusters. 
















NotB FAD binding 
domain protein 








NotD Oxidoreductase NotD’ Oxidoreductase 80% 86% 






NotG P450 NotG’ P450 87% 92% 
NotH P450 NotH’ P450 84% 92% 
NotI FAD binding 
domain protein 
NotI’ FAD binding 
domain protein 
85% 90% 
NotJ Unknown NotJ’  Unknown 80% 84% 








NotM Unknown NotM’ Unknown - - 
NotN Dehydrogenase NotN’ Unknown - - 
NotO Short-chain 
dehydrogenase 
NotO’ Unknown - - 
NotP Unknown NotP’ Unknown - - 








NotR’ Unknown - - 
        a) ND = Not Determined   
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5.6 Putative Biosynthesis of the Stephacidins and Notoamides 
Based on the results obtained from the above precursor incorporation 
experiments, in conjunction with the (+)- and (!)-notoamide genome sequencing of both 
Aspergillus species, a new biosynthetic pathway for the formation of the stephacidins and 
notoamides is illustrated in Scheme 68.  Starting with the formation of brevianamide F 
from the condensation of tryptophan and proline via NotE, subsequent reverse-
prenylation with NotF furnishes deoxybrevianamide E.  Hydroxylation at the C-6 
position of the indole moiety via NotG gives 6-hydroxydeoxybrevianamide E, which 
undergoes C-7 normal-prenylation by NotC to afford the pivotal intermediate notoamide 
S.  From this point, it is proposed that the pathway branches into at least two known 
directions.  Formation of the pyranoindole to yield notoamide E results in the 
biosynthesis of notoamide C, 3-epi-notoamide C, and notoamide D via NotB.  However, 
notoamide S could also undergo a 2-electron oxidation by either NotD or NotH to give 
the achiral azadiene, which acts as the enantio-diverging point in the biosynthesis.  The 
achiral azadiene can undergo a stereoselective [4+2] cycloaddition to yield either (+)-
notoamide T in Aspergillus sp. MF297-2 or (!)-notoamide T in Aspergillus versicolor.  
From these putative intermediates, cyclization to form the pyranoindole ring system 
furnishes antipodal stephacidin A.  Face-selective oxidation of stephacidin A, followed 
by a pinacol-type rearrangement yields enantiomeric notoamide B, which upon additional 










































































































































































































































































































































































































































































































































Scheme 68. Putative enantio-divergent biosynthesis of stephacidin A and the notoamides. 
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5.7 Future Directions 
While the above results provide further insight into the biogenesis of the 
stephacidins and notoamides, several questions remain unanswered. In particular, mid-
stage precursors between notoamide S and stephacidin A remain to be characterized.  
Future precursor incorporation studies with notoamide T could provide one of the final 
stephacidin A intermediates along this pathway.  Additionally, the exact biosynthetic 
precursor to versicolamide B currently remains elusive, but through a feeding study with 
C6-epi-stephacidin A, insight into the biosynthesis of this rare metabolite could be 










Design and Synthesis of a Novel Drug Delivery Method Specifically Targeted to 
Multiple Myeloma Cells 
 
6.1 Introduction—Part 2  
6.1.1 Multiple Myeloma 
 Multiple myeloma (MM) is a plasma cell malignancy, characterized by the 
accumulation of plasma cells predominantly in the bone marrow, leading to pathologic 
fractures, anemia, hypercalcemia, renal failure, and recurrent bacterial infections.34,35  
MM accounts for 13.4% of all hematologic malignancies diagnosed, 19% of all deaths 
resulting from hematologic malignancies, and 2% of all cancer deaths.36  Epidemiological 
studies have shown that MM is associated with older age and is found to occur more 
often in men than in women.37    
The causes of MM remain unknown; however, recent scientific advancements 
have provided a greater understanding of the cellular events responsible for the 
development of MM.34  Changes at a molecular level within the development of normal 
B-cells, adhesion molecules, cytokines, and/or bone marrow stromal cells can result in 
the preliminary stages of MM, such as monoclonal gammopathy of undetermined 
significance (MGSU) or smoldering MM (SMM).36  MGUS is a premalignant stage to 
MM and is characterized by a limitation in the proliferation of monoclonal plasma cells 
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in the bone marrow and the absence of end-organ damage.37  Unfortunately, MGUS is 
asymptomatic and treatment is limited to routine observation, without therapy.  SMM is 
an asymptomatic intervening stage with a much higher risk of progression to MM than 
observed in patients with MGUS.  Treatment of SMM is also limited to routine check-
ups, but at a more frequent rate than patients with MGUS.34  The risk of progression to 
MM or related disorders varies greatly between MGUS and SMM, about 1% per year 
compared to 10-20% per year, respectively.36 
 
6.1.2 Current Treatment 
 Starting in 1962, the prescribed MM therapy of melphalan and a glucocorticoid, 
such as prednisone, became the traditional therapeutic regimen; however, complete 
remission was rare (< 5%), and median survival did not exceed 3 years.39  The addition of 
other alkylating agents, anthracyclines, and vinca alkaloids to the standard melphalan-
prednisone regimen did not improve patient survival.  In 1983, it was documented that 
patients with high-risk myeloma had a high response rate when treated with a single high-
dose of melphalan intravenously.  In contrast with a single high-dose treatment, patients 
who were treated repeatedly with low-doses of melphalan suffered sublethal tumor cell 
damage and therefore ran the risk of procuring additional mutations by increasing 
genomic instability in tumor cells.  Over the years, several other combination drug 
treatments have emerged, such as VMCP (vincristine, melphalan, cyclophosphamide, and 
prednisone) and VBAP (vincristine, BCNU, Adriamycin, and prednisone); however, 
these treatments have been found less effective than high-dose melphalan.  
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 Until 1999 there were only two independently active compounds for treating MM 
on the market, and since then, thalidomide, revimid, and velcade have all shown efficacy 
against both advanced and refractory myeloma.39  Of these agents, velcade is a 
proteasome inhibitor and represents an entirely new class of agents used in MM 
treatment.  Velcade was FDA-approved for use in treating MM in 2003 and is currently 
under investigation for use in combination therapy with melphalan, vorinostat, and 
doxorubicin.  Arsenic trioxide is a unique agent that works by targeting mitochondria, 
resulting in programmed cell death.  This method, along with monoclonal antibodies to 
interleukin-6 (IL-6) and CD20, is currently under investigation as possible treatments for 
MM.39 
 
6.1.3 Tumor Specific Immunoglobulin Gene Sequence 
DNA hairpins have been found useful in a plethora of biological functions, such 
as the regulation of gene expression,105 DNA recombination,106 and facilitation of 
mutagenic events.107  Hairpins arise when two regions of nucleotides in single-stranded 
(ss)DNA are palindromic, and thus able to base-pair to form a double helix.  These 
hairpins also contain a loop of unpaired nucleotides.  DNA hairpins exist in two different 
states and fluctuate between the open and closed conformations.108  The closed-to-open 
transition requires enough energy to unzip the base-pairs located in the stem of the 
hairpin, whereas the open-to-closed transition requires a collision of the two arms of a 
hairpin, followed by the nucleation and the propagation of a base-paired stretch.  One 
common way to determine the conformation of the hairpin in vivo is through the use of  
fluorescent DNA probes (molecular beacons), which are oligonucleotide probes capable 
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of identifying and reporting the presence of a specific nucleic acid sequence.109  
Molecular beacons (MB) contain a fluorophore (F) and a quencher (Q), usually located at 
the 5´ and 3´ positions.  When the MB is in the closed conformation, the fluorophore is 
quenched and does not fluoresce, but upon binding of the MB to a target nucleic acid 
sequence, fluorescence is restored.  This method is useful for the detection of specific 
sequences of nucleic acids and can be further applied to drug delivery by targeting a 
specific gene sequence unique to tumor cells. 
Since MM is a malignancy of clonal antibody-secreting plasma cells, the mutated 
cells often contain a specific rearrangement of DNA, which is transcribed into a unique 
mRNA sequence.39,110  Translation of the mRNA sequence results in the formation of a 
tumor specific monoclonal antibody, which is abundant in all of the malignant cells.  
From this tumor specific transcript, a unique complementary determining region (CDR) 
gene sequence can be identified.111  Recently, Berenson and coworkers were able to 
demonstrate that a tumor specific oligonucleotide could specifically recognize the MM 
tumor cell population.42  As shown in Figure 30, using a quenched fluorescein-labeled 
oligonucleotide probe (designated as MB8226) displaying a sequence complementary to 
the CDR3 gene from the MM cell line RPMI8226, Berenson was able to establish that 
MB8226 could not only recognize the specific cell line, but also differentiate the 
RPMI8226 cell line from other MM cell lines.42  This provided additional support that 
MB8226 selectively enters and reacts with cells expressing this explicit mRNA sequence; 
and since the targeted mRNA sequence is found in a specific type of cancer cells, it was 



















A.  MB8226 with quenched 
      fluorophore
B. Binding of MB8226 to mRNA of the MM cell line RPMI8226 CDR3 gene sequence










= quenched fluorophore F = fluorescence
 
Figure 30.  A) Closed/quenched molecular beacon (MB8226). B) Open/fluorescent 
molecular beacon upon binding to mRNA of the CDR3 gene sequence from the MM cell 
line RPMI8226.  
 
6.1.4 Research Objectives—Part 2 
 In a collaborative effort with Dr. James Berenson at the UCLA David Geffen 
School of Medicine, I developed a novel targeted drug-delivery system utilizing a 
modified version of MB8226.  This oligonucleotide hairpin is equipped with a 
naphthyridine-drug derivative that is only released upon the opening of the hairpin within 
multiple myeloma cells.  This novel system minimizes exposure of healthy cells to the 
cytotoxic agent, while still delivering an effective dose of the drug to cancerous cells.   
 
6.2 Development of a Drug-Oligonucleotide Conjugate 
The challenge of converting MB8226 into a potential therapeutically active anti-
MM agent centered upon the attachment of a current MM drug to MB8226 so as to only 
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allow release of the drug within the malignant cells, thereby minimizing exposure of 
healthy cells to the cytotoxic agent.  One way to address this concern was through a 
“Trojan Horse” method.  By slightly altering the matched base pairs in the stem of 
MB8226, the desired cytotoxic agent could be contained within the stem and transported 
into the cancerous cells.  The design of the MB8226 altered stem was inspired by work 
from Nakatani and coworkers when they demonstrated that a naphthyridine ligand could 
bind to a guanine bulge in double helix DNA.43  Since the naphthyridine ligand possesses 
hydrogen bonding groups fully complementary to the target bulged base, this allows for 
thermodynamic stabilization of the DNA.   
As shown in Figure 31, the addition of an extra guanine to the stem of MB8226 
could allow for the desired “Trojan Horse” method of drug delivery.  By coupling the 
desired cancer drug to a naphthyridine moiety, the naphthyridine-drug complex could be 
inserted into the G-bulge of the closed MB8226 and held in place by hydrogen bonding.  
Since MB8226 only reacts with the RPMI8226 cell line, the MM drug would only be 
released within cancer cells upon binding of MB8226 to the complementary sequence 

















= cytotoxic agent + naphthyridine conjugate
GCATGACGCTG CAG   GT
CGTAC
A. Modified-MB8226 with drug conjugate B. Modified-MB8226 binding to mRNA of the MM cell line RPMI8226 CDR3 gene sequence
 
Figure 31.  “Trojan Horse” design  A. Closed conformation of MB8226 with the 
cytotoxic agent contained in the stem at the G-bulge.  B.  Open conformation of MB8226 
and release of the drug. 
 
 The two drugs selected for use in this experiment were vorinostat (287) and 
melphalan (288).  Vorinostat is an FDA-approved histone deacetylase inhibitor that is 
used for treating cutaneous T-cell lymphoma, and in 2008 a vorinostat-velcade 
(vorinostat-bortezomib) combination drug entered phase I clinical trials for the treatment 
of MM.44  As mentioned previously, melphalan is the mainstay treatment of MM and is a 
nitrogen mustard alkylating agent.38  In order for either of these two drugs to be used in 
the therapeutic application of MB8226, they had to be converted to the respective 


























Cl 290, N-melphalan  
Scheme 6.1.  Structures of two MM drugs (vorinostat and melphalan) and their 
naphthyridine derivatives. 
 
6.2.1 Synthesis of Naphthyridine-Modified Vorinostat 
The first proposed synthesis (Scheme 70) of the naphthyridine-vorinostat 
analogue (289) began by forming the naphthyridine core 293.43  Commercially available 
2,6-diaminopyridine (291) was reacted with 3-ketobutanal dimethyl acetal (292) in 
concentrated H3PO4 to afford 2-methyl-7-amino-1,8-naphthyridine (293) in 89% yield.112  
The formation of the suberic acid methyl ester 296 was readily achieved from 
commercially available suberic acid (294).  The bis-acid was converted to the dimethyl 
ester 295 in methanol and sulfuric acid, which was selectively saponified in methanol and 
potassium hydroxide to yield the suberic acid methyl ester 296.  Unfortunately, the 















































Scheme 70.  First attempted synthesis of N-vorinostat. 
 
The second proposed synthesis (Scheme 71) for 289 coupled 293 with the acid 
chloride of suberic acid monomethyl ester (298), which was formed from the reaction of 
296 and oxalyl chloride in benzene and DMF.  Acid chloride 298 was reacted with 293 to 
yield 297.  Several different reaction conditions were attempted to form the desired 
hydroxamic acid 289.  The reaction condition listed by Njar in the synthesis of SAHA 
was attempted;113 however, only the naphthyridine core (293) was isolated.  Several 
published variations of this reaction were attempted at various temperatures, all in which 

































Scheme 71.  Second attempted synthesis of 289. 
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As outlined in Scheme 72, the third and successful synthesis of 289 started by 
reacting 293 with a preformed suberoyl anhydride (299).  Suberic acid (294) was reacted 
with acetic anhydride to form 299, which was subsequently treated with 293 to yield acid 
300.  The acid intermediate was converted to the hydroxamic 289 in a two-step, one-pot 
sequence.  The acid was first reacted with ethyl chloroformate in the presence of 
triethylamine in THF to form 301, which was immediately treated with 50% 








































Scheme 72.  Third attempted synthesis of 289. 
  
6.2.2 Synthesis of Naphthyridine-Modified Melphalan 
With the core naphthyridine-suberic acid reaction conditions developed, the next 
step was the synthesis of the naphthyridine-melphalan derivative (Scheme 73).  Starting 
with 300, ethyl chloroformate was used to form the mixed anhydride 301, which was 
subsequently reacted with melphalan 288.  Unfortunately, only trace amounts of the 



































Scheme 73.  First Attempted Synthesis of the Naphthyridine-Melphalan Derivative. 
 
 Since the first synthesis of N-melphalan resulted in only trace amounts of product, 
a new naphthyridine linker was designed.  The original naphthyridine moiety used in the 
vorinostat derivative was designed specifically to contain the six carbon alkyl chain 
found in vorinostat, which was no longer necessary for the naphthyridine-melphalan 
derivative.  The new naphthyridine derivative was based on the original G-bulge 
naphthyridine derivative synthesized by Nakatani and co-workers.43  As outlined in 
Scheme 74, "-alanine (303) was first Boc protected (304), followed by conversion of the 
acid to activated ester 305.  The 2-amino-1,8-naphthyridine derivative 293 was reacted 
with 305 and subsequently deprotected to afford the desired naphthyridine derivative 307.  
Next, N-Boc-melphalan (provided by Dr. Berensen) was coupled to 307 using EDCI and 
NMM to afford 308.  The desired N-melphalan derivative (290) was obtained following 
































































Scheme 74.  Synthesis of N-melphalan (290). 
 
6.3 Preliminary Test Results 
Biological testing performed by Berensen and co-workers showed that the 
modification of vorinostat with naphthyridine did not change its function compared with 
the unmodified compound.115  Moreover, using cell viability and apoptosis assays, there 
was no reduction in the cytotoxic effects of N-vorinostat or N-melphalan compared to the 











Figure 32.  Cytotoxicity comparison between the parent drug and the naphthyridine 
conjugated drug (a) vorinostat (SAHA) and N-vorinostat; (b) melphalan and N-
melphalan.  
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In addition, the modification of MB8226 allowed for the conjugation of N-
vorinostat and N-melphalan, while retaining the ability to specifically react only with the 
RPMI8226 cell line.115  Upon transfection with N-vorinostat conjugated MB8226, only 
RPMI8226 showed reactivity with the conjugated oligonucleotide-drug, while the U266 
MM cell lines showed no cytotoxic effects from exposure to this tumor specific cytotoxic 











Figure 33.  Apoptosis of MM cells treated with oligonucleotide-N-vorinostat (SAHA) 
conjugate; (a) 8226 cells (matched oligonucleotide); (b) U266 cells (unmatched 
oligonucleotide). 
 
This type of treatment should allow delivery of higher concentrations of drugs 
that will be active only within tumor cells, ultimately leading to more effective and better 
tolerated therapies for patients with MM.  Further investigation would be necessary to 
explore the possibilities of this treatment.  Unfortunately, funding limitation halted our 











7.1 General Synthetic Considerations 
 [13C]2-[15N]2-L-Proline and [13C]- L-glycine were obtained from the NIH Stable 
Isotopes Resource at Los Alamos National Laboratory.  All other reagents were 
commercial grade and used without further purification unless otherwise noted.  Unless 
otherwise noted, all reactions were run under an argon atmosphere in flame or oven-dried 
glassware.  Reactions were monitored by thin layer silica gel chromatography (TLC) 
using 0.25 mm silica gel 60F plates with fluorescent indicator (Merck).  Products were 
purified via either flash column chromatography using silica gel grade 60 (230-400 mesh) 
purchased from Sorbent Technologies or preparative thin layer chromatography (1000 
µm).  Acetonitrile (CH3CN), dichloromethane (CH2Cl2), diethyl ether (Et2O), N, N-
dimethylformamide (DMF), methanol (MeOH), tetrahydrofuran (THF), toluene (PhMe), 
and triethylamine (Et3N) were all degassed with argon and passed through a solvent 
purification system containing alumina or molecular sieves.  1H-NMR spectra and 13C-
NMR spectra were obtained on Varian 300, 400, 400 MR or 500 MHz NMR 
spectrometers.  NMR spectra were taken in CDCl3 (1H, 7.26 ppm; 13C, 77.0 ppm), 
CD3OD (1H, 3.31 ppm, 49.15 ppm), d6-DMSO (1H, 2.50 ppm, 13C, 39.51 ppm) and D2O 
(1H, 4.79 ppm) obtained from Cambridge Isotope Labs.  Mass spectra were obtained on 
Fisions VG Autospec using a high/low resolution magnetic sector.       
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7.2 Experimental Procedures 










Indole 118 (4.0 g, 34.14 mmol) was dissolved in DMF (113 mL) and cooled to 0ºC.  N-
Chlorosuccinimide (4.56 g, 34.14 mmol) was added and the reaction stirred at room 
temperature for 20 hours.  The mixture was quenched with 150 mL brine and extracted 
with diethyl ether (3 x 125 mL).  The combined organic layer was washed 5 times with 
100 mL water, dried over Na2SO4 and concentrated under vacuum.  The crude material 
was purified via flash column chromatography with 4:1 hexanes-ethyl acetate.  Yield: 
4.61 g, 30.38 mmol, 89% 
 
1H NMR (300 MHz, CDCl3) % 8.05 (bs, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.7 
Hz, 1H), 7.29-7.18 (m, 3H); 13C NMR (75 MHz, CDCl3) % 135.1, 125.6, 123.3, 121.0, 




























A 1.0 M solution of 9-BBN in THF (130 mL, 65.1 mmol) was cooled to 0ºC.  Allene 120 
(7.53 mL, 76.0 mmol) was added to the solution and the reaction was capped with a 
yellow cap and wrapped in parafilm.  The reaction stirred at room temperature for 15 
hours.  Indole 119 (3.29 g, 21.7 mmol) was dissolved in THF (72 mL) and NEt3 (10.6 
mL, 76.0 mmol) and the mixture stirred at room temperature for 20 minutes.  The prenyl-
9-BBN solution was added to the indole solution and the reaction stirred for 6 hours at 
room temperature.  The reaction was concentrated and immediately purified via flash 
column chromatography 9:1 hexanes-ethyl acetate.  Yield:  2.30 g, 12.4 mmol, 57% 
 
1H NMR (300 MHz, CDCl3) % 8.00 (bs, 1H), 7.77-7.74 (m, 1H), 7.44-7.41 (m, 1H), 7.34-
7.27 (m, 2H), 6.50 (dd, J = 2.1, 0.9 Hz, 1H), 6.20 (dd, J = 17.7, 10.5 Hz, 1H), 5.30 
(1/2ABq, J = 3.6 Hz, 1H), 5.25 (1/2ABq, J = 3.6 Hz, 1H), 1.64 (s, 6H); 13C NMR (75 
MHz, CDCl3) % 146.4, 236.3, 128.9, 121.7, 120.5, 120.0, 112.6, 110.9, 98.4, 38.6, 32.4, 
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To a solution of glacial acetic acid (10 mL) in 37% aqueous formaldehyde (450 mL, 5.49 
mmol), 40% aqueous dimethylamine (2.32 mL, 5.49 mmol) was added.  A solution of 
reverse prenylated indole (900 mg, 4.86 mmol) in 5 mL of glacial acetic acid was slowly 
added.  The reaction stirred at room temperature for 16 hours.  The reaction mixture was 
diluted with 1N NaOH until pH>10.  The aqueous layer was extracted with diethyl ether 
(3 x 30 mL) and the combined organic layers were dried over Na2SO4 and concentrated.   
Crude yield:  1.14 g, 4.72 mmol, 97%. 
 
1H NMR (300 MHz, CDCl3) % 8.29 (bs, 1H), 7.77-7.74 (m, 1H), 7.34-7.31 (m, 1H), 7.21-
7.12 (m, 2H), 6.23 (dd, J = 17.7, 10.8 Hz, 1H), 5.24 (dd, J = 9.6, 1.2 Hz, 1H), 5.24 (q, J = 
1.5, 1.2 Hz, 1H), 3.74 (s, 2H), 2.33 (s, 6H), 1.62 (s, 6H); 13C NMR (75 MHz, CDCl3) 
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Glycine ethyl ester (770 mg, 5.52 mmol) and benzophenone imine (1.0 g, 5.52 mmol) 
were dissolved in 20 mL of DCM and stirred at room temperature for 24 hours.  The 
reaction mixture was filtered through celite to remove NH4Cl and the filtrate concentrated 
under vacuum.  The residue was dissolved in 20 mL of diethyl ether and washed with 
H2O (30 mL).  The ether was dried over MgSO4 and concentrated.  The product was 
recrystallized in ethyl acetate and hexanes and collected as a white solid.  Yield:  1.41 g, 
5.30 mmol, 96%. 
 
1H NMR (300 MHz, CDCl3) % 7.68-7.65 (m, 2H), 7.29-7.29 (m, 6H), 7.19-7.16 (m, 2H), 
4.21 (s, 2H), 4.20 (q, J = 14.1, 7.2 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 




























The gramine (1.14 g, 4.72 mmol), glycine benzophenone imine (1.15 g, 4.30 mmol) and 
nBu3P (0.42 mL, 1.72 mmol) were dissolved in MeCN (21.5 mL) in a large microwave 
reaction flask.  The mixture was heated to 130°C for 30 minutes.  The reaction mixture 
was concentrated and purified via flash column chromatography in 9:1 hexanes:ethyl 
acetate to provide 123.  Yield:  1.96 g, 4.21 mmol, 98%. 
 
1H NMR (300 MHz, CDCl3) % 7.98 (bs, 1H), 7.89-7.85 (m, 1H), 7.65-7.62 (m, 2H), 7.54-
7.46 (m, 2H), 7.37-7.23 (m, 5H), 7.14-7.05 (m, 3H), 6.93-6.87 (m, 1H), 6.38 (bs, 1H), 
5.93 (dd, J = 17.4, 10.5 Hz, 1H), 5.13-5.03 (m, 2H), 4.55 (dd, J = 7.2, 6.0 Hz, 1H), 4.30-
4.19 (m, 2H), 3.62 (d, J = 6.0 Hz, 2H), 1.43 (s, 3H), 1.40 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) % 172.8, 170.1, 146.4, 140.2, 139.5, 136.2, 134.2, 132.8, 
130.4, 130.3, 129.1, 128.6, 128.1, 128.0, 127.4, 121.4, 119.7, 119.2, 111.9, 110.2, 107.5, 
67.0, 61.1, 39.3, 29.1, 27.9, 14.5; IR (neat) 3405, 3057, 2972, 1621, 1575, 1462, 1185, 





































The imine (122 mg, 0.263 mmol) was dissolved in 2 mL of THF and 1N HCl (0.6 mL) 
and the reaction stirred for 30 minutes.  The THF was removed under vacuum and the 
residue with rediluted with NaHCO3 until basic.  The aqueous layer was extracted with 
DCM and the combined organic layers were dried over Na2SO4 and concentrated.  The 
crude material was purified via flash column chromatography in 3:1 hexanes:ethyl 
acetate and then flushed with 5% MeOH in DCM to obtain pure 127.  Yield:  55 mg, 
0.183 mmol, 70%. 
 
1H NMR (300 MHz, CDCl3) % 8.87 (bs, 1H) 7.53 (d, J = 7.2 Hz, 1H), 7.27 (d, J = 7.2 Hz, 
1H), 7.12-7.04 (m, 2H), 6.12 (dd, J = 17.4, 10.5 Hz, 1H), 5.14 (m, 9.3 Hz, 1H), 5.10 (d, J 
= 1.8 Hz, 1H), 4.16-4.06 (m, 2H), 3.84 (d, J = 9.6, 5.1 Hz, 1H), 3.31 (d, J = 5.1 Hz, 1H), 
3.06 (dd, J = 14.4, 9.6 Hz, 1H), 1.53 (s, 3H), 1.525 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) % 175.6, 146.3, 141.1, 134.8, 129.8, 121.5, 119.4, 118.5, 112.0, 
110.9, 106.4, 61.2, 56.0, 50.1, 39.4, 31.5, 28.1, 28.1, 14.2; IR (neat) 3399, 3243, 3081, 
2973, 1733, 1638, 1580, 1462, 1195; HRMS (ESI/APCI) calcd for C18H25N2O2 (M+H) 
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The amine (55 mg, 0.183 mmol) was dissolved in 1 mL of dioxane and cooled to 0°C.  
Di-tert-butyldicarbonate (43.9 mg, 0.201 mmol) and aqueous 0.5 M NaOH (36.6µL) 
were added to the solution.  The reaction mixture was allowed to warm to room 
temperature while stirring for 2 hours.  The solvent was removed in vacuo and the 
remaining residue was taken up in H2O and acidified with 10% KHSO4to pH 2.  The 
product was extracted with ethyl acetate (3 x 10 mL) and the combined organic layer was 
washed with brine, dried over Na2SO4 and concentrated.  The residue was purified via 
flash column chromatography in 4:1 hexanes:ethyl acetate.  Yield:  70 mg, 0.175 mmol, 
96%. 
 
1H NMR (300 MHz, CDCl3) % 8.37 (bs, 1H) 7.52 (d, J = 7.2 Hz, 1H), 7.26 (d, J = 6.6 Hz, 
1H), 7.14-7.05 (m, 2H), 6.15 (dd, J = 17.4, 10.5 Hz, 1H), 5.22-5.25 (m, 2H), 4.14-3.95 
(m, 2H), 3.38-3.21 (m, 2H), 1.56 (s, 9H), 1.36 (s, 6H), 1.03 (t, J = 6.9 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) % 173.4, 155.4, 146.3, 140.8, 134.6, 129.9, 121.6, 119.5, 118.4, 112.3, 
110.7, 105.9, 79.8, 67.3, 61.4, 55.0, 39.4, 28.7, 28.5, 28.1, 27.9, 27.6, 14.0; IR (neat) 
3378, 3083, 3057, 2976, 1697, 1503, 1462, 1167; HRMS (ESI/APCI) calcd for 
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The ester (75 mg, 0.188 mmol) was dissolved in 1.2 mL of THF and 0.7 mL of H2O.  To 
the solution, LiOH (23 mg, 0.95 mmol) was added and the reaction stirred at room 
temperature for 18 hours.  The solvent was removed under vacuum and the resulting 
slurry was acidified with 1M KHSO4 to pH 2.  The product was extracted with DCM (3 x 
25 mL) and EtOAc (15 mL).  The combined organic layers were dried over Na2SO4 and 
concentrated.  Crude yield:  48.8 mg, 0.131 mmol, 70%. 
 
1H NMR (300 MHz, CDCl3) % 7.99-7.94 (m, 1H), 7.64-7.56 (m, 1H), 7.29-7.26 (m, 1H), 
7.15-7.08 (m, 2H), 6.15 (dd, J = 17.4, 10.5 Hz, 1H), 5.22 (d, J = 8.1 Hz, 1H), 5.18 (s, 
1H), 4.67-4.58 (m, 2H), 3.48-3.41 (m, 1H), 3.26-3.28 (m, 1H), 1.57 (s, 9H), 1.31 (s, 6H); 
13C NMR (100 MHz, 20:1 CDCl3/CD3OD) % 175.2, 155.6, 146.3, 140.8, 134.4, 129.8, 
121.4, 119.4, 118.5, 112.1, 110.5, 105.9, 79.8, 60.7, 54.7, 39.3, 28.3, 27.8, 21.1, 14.3; IR 
(neat) 3368, 3087, 3053, 2974, 1712, 1502, 1460, 1164; HRMS (ESI/APCI) calcd for 
























124 129 130  
Glycine ethyl ester (20 g, 143.3 mmol) was dissolved in 286 mL of ethanol.  Ethyl 
acrylate (17.0 mL, 157.6 mmol) and triethylamine (20.3 mL, 146.2 mmol) were added 
and the reaction stirred at room temperature for 48 hours.  The solvent was removed in 
vacuo.  Crude yield:  25.6 g, 126.1 mmol, 88%. 
 
1H NMR (300 MHz, CDCl3) % 4.22-4.07 (m, 4H), 3.41 (s, 1H), 2.89 (t, J = 6.6 Hz, 1H), 

















The amine (31.4 g, 155 mmol) was dissolved in 50 mL of dioxane and cooled to 0°C. Di-
tert-butyldicarbonate (37.2 g, 170 mmol), 155 mL of 1M NaOH and 155 mL of water 
were added to the solution.  The reaction mixture stirred for 18 hours at room 
temperature.  Brine (100 mL) was added to the reaction and product was extracted with 
DCM (3 x 200 mL).  The combined organic layer was dried over Na2SO4 and 
concentrated in vacuo.  The crude material was purified by vacuum distillation and with 
the product distilling at 131°C.  Yield:  29.8 g, 98.2 mmol, 64%. 
 
1H NMR (300 MHz, CDCl3) % 4.19-4.09 (m, 4H), 3.97 (d, J = 19.8 Hz, 2H), 3.57-3.49 





















 A 1M solution of lithium bis(trimethylsilyl)amide in THF (3.5 mL, 3.3 mmol) was 
cooled to -78°C and 10 mL of THF was added.  The ester (500 mg, 1.65 mmol) was 
diluted with 5 mL of THF and the solution was added dropwise to the reaction mixture, 
which stirred for 4 hours at -78°C.  The reaction was quenched with 1M HCl (20 mL) 
and the product was extracted with diethyl ether (3 x 25 mL).  The combined organic 
layer was dried over Na2SO4, concentrated, and purified via flash column 
chromatography in 3:2 hexanes:ethyl acetate.  Yield: 300 mg, 1.17 mmol, 71%. 
 
1H NMR (300 MHz, CDCl3) % 4.27-4.20 (m, 2H), 3.93-3.76 (m, 2H), 2.69 (t, J = 7.2 Hz, 






























132 114  
The ketoproline (300 mg, 1.17 mmol) was diluted with 6 mL of toluene and cooled to 
0°C.  A 2M solution of trimethylaluminum (1.17 mL, 2.34 mmol) was slowly added and 
the reaction mixture stirred at 0°C for 3 hours.  The reaction was quenched with ice cold 
10% aqueous KHSO4 and extracted with diethyl ether (3 x 15 mL).  The organic layer 
was dried over MgSO4, concentrated, and purified via flash column chromatography in 
3:2 hexanes/ethyl acetate.  Yield: 200 mg, 0.732 mmol, 63%. 
 
1H NMR (300 MHz, CDCl3) % 4.17-4.19 (m, 2H), 4.05 (d, J = 22.2 Hz, 1H), 3.65-3.42 
(m, 2H), 2.30 (d, J = 24.3 Hz, 1H), 2.12-2.02 (m, 1H), 1.92-1.83 (m, 1H), 1.48 (s, 3H), 






















The proline (250 mg, 0.915 mmol) was stirred with TFA (1.5 mL) in 1.5 mL of DCM at 
0°C.  The reaction mixture warmed to room temperature and stirred for an additional 3 


























The indole (340 mg, 0.913 mmol) and crude proline 133 were dissolved in 10 mL of 
MeCN.  HATU (521 mg, 1.37 mmol) and iPr2NEt (0.636 mL, 3.65 mmol) were added 
and the reaction stirred for 4 hours at room temperature.  The reaction was quenched with 
1M HCl (20 mL) and extracted with DCM (3 x 50 mL).  The combined organic layer was 
dried over Na2SO4, concentrated and purified by flash column chromatography in 1:1 
hexanes/ethyl acetate.  Yield: 480 mg, 0.909 mmol, 99% 
 163 
 
1H NMR (300 MHz, CDCl3) % 7.95 (bs, 1H), 7.49 (dd, J = 21, 8.1 Hz, 1H), 7.36-7.22 (m, 
1H), 7.15-7.05 (m, 2H), 6.13 (dd, J = 17.7, 10.8 Hz, 1H), 5.62-5.55 (m, 1H), 5.28-5.18 
(m, 2H), 4.29-4.15 (m, 2H), 3.14-3.07 (m, 4H), 1.65-1.62 (m, 6H), 1.45 (s, 9H), 1.27 (t, J 









































The peptide (480 mg, 0.909 mmol) was dissolved in 1.52 mL of DCM and cooled to 0°C.  
To the solution, TFA (1.52 mL) was slowly added and the reaction warmed to room 
temperature while stirring for 3 hours.  The reaction was quenched with 5 mL of 
saturated aqueous NaHCO3 and the organic layer was separated from the aqueous phase.  
The aqueous layer was extracted with ethyl acetate (3 x 20 mL).  The combined organic 
layer was dried over Na2SO4 and concentrated.  Crude yield: 320 mg, 0.748 mmol, 83%. 
The crude free amine (320 mg, 0.748 mmol) was dissolved in 4 mL of toluene.  To the 
solution, 2-hydroxypyridine (14.2 mg, 0.149 mmol) was added and the reaction mixture 
stirred at reflux for 16 hours.  The reaction cooled to room temperature and the solvent 
was removed under vacuum.  The residue was dissolved in DCM (20 mL) and washed 
with 1M HCl (2 x 20 mL).  The organic layer was dried over Na2SO4 and concentrated. 
Crude yield: 233 mg, 0.611 mmol, 81% 
 
1H NMR (300 MHz, CDCl3) % 8.02 (bs, 1H), 7.54-7.47 (m, 1), 7.35-7.29 (m, 1H), 7.19-
7.08 (m, 2H), 6.13 (dd, J = 17.4, 10.2 Hz, 1H), 6.06 (bs, 1H),5.23-5.15 (m, 1H), 4.31-
4.23 (m, 1H), 3.79-3.68 (m, 2H), 3.57-3.50 (m, 2H), 3.31-3.13 (m, 2H), 2.21-1.86 (m, 











































The alcohol (227 mg, 0.595 mmol) was dissolved in 2.5 mL of THF and cooled to 0°C.  
Pyridine (96.2 µL, 1.19 mmol) was added and the solution stirred for 15 minutes.  
Thionyl chloride (48 µL, 0.654 mmol) was added and the reaction stirred at room 
temperature for 4 hours.  Water (10 mL) was added to the reaction mixture and the 
product was extracted with ethyl acetate (3 x 20 mL).  The organic layer was dried over 
Na2SO4, concentrated, and filtered through a silica plug with 5% MeOH in DCM.  Yield: 
195 mg, 0.534 mmol, 90%. 
 
1H NMR (300 MHz, CDCl3) % 8.03 (bs, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.34-7.31 (m, 1H), 
7.19-7.09 (m, 2H), 6.12 (dd, J = 17.4, 10.8 Hz, 1H), 5.63-5.56 (m, 1H), 5.20-5.14 (m, 
2H), 4.46 (d, J = 13.8 Hz, 1H), 3.90-3.89 (m, 2H), 3.71 (dd, J = 14.4, 3.3 Hz, 1H), 3.20 
(dd, J = 15.0, 11.4 Hz, 1H), 2.72-2.65 (m, 2H), 2.19 (s, 3H), 1.55 (s, 6H); IR (neat) 3344, 









































The enamide (195 mg, 0.534 mmol) was dissolved in 9 mL of DCM.  Trimethyloxonium 
tetrafluoroborate (236 mg, 1.60 mmol) and Cs2CO3 (3.48 g, 10.68 mmol)  were added to 
the solution and the reaction mixture stirred at room temperature for 24 hours.  The 
reaction was poured into ice water (20 mL) and extracted with DCM (3 x 35 mL).  The 
organic layer was washed with brine (50 mL), dried over Na2SO4 and concentrated.  The 
crude product was purified via flash column chromatography in 3:2 hexanes/ethyl 
acetate.  Yield: 68 mg, 0.180 mmol, 34%. 
 
1H NMR (300 MHz, CDCl3) % 7.86 (bs, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 8.1 
Hz, 1H), 7.12-7.00 (m, 2H), 6.15 (dd, J = 17.7, 10.5 Hz, 1H), 5.17 (dd, J = 17.4, 1.2 Hz, 
1H), 5.13 (dd, J = 10.5, 1.2 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 3.84-3.74 (m, 3H), 3.66 
(m, 3H), 3.07 (dd, J = 14.4, 9.3 Hz, 1H), 2.56-2.50 (m, 2H), 1.98 (s, 3H), 1.61 (s, 3H), 

































Glycine ethyl ester (3.87 g, 21.35 mmol) and benzophenone imine (3.0 g, 21.35 mmol) 
were dissolved in 71 mL of DCM and stirred at room temperature for 24 hours.  The 
reaction mixture was filtered through celite to remove NH4Cl and the filtrate concentrated 
under vacuum.  The residue was dissolved in 100 mL of diethyl ether and washed with 
H2O (100 mL).  The ether was dried over MgSO4 and concentrated.  The product was 
recrystallized in ethyl acetate and hexanes and collected as a white solid.  Yield: 5.49 g, 
20.46 mmol, 96%. 
 
1H NMR (300 MHz, CDCl3) % 7.56-7.12 (m, 10H), 4.20-4.10 (m, 4H), 1.21 (t, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) % 170.7, 139.5, 136.2, 132.6, 130.7, 130.2, 129.04, 





































The gramine (1.65 g, 6.81 mmol), [13C]-glycine benzophenone imine (1.66 g, 6.19 mmol) 
and nBu3P (0.61 mL, 2.48 mmol) were dissolved in MeCN (34.0 mL) and heated to reflux 
for 18 hours. The reaction mixture was concentrated and purified via flash column 
chromatography in 9:1 hexanes:ethyl acetate to provide 140.  Yield:  3.11 g, 6.68 mmol, 
98%.  
 
1H NMR (300 MHz, CDCl3) % 7.89 (bs, 1H), 7.60-7.57 (m, 2H), 7.47-7.19 (m, 8H), 7.09-
7.01 (m, 3H), 6.87-6.82 (m, 1H), 6.33 (bs, 1H), 5.89 (dd, J = 17.4, 10.5 Hz, 1H), 5.09-
4.99 (m, 2H), 4.25-4.11 (m, 2H), 3.58 (d, J = 2.4 Hz, 1H), 3.55 (bs, 1H), 1.39 (s, 3H), 
1.36 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) % 172.7, 170.9, 146.3, 
140.1, 139.5, 136.2, 134.1, 130.2, 129.1, 128.0, 127.9, 127.8, 121.4, 119.6, 119.1, 111.8, 
110.0, 107.6, 107.5, 67.3, 66.5, 61.0, 39.3, 31.8, 29.0, 18.4, 18.3, 17.9, 17.8, 24.8, 22.9, 










































The [13C]-imine (3.11 mg, 6.68 mmol) was dissolved in 50 mL of THF and 1N HCl (16.7 
mL) and the reaction stirred for 30 minutes.  The THF was removed under vacuum and 
the residue with diluted with NaHCO3 until basic.  The aqueous layer was extracted with 
DCM (2 x 100 mL) and the combined organic layers were dried over Na2SO4 and 
concentrated.  The crude material was purified via flash column chromatography in 3:1 
hexanes:ethyl acetate and then flushed with 5% MeOH in DCM.  The [13C]-amine (790 
mg, 2.62 mmol) was dissolved in 13 mL of dioxane and cooled to 0°C.  Di-tert-
butyldicarbonate (600 mg, 2.75 mmol) and aqueous 0.5 M NaOH (2.6 mL) were added to 
the solution.  The reaction mixture was allowed to warm to room temperature while 
stirring for 2 hours.  The solvent was removed in vacuo and the remaining residue was 
taken up in H2O and acidified with 10% KHSO4to pH 2.  The product was extracted with 
ethyl acetate (3 x 40 mL) and the combined organic layer was washed with brine, dried 
over Na2SO4 and concentrated.  The residue was purified via flash column 
chromatography in 4:1 hexanes:ethyl acetate.  Yield:  1.29 mg, 3.21 mmol, 48% (2 steps). 
 175 
[13C]-2-((tert-butoxycarbonyl)amino)-3-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-

















The [13C]-ester (1.05 g, 2.62 mmol) was dissolved in 8.73 mL of THF and 17.5 mL of 
H2O.  To the solution, LiOH (1.09 g, 26.2 mmol) was added and the reaction stirred at 
room temperature for 18 hours.  The solvent was removed under vacuum and the 
resulting slurry was acidified with 1M KHSO4 to pH 2.  The product was extracted with 
DCM (3 x  40 mL) and EtOAc (40 mL).  The combined organic layers were dried over 
Na2SO4 and concentrated.  Crude yield:  780 mg, 2.09 mmol, 80%. 
 
 1H NMR (300 MHz, CDCl3) % 7.95 (bs, 1H), 7.57 (d, J = 10.2 Hz, 1H), 7.29 (d, J = 8.4 
Hz, 1H), 7.16-7.06 (m, 2H), 6.15 (dd, J = 17.1, 10.5 Hz, 1H), 5.22 (d, J = 7.2 Hz, 1H), 
5.17 (s, 1H), 4.60 (bs, 1H), 3.46-3.39 (m, 1H), 3.27-3.15 (m, 1H), 1.57 (s, 3H), 1.56 (s, 
















































The [13C]-indole (600 mg, 1.61 mmol) and [13C]-proline (280 mg, 1.61 mmol) were 
dissolved in 16 mL of MeCN.  HATU (916 mg, 2.41 mmol) and iPr2NEt (1.12 mL, 6.44 
mmol) were added and the reaction stirred for 4 hours at room temperature.  The reaction 
was quenched with 1M HCl (30 mL) and extracted with DCM (3 x 50 mL).  The 
combined organic layer was dried over Na2SO4, concentrated and purified by flash 
column chromatography in 1:1 hexanes/ethyl acetate.  Yield: 545 mg, 1.03 mmol, 64%. 
 
1H NMR (300 MHz, CDCl3) % 8.00 (bs, 1H), 7.59 (d, J = 9.0 Hz, 1H), 7.28 (d, J = 8.1 
Hz, 1H), 7.15-7.04 (m, 2H), 6.14 (dd, J = 17.1, 10.5 Hz, 1H), 5.19 (d, J = 7.5 Hz, 2H), 
5.14 (s, 1H), 4.17-4.05 (m, 2H), 3.85 (dd, J = 9.6, 4.8 Hz, 1H), 3.33 (dd, J = 14.1, 4.8 Hz, 














































The [13C2]-peptide (900 mg, 1.69 mmol) was dissolved in 2.8 mL of DCM and cooled to 
0°C.  To the solution, TFA (2.8 mL) was slowly added and the reaction warmed to room 
temperature while stirring for 3 hours.  The reaction was quenched with saturated 
aqueous NaHCO3 to pH 9 and the organic layer was separated from the aqueous phase.  
The aqueous layer was extracted with ethyl acetate (3 x 60 mL).  The combined organic 
layer was dried over Na2SO4 and concentrated.  Crude yield: 730 mg, 1.69 mmol. 
The crude [13C2]-free amine (790 mg, 1.69 mmol) was dissolved in 8.5 mL of toluene.  
To the solution, 2-hydroxypyridine (32 mg, 0.338 mmol) was added and the reaction 
mixture stirred at reflux for 16 hours.  The reaction cooled to room temperature and the 
solvent was removed under vacuum.  The residue was dissolved in DCM (40 mL) and 
washed with 1M HCl (2 x 40 mL).  The organic layer was dried over Na2SO4 and 
concentrated. Crude yield: 498 mg, 1.3 mmol, 77%.  
 
Mixture of diastereomers: 1H NMR (300 MHz, CDCl3) % 8.02 (bs, 1H), 7.55-7.47 (m, 
1H), 7.35-7.29 (m, 1H), 7.18-7.08 (m, 2H), 6.13 (dd, J = 17.1, 10.2 Hz, 1H), 5.23-5.15 
(m, 2H), 4.31-4.23 (m, 1H), 3.78-3.70 (m, 1H), 3.58-3.44 (m, 2H), 3.30-3.13 (m, 1H), 





























To a solution of glacial acetic acid (1.6 mL) in 37% aqueous formaldehyde (78.6 µL, 
0.968 mmol), 40% aqueous dimethylamine (0.410 mL, 3.64 mmol) was added.  A 
solution of 7-benzyloxyindole (200 mg, 0.857 mmol) in 1 mL of glacial acetic acid was 
slowly added.  The reaction stirred at room temperature for 16 hours.  The reaction 
mixture was diluted with 1N NaOH until pH>10.  The aqueous layer was extracted with 
diethyl ether (3 x 30 mL) and the combined organic layers were dried over Na2SO4 and 
concentrated.  Crude yield:  225 mg, 0.806 mmol, 94%. 
 
1H-NMR (300 MHz, CDCl3) % 8.39 (bs, 1H), 7.50-7.31 (m, 6H), 7.11 (d, J = 2.4 Hz, 1H), 





















To a solution of glacial acetic acid (1.6 mL) in 37% aqueous formaldehyde (78.6 µL, 
0.968 mmol), 40% aqueous dimethylamine (0.410 mL, 3.64 mmol) was added.  A 
solution of 7-benzyloxyindole (200 mg, 0.857 mmol) in 1 mL of glacial acetic acid was 
slowly added.  The reaction stirred at room temperature for 16 hours.  The reaction 
mixture was diluted with 1N NaOH until pH>10.  The aqueous layer was extracted with 
diethyl ether (3 x 30 mL) and the combined organic layers were dried over Na2SO4 and 
concentrated.  Crude yield:  218 mg, 0.780 mmol, 91%. 
 
1H-NMR (300 MHz, CDCl3) % 7.96 (bs, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.48-7.31 (m, 5H), 







































The gramine (115 mg, 0.411 mmol), glycine benzophenone imine (100 mg, 0.347 mmol) 
and nBu3P (37 µL, 0.15 mmol) were dissolved in MeCN (1.87 mL) in a large microwave 
reaction flask.  The mixture was heated to 130°C for 30 minutes.  The reaction mixture 






























The gramine (115 mg, 0.411 mmol), glycine benzophenone imine (100 mg, 0.347 mmol) 
and nBu3P (37 µL, 0.15 mmol) were dissolved in MeCN (1.87 mL) in a large microwave 
reaction flask.  The mixture was heated to 130°C for 30 minutes.  The reaction mixture 
was concentrated and used without further purification.  Crude yield:  206 mg, 0.411 
mmol. 
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The imine (206 mg, 0.411 mmol) was dissolved in 3 mL of THF and 1N HCl (1 mL) and 
the reaction stirred for 30 minutes.  The THF was removed under vacuum and the residue 
with diluted with NaHCO3 until basic.  The aqueous layer was extracted with DCM and 
the combined organic layers were dried over Na2SO4 and concentrated.  The crude 
material was purified via flash column chromatography in 3:1 hexanes:ethyl acetate and 
then flushed with 5% MeOH in DCM to obtain pure 175.  Yield:  89.6 mg, 0.265 mmol, 
76%. 
 
1H-NMR (300 MHz, CDCl3) % 8.40 (bs, 1H), 7.49-7.35 (m, 5H), 7.25 (d, J = 7.5 Hz, 1H), 
7.02 (t, J = 7.8 Hz, 2H), 6.72 (d, J = 7.8 Hz, 1H), 5.19 (s, 2H), 4.16 (q, J = 7.2, 6.9 Hz, 



























174 176  
The imine (206 mg, 0.411 mmol) was dissolved in 3 mL of THF and 1N HCl (1 mL) and 
the reaction stirred for 30 minutes.  The THF was removed under vacuum and the residue 
with diluted with NaHCO3 until basic.  The aqueous layer was extracted with DCM and 
the combined organic layers were dried over Na2SO4 and concentrated.  The crude 
material was purified via flash column chromatography in 3:1 hexanes:ethyl acetate and 
then flushed with 5% MeOH in DCM to obtain pure 176.  Yield:  110 mg, 0.325 mmol, 
93%. 
 
1H-NMR (300 MHz, CDCl3) % 8.02 (bs, 1H), 7.51-7.32 (m, 6H), 6.96-6.87 (m, 3H), 5.10 
(s, 2H), 4.16 (q, J = 6.9, 7.2 Hz, 2H), 3.81-3.77 (m, 1H), 3.24 (dd, J = 14.4, 4.8 Hz, 1H), 





























175 177  
The amine (89.6 mg, 0.265 mmol) was dissolved in 1.33 mL of dioxane and cooled to 
0°C.  Di-tert-butyldicarbonate (63.7 mg, 0.292 mmol) and aqueous 0.5 M NaOH (53 µL) 
were added to the solution.  The reaction mixture was allowed to warm to room 
temperature while stirring for 2 hours.  The solvent was removed in vacuo and the 
remaining residue was taken up in H2O and acidified with 10% KHSO4to pH 2.  The 
product was extracted with ethyl acetate (3 x 20 mL) and the combined organic layer was 
washed with brine, dried over Na2SO4 and concentrated.  The crude material was taken 
on without further purification. Crude yield:  100 mg, 0.228 mmol, 86%. 
 
1H-NMR (300 MHz, CDCl3) % 8.42 (bs, 1H), 7.49-7.35 (m, 5H), 7.19 (d, J = 8.1 Hz, 1H), 
7.02 (t, J = 8.1 Hz, 1H), 6.96 (m, 1H), 6.71 (d, J = 7.5 Hz, 1H), 5.19 (s, 2H), 5.10 (d, J = 
8.1 Hz, 1H), 4.65-4.59 (m, 1H), 4.12 (q, J  = 7.2, 6.9 Hz, 2H), 3.27 (d, J = 5.4 Hz, 2H), 


























176 178  
The amine (110 mg, 0.325 mmol) was dissolved in 1.63 mL of dioxane and cooled to 
0°C.  Di-tert-butyldicarbonate (78.1 mg, 0.358 mmol) and aqueous 0.5 M NaOH (65 µL) 
were added to the solution.  The reaction mixture was allowed to warm to room 
temperature while stirring for 2 hours.  The solvent was removed in vacuo and the 
remaining residue was taken up in H2O and acidified with 10% KHSO4to pH 2.  The 
product was extracted with ethyl acetate (3 x 20 mL) and the combined organic layer was 
washed with brine, dried over Na2SO4 and concentrated.  Crude yield:  140 mg, 0.319 
mmol, 98%. 
 
1H-NMR (300 MHz, CDCl3) % 7.96 (bs, 1H), 7.47-7.31 (m, 6H), 6.89-6.85 (m, 3H), 5.09 
(s, 2H), 4.62-4.56 (m, 1H), 4.11 (q, J = 7.2, 7.2 Hz, 2H), 3.24 (d, J = 5.4 Hz, 2H), 1.42 (s, 

























177 162  
The ester (100 mg, 0.228 mmol) was dissolved in 6 mL of THF and 3 mL of H2O.  To the 
solution, LiOH (27 mg, 1.14 mmol) was added and the reaction stirred at room 
temperature for 18 hours.  The solvent was removed under vacuum and the resulting 
slurry was acidified with 1M KHSO4 to pH 2.  The product was extracted with DCM (3 x 
35 mL) and EtOAc (35 mL).  The combined organic layers were dried over Na2SO4 and 
concentrated.  Crude yield:  81 mg, 0.198 mmol, 87%. 
 
1H-NMR (300 MHz, CDCl3) % 11.18 (bs, 1H), 8.44 (bs, 1H), 7.46-7.37 (m, 5H), 7.24 (d, 
J = 10.5 Hz, 1H), 7.02-6.87 (m, 2H), 6.69 (d, J = 7.5 Hz, 1H), 5.16 (s, 2H), 4.66 (m, 1H), 





























178 163  
The ester (140 mg, 0.319 mmol) was dissolved in 8 mL of THF and 4 mL of H2O.  To the 
solution, LiOH (38 mg, 1.60 mmol) was added and the reaction stirred at room 
temperature for 18 hours.  The solvent was removed under vacuum and the resulting 
slurry was acidified with 1M KHSO4 to pH 2.  The product was extracted with DCM (3 x 
35 mL) and EtOAc (35 mL).  The combined organic layers were dried over Na2SO4 and 
concentrated.  Crude yield:  116 mg, 0.283 mmol, 89%. 
 
1H-NMR (300 MHz, CDCl3) % 10.18 (bs, 1H), 8.23 (bs, 1H), 7.48-7.26 (m, 6H), 6.83 (d, 
J = 9.0 Hz, 3H), 5.12 (d, J = 7.5 Hz, 1H), 5.04 (s, 2H), 4.65 (m, 1H), 4.3.34-3.19 (m, 1H), 

























To a stirred solution of R-(+)-$-Methyl-benzylamine (5.00 g, 41.3 mmol) in dry DMF 
(50 mL) was added K2CO3 (18.8 g, 136 mmol) and NaI (20.4 g, 136 mmol) at room 
temperature under argon.  To this solution, 4-bromo-1-butene (5.05 g, 37.6 mmol) was 
added and the reaction mixture stirred at 100oC for 22 hours.  The reaction mixture was 
cooled to room temperature, diluted with diethyl ether (100 mL) and water (100 mL).  
The phases were separated and the aqueous layer was extracted twice with diethyl ether 
(50 mL) and once with methylene chloride (50 mL).  The combined organic phases were 
dried over anhydrous Na2SO4 and concentrated.  The crude oil was purified via flash 
column chromatography (hexane/diethyl ether: 90:10) to yield 181 as a clear yellow oil.  
Yield: 4.0 g, 22.8 mmol, 61%. 
 
1H-NMR (CDCl3, 300 MHz) % 1.37 (d, J = 6.6 Hz, 3H), 2.24 (m, 2H), 2.55 (m, 2H), 3.78 
(q, J = 6.6 Hz, 1H), 5.03 (d, i = 10.3 Hz, 1H), 5.08 (d, J = 17.9, 1H), 5.76 (ddt, J = 6.6, 



















To a stirred solution of 181 (1.0 g, 5.70 mmol) in dry DMSO (6 mL) was slowly added 
ethyl bromoacetate (0.351 mL, 3.17 mmol); after 30 minutes of stirring, dry NEt3 (0.442 
mL, 3.17 mmol) was slowly added followed by a new addition of ethyl bromoacetate 
(0.351 mL, 3.17 mmol) and NEt3 (0.442 mL, 3.17 mmol).  The reaction mixture was 
heated to 65oC for 46 hours, cooled to room temperature, and diluted with diethyl ether 
(15 mL).  Water (15 mL) was added and the separated organic phase was washed with 
brine (15 mL).  The organic phase was dried over anhydrous Na2SO4 and concentrated 
under vacuum.  To crude oil was purified by heating the reaction flask to 60oC while 
under vacuum overnight, providing a clear yellow oil.  Yield: 864 mg, 3.3 mmol, 58%. 
 
 1H-NMR (CDCl3, 300 MHz) % 1.27 (t, J = 7.0 Hz, 3H), 1.36 (d, J = 6.6 Hz, 3H), 2.12-
2.30 (m, 2H), 2.60-2.78 (m, 2H), 3.30 (1/2ABq, J = 17.2 Hz, 1H) 3.45 (1/2ABq, i = 17.2 
Hz, 1H), 4.06 (q, J = 7.0 Hz, 1H), 4.15 (q, J = 7.3 Hz, 2H), 4.97 (dq, J = 1.2, 10.5 Hz, 
1H), 5.01 (dq, J = 1.8, 17.6 Hz, 1H), 5.76 (ddt, J = 6.6, 10.3, 17.2 Hz, 1H), 7.23 (t, J = 

















182 183  
To a solution of 182 (400 mg, 1.54 mmol) in dry diethyl ether (6 mL) was added a 
solution of freshly prepared LDA (1.8 M) at -78oC.  The temperature was raised to -20oC 
and then cooled back down to  -78oC.  Freshly prepared 1 M solution of anhydrous ZnBr2 
(1.21 g, 4.62 mmol) in 4 mL of dry diethyl ether was added dropwise.  The reaction 
mixture was removed from the ice bath and warmed to room temperature overnight.  The 
reaction mixture was quenched with saturated aqueous NH4Cl (5 mL) and diluted with 
diethyl ether (5 mL).  The phases were separated and the aqueous layer was extracted 
twice with diethyl ether (2 x 15 mL).  The combined organic phases were dried over 
anhydrous Na2SO4 and concentrated under vacuum.  The crude oil was purified via flash 
column chromatography (hexane/diethyl ether, 70:30) to yield 183 as a clear yellow oil. 
Yield: 193 mg, 0.740 mmol, 48%. 
 
1H-NMR (CDCl3, 300 MHz) % 0.92 (d, J = 7.0 Hz, 3H), 1.21 (t, J = 7.3 Hz, 3H), 1.35 (d, 
J = 6.9 Hz, 3H), 1.52-1.70 (m, 1H), 1.88-2.02 (m, 1H), 2.32-2.50 (m, 1H) 2.78-2.90 (m, 
1H), 2.96-3.03 (m, 1H), 3.31 (d, J = 8.4 Hz, 1H), 3.62-3.76 (m, 1H), 4.09 (q, J = 7.0 Hz, 























Proline (50 mg, 0.194 mmol) was dissolved in 2 mL of THF and the solution was cooled 
to -78°C. A 1M solution of sodium bis(trimethylsilyl)amide in THF (1.52 mL, 0.388 
mmol) was added and the reaction stirred for 30 minutes.  To the cooled solution, allyl 
iodide (35.5 µL, 0.388 mmol) was added and the mixture warmed to room temperature 
while stirring for 20 hours.  The reaction was quenched with saturated aqueous NH4Cl 
and extracted with ethyl acetate (3 x 15 mL).  The combined organic layer was washed 
with brine, dried over Na2SO4 and concentrated.  The crude product was purified via 
flash column chromatography (hexanes/ethyl acetate, 95:5).  Yield:  14 mg, 0.049 mmol, 
25%.  
 
1H-NMR (300 MHz, CDCl3) % 5.73-5.59 (m, 1H), 5.13-5.07 (m, 2H), 4.23-4.04 (m, 2H), 
3.82-3.66 (m, 1H), 3.24-3.10 (m, 1H), 3.04-2.97 (m, 1H), 2.52-2.25 (m, 2H), 1.81-1.65 


















197 199  
Commercially available nitrophenol (1.0 g, 6.53 mmol) was dissolved in 6.5 mL of DMF.  
Benzyl chloride (0.826 mL, 7.18 mmol) and potassium carbonate (0.903 mg, 6.53 mmol) 
were added and the reaction mixture stirred for 4 hours at 100oC.  The reaction mixture 
cooled to room temperature and was poured into 15 ml of water and extracted with ethyl 
acetate (3 x 30 mL).  The organic layer was washed with 30 mL of each 1M sodium 
hydroxide, water, and brine, then dried over Na2SO4 and concentrated under vacuum.  
The residue was recrystallized from ethyl acetate and hexanes to afford the pure desired 
product.  Yield: 1.22 g, 5.03 mmol, 77%. 
 
1H-NMR (300 MHz, CDCl3) % 7.60 (d, J = 2.7 Hz, 1H), 7.44-7.33 (m, 5H), 7.23 (d, J = 
8.4 Hz, 1H), 7.12 (dd, J = 8.7, 2.7 Hz, 1H), 5.10 (s, 2H), 2.53 (s, 3H); HRMS (ESI/APCI) 



















199 201  
Compound 199 (1.06 g, 4.36 mmol) was dissolved in DMF-DMA (1.74 mL, 13.08 
mmol) and pyrrolidine (1.09 mL, 13.08 mmol).  The reaction mixture was heated to 
110oC and stirred for 19 hours.  The mixture was cooled to room temperature and ethanol 
was added.  The solution was filtered to afford red/black/gold crystals.  Yield: 1.33 g, 
4.10 mmol, 94%. 
 
1H-NMR (300 MHz, CDCl3) % 7.50 (d, J = 2.7 Hz, 1H), 7.44-7.34 (m, 6H), 7.10 (d, J = 
13.5 Hz, 1H), 7.06 (dd, J = 9.0, 2.7 Hz, 1H), 5.86 (d, J = 13.5 Hz, 1H), 5.04 (s, 2H), 3.31-
3.27 (m, 4H), 1.95-1.91 (m, 4H); 13C NMR (75 MHz, CDCl3) % 154.2, 144.4, 139.8, 
136.5, 130.3, 128.9, 128.4, 127.9, 122.5, 109.6, 91.7, 70.7, 49.4, 25.5; HRMS 




















201 202  
Formation of the Ni2B:  To a 0.5 M solution of ethanol (30 mL) and Ni(OAc)2 (3.68 g, 
14.8 mmol), NaBH4 (1.12 g, 29.6 mmol) was slowly added portionwise.  The reaction 
mixture stirred for one hour at room temperature.   
The enamine (2.18 g, 6.72 mmol) was dissolved in 6.7 mL of ethanol and hydrazine 
monohydrate (1.43 mL, 29.6 mmol) was added to the solution.  The reaction was heated 
to 80°C and stirred for 1 hour.  The mixture was cooled to room temperature and slowly 
added to the freshly prepared solution of Ni2B.  The mixture was heated to 50°C and 
stirred for an additional hour, after which the reaction cooled to room temperature and 
was filtered through a pad of celite.  The filtrate was concentrated under vacuum and the 
remaining residue was diluted with 100 mL of ethyl acetate.  The organic layer was 
washed with 1M HCl (150 mL), saturated aqueous NaHCO3 (150 mL), and brine (150 
mL).  The organic phase was dried over Na2SO4 and concentrated.  Crude yield: 1.14 g, 
5.11 mmol, 76%.  
 
1H-NMR (300 MHz, CDCl3) % 8.01 (bs, 1H), 7.54-7.32 (m, 6H), 7.10 (dd, J = 3.3, 2.4 















The 6-benzyloxyindole (1.14 g, 5.11 mmol) and 5% Pd/C (3 wt. %) were dissolved in 10 
mL of ethanol in a purged hydrogenation vessel.  To the reaction, 10 atm. of H2 was 
added and the reaction stirred for 3 hours.  The reaction mixture was purged with Ar and 
then filtered through a pad of celite, washing the catalyst with ethanol.  The filtrate was 
concentrated and taken on immediately to the next reaction. 
 
1H-NMR (300 MHz, CDCl3) % 7.28 (d, J = 9.0 Hz, 1H), 6.92 (d, J = 3.3 Hz, 1H), 6.71 
(m, 1H), 6.54 (dd, J = 8.4, 2.1 Hz, 1H), 6.26 (dd, J = 3.3, 0.9 Hz, 1H); 13C NMR (75 
MHz, CDCl3) % 152.8, 137.1, 131.0, 123.2, 121.1, 110.1, 101.9, 97.0; HRMS (ESI/APCI) 













Crude 6-hydroxyindole (780 mg, 5.85 mmol) was taken up in acetonitrile (150 mL) and 
cooled to 0°C.  Di-tert-butyl dicarbonate (895 mg, 4.09 mmol) and a catalytic amount of 
DMAP were added and the reaction mixture stirred for 16 hours at room temperature.  
The reaction was concentrated and purified via flash column chromatography in 95:5 
hexanes/ethyl acetate.  The product was collected as a white solid.  Yield: 960 mg, 4.11 
mmol, 70%. 
 
White crystalline solid (mp 141-143ºC).  1H-NMR (300 MHz, CDCl3) % 8.16 (bs, 1H), 
7.60 (d, J = 8.4 Hz, 1H), 7.21 (m, 1H), 7.18 (t, J = 5.7 Hz, 1H) 6.93 (dd, J = 8.7, 2.1 1H), 
6.52 (m, 1H), 1.58 (s, 9H); 13C NMR (75 MHz, CDCl3) % 153.0, 147.0, 135.7, 126.0, 
125.2, 121.2, 114.2, 104.0, 102.7, 83.5, 28.0; IR (neat) 3413, 2981, 1738, 1457, 1395, 


















The 6-OBoc indole (7.26 g, 31.1 mmol) was dissolved in 100 mL of DMF and cooled to 
0°C.  N-Chlorosuccinimide (4.16 g, 31.1 mmol) was slowly added to the reaction mixture 
in portions.  The solution stirred for 22 hours while warming to room temperature.  The 
reaction was quenched with brine (20 mL) and extracted with diethyl ether (3 x 35 mL).  
The combined organic layer was washed 5 times with 35 mL of water, dried over 
Na2SO4, and concentrated. The crude oil was purified via flash column chromatography 
85:15 hexanes/ethyl acetate to afford the 3-chloroindole as a white solid (mp 125-128OC).  
Yield: 6.91 g, 25.8 mmol,  83%. 
 
1H-NMR (300 MHz, CDCl3) % 8.18 (bs, 1 H), 7.55 (d, J = 8.7 Hz, 1H), 7.12 (d, J = 1.8 
Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H), 6.99 (dd, J = 8.1, 2.1 Hz, 1H)  1.58 (s, 9H);  13C NMR 
(75 MHz, CDCl3) % 153.0, 147.7, 134.8, 123.6, 122.0, 119.0, 114.8, 106.5, 104.6, 84.0, 



















A 0.5M solution of 9-BBN in THF (171 mL, 85.5 mmol) was cooled to 0°C and allene14 
(9.89 mL, 99.8 mmol) was slowly added.  The reaction mixture was capped with a yellow 
cap and wrapped in parafilm.  The reaction stirred for 16 hours.  Indole 103 (7.63 g, 28.5 
mmol) was dissolved in THF (95 mL) and triethylamine (12.9 mL, 92.6 mmol).  The 
reaction stirred for 20 minutes at room temperature and the solution of prenyl-9BBN was 
added via cannula.  The reaction stirred for 4 hours, then concentrated and immediately 
purified via silica gel column chromatography (5% ethyl acetate in hexanes).  The 
product was partitioned between hexanes and acetonitrile in order to remove the excess 
9-BBN.  The crude product was immediately taken on to the next step.  Yield: 4.15 g, 
12.8 mmol, 48%.  
 
1H-NMR (300 MHz, CDCl3) % 8.02 (bs, 1H), 7.46 (d, J = 8.7 Hz, 1H), 7.11 (d, J = 2.1 
Hz, 1H), 6.87 (dd, J = 8.7, 2.1 Hz, 1H), 6.26 (m, 1H), 5.99 (dd, J = 27.9, 10.2 Hz, 1H), 
5.10 (d, J = 0.6 Hz, 1H), 5.05 (dd, J = 5.7, 1.2 Hz, 1H), 1.56 (s, 9H), 1.44 (s, 6H). 13C 
NMR (75 MHz, CDCl3) % 153.0, 146.8, 146.5, 146.1, 135.8, 126.7, 120.5, 113.8, 112.5, 
























Aqueous formaldehyde (1.26 mL, 15.5 mmol) was diluted with glacial acetic acid (35 
mL).  Aqueous dimethylamine (6.5 mL, 58.5 mmol) was added, followed by addition of 
indole 205 (4.15 g, 13.7 mmol) diluted in glacial acetic acid (10 mL).  The reaction 
stirred at room temperature for 14 hours.  The reaction mixture was diluted with 1M 
NaOH to a pH>10.  The aqueous layer was extracted with diethyl ether (3 x 40 mL) and 
the combined organic layer was dried over Na2SO4 and concentrated to afford an amber 
oil that was taken on to the next reaction without further purification.  Crude yield: 4.14 
g, 13.02 mmol, 84%. 
1H-NMR (300 MHz, CDCl3) % 7.99 (bs, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.08 (d, J = 2.1 
Hz, 1H), 6.87 (dd, J = 8.4, 2.1 Hz, 1H), 6.12 (dd, J = 17.7, 11.1 Hz, 1H), 5.16 (dd, J = 
6.0,  0.9 Hz, 1H), 5.12 (d, J = 0.3 Hz, 1H), 3.55 (s, 2H), 2.19 (s, 6H), 1.56 (s, 9H), 1.53 
(s, 6H); 13C NMR (100 MHz, CDCl3) % 152.9, 146.5, 146.3, 142.0, 133.7, 128.6, 119.7, 
113.4, 112.32, 109.0, 103.1, 83.3, 54.1, 45.5, 39.6, 28.0, 27.3; IR (neat) 3385, 2933, 
1734, 1466, 1142, 1013, 886 cm-1; HRMS (ESI/APCI) calcd for C21H31N2O3 (M+H) 

































Gramine 206 (4.14 g, 11.5 mmol), 122 (2.80 g, 10.5 mmol), tributylphosphine ( 850 µL, 
4.2 mmol) and MeCN (53 mL) were combined and stirred for 20 hours at reflux under 
Ar.  The reaction was concentrated and purified via flash column chromatography in 10% 
ethyl acetate in hexanes to afford 2.76 g of a yellow amorphous solid, which was 
dissolved in THF (36 mL).  1M HCl (12.0 mL) was added and the reaction mixture 
stirred for 30 minutes at room temperature.  The solvent was removed under reduced 
pressure and the residue was rediluted with saturated aqueous NaHCO3 until basic.  The 
mixture was extracted with CH2Cl2 (x2), dried over Na2SO4 and concentrated.  The crude 
residue was purified by flash column chromatography (3:1 hexanes/ethyl acetate; 5:95 
MeOH/CH2Cl2) to give 207 as a yellow oil.  Yield: 1.51 g, 3.62 mmol, 76%. 
 1H-NMR (300 MHz, CDCl3) % 8.44 (bs, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 1.8 
Hz, 1H), 6.83 (dd, J = 8.7, 2.1 Hz, 1H), 6.00 (dd, J = 17.7, 10.2 Hz, 1H), 5.07-5.01 (m, 
2H), 4.12-4.00 (m, 2H), 3.75 (dd, J = 9.6, 5.1 Hz, 1H), 3.22 (dd, J = 14.4, 4.8 Hz, 1H), 
2.95 (dd, J = 14.4, 9.6 Hz, 1H), 1.53 (s, 9H), 1.42 (s, 6H), 1.12 (t, J = 6.9 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) % 175.6, 153.1, 146.5, 146.1, 141.6, 134.2, 127.9, 119.0, 113.3, 
112.0, 106.8, 103.7, 83.4, 61.0, 56.1, 39.3, 31.3, 27.9, 27.8, 14.4, 14.2; IR (neat) 3389, 
 224 
2977, 1734, 1465, 1243, 1143, 885 cm-1; HRMS (ESI/APCI) calcd for C23H33N2O5 



























207 208  
To a solution of amine 207 (1.50 g, 3.60 mmol) in dioxane (18 mL), di-tert-
butyldicarbonate (824 mg, 3.78 mmol) and 1M NaOH (3.60 mL, 3.60 mmol) were added.  
The reaction mixture stirred at room temperature for 1 hour, and then concentrated under 
reduced pressure to remove the dioxane.  The resulting slurry was taken up in H2O, 
acidified to pH 2 with 1M KHSO4, and extracted with EtOAc (3 x 50 mL).  The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure to afford 208 as a yellow amorphous solid that was used without further 
purification.  Crude yield: 1.85 g, 3.58 mmol. 
  
1H-NMR (300 MHz, CDCl3) % 8.11 (bs, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.06 (s, 1H), 6.86 
(d, J = 8.4 Hz, 1H), 6.07 (dd, J = 17.7, 10.5 Hz, 1H), 5.17-5.06 (m, 3H), 4.49 (m, 1H), 
4.05-3.90 (m, 2H), 3.28-3.12 (m, 2H), 1.55 (s, 9H), 1.52 (s, 9H), 1.32 (s, 6H), 1.02 (t, J = 
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) % 173.1, 152.8, 146.7, 146.0, 141.4, 134.0, 
128.0, 119.0, 113.5, 112.4, 106.1, 103.4, 83.3, 79.8, 61.4, 54.8, 39.4, 28.4, 28.0, 27.8, 
27.6, 14.4, 14.0; IR (neat) 3388, 2979, 1755, 1464, 1369, 1143 cm-1; HRMS (ESI/APCI) 

































Crude ester 208 (1.85 g, 3.58 mmol) was dissolved in 2:1 H2O/THF (36 mL) and LiOH 
(826 mg, 36.0 mmol) was added.  The reaction stirred at room temperature overnight.  
The solvent was removed under reduced pressure and the resulting slurry was taken up in 
H2O, acidified to pH 2 with 1M KHSO4, and extracted with CH2Cl2 (2 x 50 mL) and  
EtOAc (2 x 50 mL).  The combined organic layers were dried over Na2SO4 and 
concentrated under reduced pressure to afford 190 as a yellow amorphous solid that was 
used without further purification. Crude yield: 1.46 g, 2.98 mmol, 83%. 
 1H-NMR (300 MHz, CDCl3) % 11.98 (bs, 1H) 9.70 (bs, 1H), 8.20 (d, J = 21.3 Hz, 1H), 
7.51 (t, J = 9.6 Hz, 1H), 7.08 (s, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.07 (dd, J = 17.4, 10.2 
Hz, 1H), 5.16-5.11 (m, 2H), 4.60-4.50 (m, 1H), 3.41-3.35 (m, 1H), 3.19-3.11 (m, 1H), 
1.55 (s, 9H), 1.48 (s, 6H), 1.29-1.22 (m, 18H); 13C NMR (75 MHz, CDCl3) % 177.2, 
171.7, 155.6, 146.0, 134.1, 119.0, 113.6, 112.5, 103.6, 83.5, 80.2, 60.8, 39.3, 28.4, 28.0, 





















209 212  
Commercially available nitrophenol (5.0 g, 32.7 mmol) was dissolved in 32.7 mL of 
DMF.  Benzyl chloride (4.13 mL, 35.9 mmol) and potassium carbonate (4.51 g, 32.7 
mmol) were added and the reaction mixture stirred for 4 hours at 100oC.  The reaction 
mixture cooled to room temperature and was poured into 15 ml of water and extracted 
with ethyl acetate (3 x 70 mL).  The organic layer was washed with 50 mL of each 1M 
sodium hydroxide, water, and brine, then dried over Na2SO4 and concentrated under 
vacuum.  The residue was recrystalized from ethyl acetate and hexanes to afford the pure 
desired product.  Yield: 7.16 g, 29.4 mmol, 90%.  
 
1H-NMR (300 MHz, CDCl3) % 7.38-7.25 (m, 5H), 7.35 (t, J = 7.8 Hz, 1H), 6.87 (dd, J = 

























212 213  
To a solution of nitrotoluene 212 (4.0 g, 16.44 mmol) in 16 mL of DMF, was added 
DMF-DMA (4.37 mL, 32.9 mmol) and pyrrolidine (2.75 mL, 32.9 mmol).  The reaction 
was heated to 150°C and stirred for 6 hours.  The mixture was cooled to 0°C and diluted 
with 16 mL of isopropyl ether.  To the cooled solution, semicarbazine HCl (2.2 g, 19.7 
mmol) in 1M HCl (19 mL) at 0°C was added and the reaction stirred for 10 minutes at 
room temperature.  The precipitate was filtered and washed with water and isopropyl 
ether.  Yield: 2.3 g, 7.0 mmol, 43%.  
 
1H-NMR (300 MHz, CDCl3) % 9.96 (bs, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.39-7.33 (m, 4H), 
7.30 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 5.4 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.13 (bs, 1H), 

































The semicarbazide (500 mg, 1.52 mmol), 5% Pd/C (10 mol%), and ethanol (5 mL) was 
stirred in a hydrogenation vessel under 42 psi of H2 for 2 hours.  The vessel was purged 
with Ar and the mixture was filtered through a pad of celite.  The catalyst was washed 
with ethanol and the filtrate was concentrated.  The residue was dissolved in CHCl3 (20 
mL) and washed with 10% aqueous citric acid (35 mL).  The organic layer was separated 
and dried over MgSO4 and concentrated.  Crude yield: 147 mg, 1.10 mmol. 
The crude 7-hydroxyindole (147 mg, 1.10 mmol) was dissolved in 2.2 mL of MeCN and 
the solution was cooled to 0°C.  Di-tert-butyldicarbonate (216 mg, 0.99 mmol) and a 
catalytic amount of DMAP were added to the reaction mixture and the reaction stirred for 
16 hours at room temperature.  The reaction was concentrated and purified via flash 
column chromatography using 9:1 hexanes/ethyl acetate.  Yield: 150 mg, 0.643 mmol, 
58%.  
 
1H-NMR (300 MHz, CDCl3) % 8.45 (bs, 1H), 7.56-7.53 (m, 1H), 7.18-7.12 (m, 3H), 6.61-






















The 7-OBoc indole (593 mg, 2.54 mmol) was dissolved in 12 mL of MeOH and cooled to 
0°C.  N-Chlorosuccinimide (393 mg, 2.54 mmol) was slowly added to the reaction 
mixture in portions.  The solution stirred for 22 hours while warming to room 
temperature.  The reaction was quenched with brine (20 mL) and extracted with diethyl 
ether (3 x 35 mL).  The combined organic layer was washed with 35 mL of water, dried 
over Na2SO4, and concentrated. The crude oil was purified via flash column 
chromatography 85:15 hexanes/ethyl acetate.  Yield: 500 mg, 1.87 mmol, 74%. 
 
1H-NMR (300 MHz, CDCl3) % 8.31 (bs, 1H), 7.50 (dd, J = 6.3, 3.0 Hz, 1H), 7.18-7.15 
























201 188  
Enamine 201 (24.3 g, 74.9 mmol), and 10 wt.% Pd/C were dissolved in 250 mL of THF 
in a par shaker hydrogenation vessel.  The vessel was purged with Ar and then filled with 
H2 (40 psi) on the par shaker.  The reaction mixture stirred for 3 hours.  Following a 
quench with Ar, the mixture was filtered through a silica plug and rinsed with diethyl 
ether to provide pure 188 as a yellow foam.  Yield: 9.97 g, 74.9 mmol, quantitative. 
 
1H-NMR (300 MHz, CDCl3) % 7.28 (d, J = 9.0 Hz, 1H), 6.92 (d, J = 3.3 Hz, 1H), 6.71 
(m, 1H), 6.54 (dd, J = 8.4, 2.1 Hz, 1H), 6.26 (dd, J = 3.3, 0.9 Hz, 1H); 13C NMR (75 
MHz, CDCl3) % 152.8, 137.1, 131.0, 123.2, 121.1, 110.1, 101.9, 97.0; HRMS (ESI/APCI) 
















209 210  
Commercially available nitrophenol 209 (500 mg, 3.27 mmol) was dissolved in 3.3 mL 
of MeCN and the solution was cooled to 0°C. Di-tert-butyldicarbonate (785 mg, 3.60 
mmol) and a catalytic amount of DMAP were added to the cooled reaction mixture.  The 
solution was allowed to warm to room temperature while stirring for 18 hours.  The 
reaction was concentrated and purified via flash column chromatography using 9:1 
hexanes/ethyl acetate.  Yield:  800 mg, 3.14 mmol, 96%.  
 
1H-NMR (300 MHz, CDCl3) % 7.85 (d, J = 1.5 Hz, 1H), 7.34 (m, 2H), 2.59 (s, 3H), 1.56 





































The crude acid was dissolved in acetonitrile (30 mL) and L-proline ethyl ester (426 mg, 
2.98 mmol) was added.  HATU (1.70 g, 4.47 mmol) and iPr2NEt (2.0 mL, 11.9 mmol) 
were added and the reaction stirred for 3 hours at room temperature.  The reaction was 
quenched with 1M HCl (40 mL) and extracted with CH2Cl2 (3 x 75 mL).  The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure.  The 
crude residue was purified by flash column chromatography and eluted with 3:1 
hexanes/EtOAc to afford 1.08 g (59%) of 218 as a yellow amorphous solid.  
1H-NMR (300 MHz, CDCl3) % 8.35 (m, 1H), 7.48-6.74 (m, 3H), 6.04 (m, 1H), 5.52 (m, 
1H), 5.15-5.06 (m, 2H), 4.62-1.98 (m, 9H), 1.51-1.12 (m, 3H); 13C NMR (75 MHz, 
CDCl3) % 172.1, 171.3, 154.9, 152.7, 146.6, 145.3, 141.6, 133.6, 127.8, 119.2, 119.1, 
113.4, 112.6, 106.0, 103.4, 83.2, 79.4, 61.1, 60.6, 59.3, 53.1, 46.6, 39.2, 28.5, 27.9, 27.4, 
14.4, 14.3; IR (neat) 3351, 2979, 1753, 1634, 1497, 1450, 1143 cm-1; HRMS (ESI/APCI) 










































TFA (0.6 M) was added to a solution of 218 (1.08 g, 1.76 mmol) in CH2Cl2 (0.6 M) at 
0°C.  The reaction stirred for 3 hours at room temperature.  The mixture was quenched 
with saturated NaHCO3 to a pH 10 and extracted with EtOAc (3 x 20 mL).  The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure.  The residue was dissolved in toluene (0.2 M) and 2-hydroxypyridine (31 mg, 
0.328 mmol) was added.  The reaction refluxed for 14 hours under Ar atmosphere, cooled 
to room temperature, and concentrated under reduced pressure.  The residue was 
rediluted with CH2Cl2 (30 mL) and washed with 1M HCl (30 mL).  The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure.  The crude residue was 
purified via flash column chromatography eluting with 5:95 MeOH/CH2Cl2 to afford 160 
mg (27%) of the desired cis diastereomer as a cream foam.  The trans diastereomer was 
isolated in 23% yield (140 mg) as yellow foam.  
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Cis: 1H NMR (400 MHz, 20:1 CDCl3/CD3OD) % 8.15 (m, 1H), 7.17 (d, J = 8.4 Hz, 1H), 
6.71 (d, J = 2.4 Hz, 1H), 6.58 (dd, J = 8.4, 2.0 Hz, 1H), 6.04 (dd, J = 17.6, 10.4, 1H), 
5.10-5.05 (m, 2H), 4.35 (dd, J = 11.2, 2.4 Hz, 1H), 4.00 (t, J = 7.6 Hz, 1H), 3.86-3.54 (m, 
3H), 3.08 (dd, J = 14.8, 11.6 Hz, 1H), 2.30-1.82 (m, 6H), 1.45-1.38 (m, 6H); 13C NMR 
(75 MHz, 20:1 CDCl3/CD3OD) % 169.7, 166.3, 153.0, 146.1, 140.3, 135.9, 123.0, 118.3, 
112.3, 110.0, 103.9, 96.9, 59.4, 55.1, 45.6, 39.1, 28.5, 28.0, 26.1, 25.9, 22.7; IR (neat) 
3353, 2925, 1664, 1457 cm-1;  HRMS (ESI/APCI) calcd for C21H26N3O3 (M+H) 

















Trans: 1H NMR (300 MHz, (CD3)2CO) % 7.91 (bs, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.81 (d, 
J = 2.4 Hz, 1H), 6.64 (dd, J = 8.4, 2.1 Hz, 1H), 6.22 (dd, J = 17.4, 10.5 Hz, 1H), 5.67-
5.63 (m, 1H), 5.14-5.03 (m, 2H), 4.42-4.38 (m, 1H), 4.20-4.17 (m, 1H), 3.64-3.42 (m, 
3H), 3.07-2.98 (m, 1H), 2.00-1.82 (m, 3H), 1.56 (s, 3H), 1.54 (s, 3H); IR (neat) 3358, 
2920, 1662, 1456 cm-1;  HRMS (ESI/APCI) calcd for C21H25N3O3Na (M+Na) 390.1788, 











































Davis oxaziridine (208 mg, 0.871 mmol) was added to a solution of 220 (160 mg, 0.436 
mmol) in CH2Cl2 (9 mL).  The reaction mixture was stirred 13 hours at room temperature 
and concentrated under reduced pressure.  The residue was purified via flash column 
chromatography eluting with MeOH/CH2Cl2 (5:95) to give 52 mg (31%) of 43 as a white 
amorphous solid and 26 mg (15%) of 15 as a white amorphous solid. 
  1H-NMR (300 MHz, acetone-d6) % 9.68 (bs, 1H), 8.59 (bs, 1H), 7.02 (d, J = 8.7 Hz, 1H), 
6.49 (dd, J = 8.1, 5.7 Hz, 2H), 6.33 (bs, 1H), 6.12 (dd, J = 17.4, 10.8 Hz, 1H), 5.05 (dd, J 
= 16.8, 10.8 Hz, 1H), 5.04 (dd, J = 16.8, 10.8 Hz, 1H), 4.00 (t, J = 6.9 Hz, 1H), 3.49-3.34 
(m, 2H), 3.28 (d, J = 9.6 Hz, 1H), 3.10 (d, J = 14.7 Hz, 1H), 2.18-2.11 (m, 1H), 2.10 (d, J 
= 6.6 Hz, 1H), 1.98-1.80 (m, 3H), 1.11 (s, 3H), 1.06 (s, 3H); 13C NMR (75 MHz, CDCl3) 
% 183.2, 170.4, 165.7, 157.7, 143.3, 142.9, 126.8, 120.3, 114.5, 109.2, 98.6, 59.0, 57.8, 
53.0, 45.9, 42.5, 31.7, 29.9, 28.2, 22.7, 21.8; IR (neat) 3265, 2971, 1670, 1429, 1155   

































To a solution of acid 113 (500 mg, 1.34 mmol) in 13.4 mL MeCN was added L-proline 
ethyl ester (192 mg, 1.34 mmol).  HATU (764 mg, 2.01 mmol) and iPr2NEt (0.93 mL, 
5.36 mmol) were added to the solution and the reaction stirred at room temperature for 4 
hours.  The reaction was quenched with 20 mL 1M HCl and extracted with CH2Cl2 (3 x 
30 mL).  The combined organic layer was dried over Na2SO4 and concentrated under 
vacuum.  The crude material was purified via flash column chromatography using 3:1 
hexanes/ethyl acetate.  Yield:  400.1 mg, 0.804 mmol, 60%  
 
1H-NMR (300 MHz, CDCl3) % 7.98-7.93 (m, 1H), 7.54-7.46 (m, 1H), 7.11-7.02 (m, 2H), 
6.12 (dd, J = 10.5, 9.9 Hz, 1H), 5.60 (d, J = 8.4 Hz, 1H), 5.26-5.17 (m, 2H), 4.76-4.42 
(m, 2H), 4.16-4.02 (m, 3H), 3.42-3.10 (m, 4H), 1.63 (s, 9H), 1.43 (s, 6H), 1.28-1.17 (m, 
6H); 13C NMR (75 MHz, CDCl3) % 172.2, 171.8, 171.4, 155.0, 145.6, 140.8, 134.1, 
129.8, 121.8, 121.7, 119.4, 118.7, 112.5, 110.7, 106.0, 79.4, 61.8, 61.2, 60.6, 59.4, 53.1, 
46.6, 39.3, 31.1, 28.7, 28.6, 28.0, 27.6, 24.1, 22.1, 21.3, 14.4, 14.3, 14.2; HRMS 






































Peptide 243 (400 mg, 0.803 mmol) was dissolved in 2 mL CH2Cl2 and cooled to 0ºC .  
TFA (2 mL) was added and the ice bath was removed.  The reaction stirred at room 
temperature for 3 hours.  The reaction was quenched with saturated aqueous NaHCO3 to 
pH 10, extracted with ethyl acetate (3 x 50 mL), and dried over Na2SO4.  The organic 
layer was concentrated under vacuum.  The crude amine (320 mg, 0.805 mmol) was 
dissolved in toluene (8 mL) and 2-hydroxypyridine (15.3 mg, 0.161 mmol) was added to 
the solution.  The reaction was heated to reflux and stirred for 15 hours.  The mixture was 
concentrated and the residue was diluted with 10 mL CH2Cl2.  The organic layer was 
washed with 15 mL 1M HCl, dried over Na2SO4, and concentrated.  The crude material 
was purified via flash column chromatography with 3% MeOH in CH2Cl2 to afford a 1:1 
mixture of cis:trans diastereomers (79% overall yield).  
 
Cis: 1H-NMR (300 MHz, CDCl3) % 8.08 (bs, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.32 (d, J = 
8.1 Hz, 1H), 7.20-7.08 (m, 2H), 6.13 (dd, J = 17.7, 10.5 Hz, 1H), 5.69 (bs, 1H), 5.21 (s, 
1H), 5.16 (d, J = 4.8 Hz, 1H), 4.44 (d, J = 10.5 Hz, 1H), 4.10-4.04 (m, 1H), 3.78-3.55 (m, 
3H), 3.19 (dd, J = 15.5, 12.0 Hz, 1H), 2.39-2.31 (m, 1H), 2.10-1.86 (m, 4H), 1.56 (s, 6H); 
13C NMR (100 MHz, CDCl3) % 169.4, 166.0, 145.8, 141.6, 134.5, 129.2, 122.4, 120.3, 
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118.0, 113.0, 111.1, 104.8, 59.4, 55.1, 45.6, 39.2, 29.9, 28.6, 28.1, 28.0, 26.2, 22.8; 
























































Deoxybrevianamide E 7 (220 mg, 1.25 mmol) was dissolved in CH2Cl2 (12.5 mL) and 
Davis oxaziridine (300 mg, 2.5 mmol) was added to the solution.  The reaction stirred at 
room temperature for 18 hours.  The mixture was concentrated and purified via flash 
column chromatography in 3% MeOH in DCM.  The combined oxindoles were isolated 
and purified a second time via reverse phase prep-TLC (10% acetone in H2O).  The plate 
was run 4 times and the R and S isomers were isolated separately.  
 
 252 
235: 1H-NMR (300 MHz, CDCl3) % 7.29, (d, J = 1.5 Hz, 1H), 7.22-7.17 (m, 1H), 6.89-
6.73 (m, 2H), 6.32 (dd, J = 17.7, 10.8 Hz, 1H), 5.14-5.04 (m, 2H), 3.93 (t, J = 8.1 Hz, 
1H), 3.72 (dd, J = 11.4, 7.8 Hz, 1H), 3.60-3.47 (m, 2H), 2.89 (dd, J = 13.2, 11.4 Hz, 1H), 


















236: 1H-NMR (300 MHz, CDCl3) % 7.32, (d, J = 8.4 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 
6.79 (t, J = 8.1 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 6.40 (dd, J = 17.7, 10.8 Hz, 1H), 5.15 
(dd, J = 27.0, 17.7 Hz, 2H), 4.30 (d, J = 14.1 Hz, 1H), 4.01 (t, J = 8.7 Hz, 1H), 3.52-3.47 
(m, 1H), 3.37-3.29 (m, 1H), 3.16-3.07 (m, 1H), 2.71 (dd, J = 13.8, 10.8 Hz, 1H), 2.19-
1.99 (m, 3H), 1.80-1.70 (m, 2H), 1.39 (s, 3H), 1.35 (s, 3H); 13C NMR (100 MHz, d6-
acetone) % 169.12, 164.7, 149.0, 145.5, 1311.9, 129.5, 125.0, 119.2, 111.7, 110.4, 94.8, 
87.6, 59.6, 59.3, 45.0, 35.7, 27.1, 24.7, 24.1, 23.0; HRMS (ESI/APCI) calcd for 














































= 13C  
To a solution of 13C labeled acid 142 (820 mg, 2.19 mmol) in 22 mL MeCN was added 
[13C]2-[15N]-L-proline ethyl ester (317 mg, 2.19 mmol).  HATU (1.25 g, 3.29 mmol) and 
iPr2NEt (1.53 mL, 8.76 mmol) were added to the solution and the reaction stirred at room 
temperature for 4 hours.  The reaction was quenched with 30 mL 1M HCl and extracted 
with CH2Cl2 (3 x 40 mL).  The combined organic layer was dried over Na2SO4 and 
concentrated under vacuum.  The crude material was purified via flash column 
chromatography using 3:1 hexanes/ethyl acetate.  Yield:  920 mg, 1.84 mmol, 84% 
 
1H-NMR (300 MHz, CDCl3) % 8.16 (bs, 1H),7.51-7.45 (m, 1H), 7.25-7.21 (m, 1H), 7.09-
7.00 (m, 2H), 6.12 (dd, J = 17.4, 10.5 Hz, 1H), 5.62 (d, J = 8.4 Hz, 1H), 5.24-5.14 (m, 
2H), 4.13-4.06 (m, 2H), 3.43-3.06 (m, 4H), 1.62 (s, 3H), 1.59 (s, 3H), 1.43 (s, 9H), 1.22-
1.17 (m, 3H); 13C NMR (100 MHz, CDCl3) % 172.1, 171.8, 171.4, 171.2, 145.6, 140.7, 
133.9, 129.9, 121.9, 121.8, 119.5, 119.0, 118.8, 112.6, 112.5, 110.4, 106.2, 106.1, 79.4, 
61.2, 60.6, 46.6, 46.5, 39.3, 31.2, 31.1, 30.1, 28.6, 28.3, 28.0, 27.5, 24.1, 22.1, 21.3, 14.4, 







































[13C]2-[15N]-Peptide 248 (920 mg, 1.84 mmol) was dissolved in 3 mL CH2Cl2 and cooled 
to 0ºC .  TFA (3 mL) was added and the ice bath was removed.  The reaction stirred at 
room temperature for 3 hours.  The reaction was quenched with saturated aqueous 
NaHCO3 to pH 10, extracted with ethyl acetate (3 x 50 mL), and dried over Na2SO4.  The 
organic layer was concentrated under vacuum.  The crude amine (500 mg, 1.25 mmol) 
was dissolved in toluene (6.25 mL) and 2-hydroxypyridine (23 mg, 0.25 mmol) was 
added to the solution.  The reaction was heated to reflux and stirred for 15 hours.  The 
mixture was concentrated and the residue was diluted with 15 mL CH2Cl2.  The organic 
layer was washed with 20 mL 1M HCl, dried over Na2SO4, and concentrated.  The crude 
material was purified via flash column chromatography with 3% MeOH in CH2Cl2 to 
afford 156.4 mg (35%) of the cis diastereomer. 
 
Cis: 1H-NMR (300 MHz, CDCl3) % 8.27 (bs, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 
8.1 Hz, 1H), 7.19-7.07 (m, 2H), 6.12 (dd, J = 17.4, 10.5 Hz, 1H), 5.70 (d, J = 4.8 Hz, 
1H), 5.18 (d, J = 3.0 Hz, 1H), 5.13 (d, J = 3.9 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.06-
4.04 (m, 1H), 3.77-3.55 (m, 3H), 3.23-3.13 (m, 1H), 2.37-2.30 (m, 1H), 2.18-1.85 (m, 
3H), 1.54 (s, 6H); 13C NMR (100 MHz, CDCl3) % 169.5, 166.2, 166.0, 145.8, 141.7, 
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134.6, 129.2, 122.3, 120.3, 118.0, 112.9, 111.1, 104.6, 60.6, 59.7, 59.1, 59.0, 55.5, 55.4, 
54.8, 54.7, 45.7, 45.5, 45.4, 39.2, 28.6, 28.1, 26.1, 22.8, 21.3, 14.4. 13C-enriched peaks: 


























To a solution of 3-cis-"-hydroxyproline 80 (500 mg, 3.81 mmol) in THF (19 mL) was 
added di-tert-butyldicarbonate (873 mg, 4.00 mmol) and 1M NaOH (3.81 mL).  The 
reaction mixture stirred at room temperature for 30 hours and the THF was removed 
under vacuum.  Water (10 mL) was added to the residue and the slurry was acidified to 
pH 2 with saturated KHSO4.  The crude product was extracted with EtOAc (3x 35 mL), 
dried over Na2SO4 and concentrated.  The crude material was a white foam that was 
recrystallized from hot EtOAc and hexanes. Yield:  872 mg, 3.77 mmol, 99%. 
 
1H-NMR (300 MHz, CDCl3) % 4.64-4.61 (m, 1H), 4.39-4.31 (m, 1H), 3.65-3.42 (m, 2H), 
2.02 (m, 2H), 1.41 (d, J = 13.2 Hz, 9H); 13C NMR (75 MHz, CDCl3) % 174.3, 155.7, 




































Amine 252 (182 mg, 0.606 mmol) and proline 251 (140 mg, 0.606 mmol) were stirred 
together in MeCN (6 mL) at room temperature.  HATU (345 mg, 0.909 mmol) and 
DIPEA (0.422 mL, 2.42 mmol) were added to the reaction mixture and the reaction 
stirred at room temperature for 5 hours.  The reaction was quenched with 1M HCl until 
acidic and extracted with CH2Cl2 (3x 15 mL).  The combined organic layers were dried 
over Na2SO4 and concentrated.  The crude product was purified via flash column 
chromatography via 50:50 hexanes-EtOAc.  Yield:  308 mg, 0.600 mmol, 99%   
 
1H-NMR (300 MHz, CDCl3) % 7.99 (bs, 1H), 7.54 (d, J = 8.17 Hz, 1H), 7.47 (d, J = 7.2 
Hz, 1H), 7.17-7.09 (m, 2H), 6.15 (dd, J = 17.7, 11.1 Hz, 1H), 5.28 (bs, 1H), 5.24-5.19 
(m, 2H), 4.86-4.73 (m, 1H), 4.35-4.28 (m, 2H), 4.08-3.98 (m, 2H), 3.38-3.17 (m, 4H), 
2.01-2.81 (m, 2H), 1.56 (s, 9H), 1.42 (m, 6H), 1.25 (t, J = 8.4 Hz, 3H); 13C NMR (75 
MHz, CDCl3) % 174.0, 172.9, 171.5, 166.0, 145.9, 141.1, 134.6, 129.8, 121.8, 119.8, 
117.7, 112.4, 111.0, 104.9, 80.8, 73.1, 67.5, 61.7, 60.6, 54.5, 38.8, 28.3, 27.9, 27.8, 27.6, 
21.3, 14.4, 13.9; HRMS (ESI/APCI) calcd for C28H39N3O6Na (M+Na) 536.2731, found 








































To a stirred solution of indole 253 (308 mg, 0.600 mmol) in CH2Cl2 (2 mL) at 0ºC was 
slowly added TFA (2 mL).  The reaction mixture stirred for 3 hours while warming to 
room temperature.  The reaction was concentrated under vacuum and the residue was 
basified with aqueous saturated NaHCO3 to pH 10.  The crude material was extracted 
with EtOAc (3x 50 mL), the combined organic layers were dried over Na2SO4 and 
concentrated.  The crude free amine (248 mg, 0.600 mmol) was dissolved in toluene (6 
mL) and to the solution was added 2-hydroxy-pyridine (11 mg, 0.121 mmol).  The 
reaction stirred at reflux for 15 hours.  The mixture was concentrated under vacuum, 
diluted with CH2Cl2 and washed with 1M HCl (2x 20 mL).  The organic layer was dried 
over Na2SO4 and concentrated.  The crude material was purified via flash column 
chromatography with 3% MeOH in CH2Cl2 to afford a 1:1 ratio of cis:trans 
diketopiperazines, which were taken on as a mixture of diastereomers.  Yield: 191 mg, 
0.522 mmol, 87%. 
 264 
Cis:  1H-NMR (300 MHz, CDCl3) % 8.57 (bs, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.29 (d, J = 
7.8 Hz, 1H), 7.15-7.03 (m, 2H), 6.08 (dd, J = 17.7, 10.5 Hz, 1H), 5.93 (bs, 1H), 5.13 (d, J 
= 2.7 Hz, 1H), 5.08 (d, J = 2.4 Hz, 1H), 4.60 (bs, 1H), 4.41 (d, J = 11.4 Hz, 1H), 3.99-
3.52 (m, 4H), 3.17 (dd, J = 15, 11.7 Hz, 1H), 2.13-1.94 (m, 3H), 1.49 (d, J = 3.3 Hz, 6H); 
13C NMR (75 MHz, CDCl3) % 167.6, 166.0, 145.8, 142.0, 134.8, 129.3, 122.2, 120.1, 
118.0, 112.8, 111.2, 104.5, 71.0, 64.8, 55.2, 44.2, 39.2, 30.6, 28.2, 28.0, 26.6 ; HRMS 
















Trans:  1H-NMR (300 MHz, CDCl3) % 8.35 (bs, 1H), 7.45 (m, 1H), 7.12 (m, 1H), 7.01-
6.98 (m, 2H), 6.28 (m, 1H), 6.05 (dd, J = 17.4, 10.5 Hz, 1H), 5.27 (s, 1H) 5.14-5.07 (m, 
2H), 4.49 (bs, 1H), 4.22-4.19 (m, 1H), 3.83-3.15 (m, 6H), 2.00-1.94 (m, 1H), 1.78-1.67 
(m, 1H), 1.46 (s, 6H); 13C NMR (75 MHz, CDCl3) % 167.5, 166.6, 146.2, 141.8, 134.4, 
129.2, 121.9, 119.8, 118.7, 112.1, 110.7, 105.1, 70.9, 64.1, 58.5, 44.4, 39.3, 30.3, 30.1, 








































Alcohol 254 (113 mg, 0.308 mmol) was dissolved in MeCN (6 mL).  To the solution, 
40% DEAD in toluene (0.401 mL, 0.923 mmol) was added and the reaction stirred for 10 
minutes at room temperature.  Freshly distilled tributylphosphine (0.227, 0.923 mmol) 
was added and the reaction mixture stirred for 2 hours at room temperature.  The solution 
was concentrated and purified via flash column chromatography in 3% MeOH in CH2Cl2 
to afford a yellow oil.  Yield: 101 mg, 0.290 mmol, 94%. 
 
1H-NMR (300 MHz, CDCl3) % 8.65 (bs, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.28 (d, J = 7.5 
Hz, 1H), 7.13-7.03 (m, 2H), 6.13-6.03 (m, 2H), 5.79 (bs, 1H), 5.13-5.07 (m, 2H), 4.49 (d, 
J = 10.5 Hz, 1H), 4.08-4.00 (m, 2H), 3.70 (dd, J = 14.4, 3.6 Hz, 1H), 3.22 (dd, J = 14.4, 
11.1 Hz, 1H), 2.77-2.70 (m, 2H), 1.51 (d, J = 3.0 Hz, 6H); 13C NMR (75 MHz, CDCl3) % 
162.8, 156.7, 146.0, 142.1, 134.7, 133.2, 129.0, 122.1, 120.0, 119.3, 118.3, 112.3, 111.1, 
104.4, 57.7, 45.8, 39.3, 31.1, 28.2, 28.1, 28.0; HRMS (ESI/APCI) calcd for C21H24N3O2 















































To a cooled solution (0º) of enamide 255 (101 mg, 0.290 mmol) in 25 mL MeOH was 
added 20% aqueous KOH (5 mL) and the reaction stirred for 16 hours at room 
temperature.  The mixture was quenched with saturated aqueous NH4Cl (30 mL) and 
extracted with CH2Cl2 (3x 30 mL).  The combined organic layers were dried over 
Na2SO4 and concentrated under vacuum.  The syn-isomer was collected by crashing the 
anti-diastereomer out of the solution.  Using EtOAc and MeOH, the anti- product 
precipitated out as a white solid, leaving the syn-isomer in solution.  Total combined 
yield: 79 mg, 0.226 mmol, 78%.  syn: 55.8 mg  anti: 23.2 mg 
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257: 1H-NMR (400 MHz, 10:1 CDCl3/CD3OD) % 7.43-7.40 (m, 1H), 7.24-7.22 (m, 1H), 
7.05-6.95 (m, 2H), 3.66 (d, J = 15.6 Hz, 1H), 3.50-3.41 (m, 2H), 3.36-3.27 (m, 2H), 2.73-
2.60 (m, 2H), 2.53-2.50 (m, 1H), 2.16-2.10 (m, 1H), 2.02-1.82 (m, 4H), 1.27 (s, 3H), 1.02 
(s, 3H); 13C NMR (100 MHz, 1:2 CDCl3/CD3OD) % 174.5, 170.0, 140.2, 137.0, 126.8, 
121.3, 118.7, 117.9, 110.8, 103.6, 66.9, 60.6, 44.2, 34.9, 30.9, 29.3, 28.2, 24.5, 23.3, 21.9, 

















258: 1H-NMR (400 MHz, 10:1 CDCl3/CD3OD) % 7.43 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 
8.0 Hz, 1H), 7.07-6.96 (m, 2H), 3.76 (d, J = 16.4 Hz, 1H), 3.49-3.41 (m, 3H), 3.34-3.27 
(m, 1H), 2.90 (d, J = 17.6 Hz, 1H), 2.72-2.65 (m, 2H), 2.24-2.21 (m, 1H), 2.10-1.78 (m, 
4H), 1.27 (s, 3H), 1.17 (s, 3H); 13C NMR (100 MHz, 1:21 CDCl3/CD3OD) % 174.0, 
170.2, 140.5, 137.0, 127.2, 121.5, 119.0, 118.0, 110.9, 102.7, 67.3, 61.7, 46.0, 44.3, 34.8, 
32.6, 29.3, 24.5, 23.3, 21.9; HRMS (ESI/APCI) calcd for C21H24N3O2 (M+H) 350.1863, 














































The syn-isomer 238 (56 mg, 0.160 mmol) was dissolved in CH2Cl2 (3.2 mL) and Davis 
oxaziridine (76 mg, 0.321 mmol) was added to the reaction mixture.  The solution stirred 
at room temperature for 18 hours.  The mixture was concentrated and purified via silica 
gel flash column chromatography using 50:1 CH2Cl2-MeOH to furnish a 1:1 mixture of 
diastereomers.  
 
238: 1H-NMR (400 MHz, CDCl3) % 7.36 (d, J = 7.6 Hz, 1H), 7.26-7.22 (m, 1H), 7.14-
7.08 (m, 2H), 3.99 (bs, 1H), 3.66-3.61 (m, 1H), 3.37-3.29 (m, 3H), 2.75 (d, J = 16 Hz, 
1H), 2.66-2.59 (m, 1H), 2.29 (d, J = 16 Hz, 1H), 2.10-2.02 (m, 1H), 1.95-1.85 (m, 3H), 
1.77-1.70 (m, 2H), 1.23 (s, 3H), 1.03 (s, 3H); 13C NMR (100 MHz, CDCl3) % 189.8, 
173.5, 167.9, 153.3, 139.6, 129.9, 126.3, 122.0, 120.7, 83.0, 66.9, 60.0, 48.1, 44.3, 38.5, 
33.9, 31.2, 29.3, 28.6, 24.4, 21.0; HRMS (ESI/APCI) calcd for C21H23N3O3Na (M+Na) 























259: 1H-NMR (300 MHz, CDCl3) % 7.52 (d, J = 7.8 Hz, 1H), 7.43-7.33 (m, 2H), 7.24-
7.16 (m, 1H), 3.96 (s, 1H), 3.40 (t, J = 6.6 Hz, 1H), 2.80 (d, J = 15.6 Hz, 1H), 2.76-2.67 
(m, 1H), 2.01-1.93 (m, 6H), 1.86-1.73 (m, 3H), 1.43 (s, 3H), 1.30 (s, 3H); 13C NMR (100 
MHz, CDCl3) % 188.1, 172.4, 168.2, 151.9, 140.5, 130.0, 126.4, 122.2, 121.0, 82.3, 67.1, 
61.9, 50.3, 44.0, 40.4, 37.9, 32.5, 28.9, 27.3, 24.3, 20.0; HRMS (ESI/APCI) calcd for 





















































To a solution of a mixture of diketopiperazine diastereomers 4.63 (228 mg, 0.621 mmol) 
in CH2Cl2 (12 mL), was added Davis oxaziridine (296 mg, 1.24 mmol).  The reaction 
mixture stirred for 15 hours at room temperature.  The solution was concentrated and 
purified via flash column chromatography in 5% MeOH in CH2Cl2. Combined yield: 209 
mg, 0.503 mmol, 81%. 
 
 278 
260: 1H-NMR (300 MHz, CDCl3) % 8.56 (bs, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.03 (t, J = 
7.8 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.77 (s, 1H), 6.04 (dd, J = 17.1, 10.8 Hz, 1H), 5.06 
(dd, J = 29.1, 11.1 Hz, 2H), 4.57 (t, J = 3.0 Hz, 1H), 3.88 (s, 1H), 3.75-3.52 (m, 3H), 
3.26-3.14 (m, 3H), 2.30-2.22 (m, 1H), 2.12-2.05 (m, 1H), 1.93-1.72 (m, 3H), 1.13 (s, 
3H), 1.08 (s, 3H); 13C NMR (100 MHz, CDCl3) % 182.0, 168.6, 165.1, 142.5, 141.6, 
129.6, 128.8, 126.3, 122.7, 114.8, 109.8, 70.8, 64.2, 58.1, 52.9, 44.4, 42.6, 31.5, 30.4, 




















261: 1H-NMR (300 MHz, CDCl3) % 7.27 (d, J = 8.7 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 
6.78 (t, J = 7.2 Hz, 1H), 6.61 (d, J = 7.8 Hz, 1H), 6.38 (dd, J = 17.7, 10.8 Hz, 1H), 6.25 
(s, 1H), 5.16 (dd, J = 23.7, 17.4 Hz, 2H), 4.53 (t, J = 3.3 Hz, 1H), 4.23 (d, J = 10.2 Hz, 
1H), 4.01 (s, 1H), 3.48-3.40 (m, 3H), 3.34-3.24 (m, 2H), 2.71 (dd, J = 13.8, 11.1 Hz, 1H), 
2.02-1.95 (m, 1H), 1.87-1.74 (m, 1H), 1.39 (s, 3H), 1.37 (s, 3H); 13C NMR (75 MHz, 
CDCl3) % 168.2, 164.6, 147.8, 144.4, 130.8, 124.9, 120.6, 113.6, 110.6, 95.9, 87.8, 70.6, 
64.1, 59.8, 45.0, 43.9, 35.8, 30.6, 25.9, 23.6; HRMS (ESI/APCI) calcd for C21H26N3O4 











































The R-oxindole 260 (114 mg, 0.297 mmol) was dissolved in CH2Cl2 (6 mL) and 40% 
DEAD in toluene (0.388 mL, 0.892 mmol) was added.  The mixture stirred for 10 
minutes at room temperature, and tributylphosphine (0.220 mL, 0.892 mmol) was added.  
The reaction stirred at room temperature for 4 hours, was concentrated under vacuum, 
and purified vial flash column chromatography using a gradient elution (70:30 hexanes-
ethyl acetate to 30:70 hexanes-ethyl acetate).  Yield: 72.7 mg, 0.199 mmol, 67%. 
 
1H-NMR (300 MHz, CDCl3) % 7.22 (d, J = 7.8 Hz, 1H), 7.18-7.10 (m, 1H), 6.84-6.72 (m, 
1H), 6.62 (d, J = 7.8 Hz, 1H), 6.46 (s, 1H), 6.42-6.29 (m, 1H), 6.06 (t, J = 3.0 Hz, 1H), 
5.25-5.05 (m, 2H), 4.15-3.95 (m, 1H), 3.92-3.76 (m, 1H), 2.90-2.82 (m, 1H), 2.79-2.65 
(m, 3H), 1.44 (s, 3H), 1.34 (s, 3H), 1.26 (m, 2H). HRMS (ESI/APCI) calcd for 






















































The anti-cycloadduct 258 (20 mg, 0.057 mmol) was dissolved in CH2Cl2 (2.2 mL) and 
Davis oxaziridine (41 mg, 0.172 mmol) was added.  The reaction stirred at room 
temperature for 6 hours, was concentrated under vacuum, and purified via prep-TLC in 
3% MeOH in DCM (x3).   
 
R and S mixture: 1H-NMR (300 MHz, CDCl3) % 7.55 (d, J = 7.5 Hz, 1H), 7.44 (d, J = 7.5 
Hz, 1H), 7.40-7.35 (m, 1H), 7.12 (s, 1H), 3.45-3.32 (m, 4H), 2.87-2.71 (m, 3H), 2.07-
1.98 (m, 6H), 1.88-1.79 (m, 3H), 1.68-1.59 (m, 2H), 1.46 (s, 3H), 1.34 (s, 3H), 1.30 (s, 
3H), 1.24 (s, 3H). HRMS (ESI/APCI) calcd for C21H23N3NaO3 (M+Na) 388.1632, found 

























































13C-Amine 267 (610 mg, 1.46 mmol) and [13C]-[15N]-N-Boc-L-proline (317 mg, 1.46 
mmol) were stirred in acetonitrile (15 mL) at 0ºC. HATU (832 mg, 2.19 mmol) and 
iPr2NEt (1.0 mL, 5.84 mmol) were added and the reaction stirred for 3 hours at room 
temperature.  The reaction was quenched with 1M HCl (30 mL) and extracted with 
CH2Cl2 (3 x 50 mL).  The combined organic layer was washed with brine (50 mL), dried 
over Na2SO4, and concentrated under reduced pressure.  The crude residue was purified 
by flash column chromatography and eluted with 1:1 hexanes/EtOAc to afford 860 mg 
(95%) of 269 as a yellow amorphous solid. 
  
1H-NMR (300 MHz, CDCl3) % 8.40 (bs, 1H), 7.42-7.34 (m, 1H), 7.02 (d, J = 1.2 Hz, 1H) 
6.83-6.81 (m, 1H), 6.09-5.98 (m, 1H), 5.13-5.06 (m, 2H), 4.80-4.69 (m, 1H), 4.22-3.74 
(m, 3H), 3.47-2.95 (m, 4H), 2.00-1.67 (m, 2H) 1.66-1.16 (m, 28H), 1.12-0.92 (m, 2H); 
13C NMR (75 MHz, CDCl3) % 172.6, 172.4, 171.9, 170.7, 169.5, 169.2, 154.9, 152.8, 
146.6, 145.7, 141.6, 134.1, 128.1, 118.5, 118.2, 113.5, 112.4, 105.4, 105.2, 103.7, 83.3, 
80.6, 77.0, 61.4, 53.8, 53.0, 47.3, 39.3, 28.4, 27.9, 27.6, 14.1, 13.8; IR (neat) 3342, 2984, 
 285 
1750, 1644, 1481, 1447, 1140 cm-1; HRMS (ESI/APCI) calcd for C31[13C]2H47N2[15N] 






















































TFA (0.3 M) was slowly added to a solution of 269 (400 mg, 0.65 mmol) in CH2Cl2 (0.3 
M) at 0°C.  The reaction stirred for 3 hours at room temperature.  The mixture was 
quenched with saturated NaHCO3 to a pH 9 and extracted with EtOAc (3 x 20 mL).  The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure.  The residue was dissolved in toluene (0.2 M) and 2-hydroxypyridine (8.6 mg, 
0.09 mmol) was added.  The reaction refluxed for 14 hours under Ar atmosphere, cooled 
to room temperature, and concentrated under reduced pressure.  The residue was 
rediluted with CH2Cl2 (10 mL) and washed with 1M HCl (20 mL).  The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure.  The crude residue was 
purified via flash column chromatography eluting with 3:97 MeOH/CH2Cl2 to afford 68 
mg (40%) of the desired cis-diastereomer as cream foam. The trans-diastereomer was 
isolated in 38% yield (64 mg) as yellow foam (overall: 52% for two steps).   
 
266, Cis: 1H NMR (300 MHz, 20:1 CDCl3/CD3OD) % 8.05 (bs, 1H), 7.22 (d, J = 8.7 Hz, 
1H), 6.74 (d, J = 2.1 Hz, 1H), 6.61 (dd, J = 8.4, 2.1 Hz, 1H), 6.08 (dd, J = 17.4, 10.5, 
1H), 5.15-5.09 (m, 2H), 4.38 (d, J = 11.4 Hz, 1H), 4.09-4.01 (m, 1H), 3.72-3.54 (m, 3H), 
 287 
3.16-3.06 (m, 1H), 2.38-1.81 (m, 6H), 1.49-1.44 (m, 6H); 13C NMR (75 MHz, CDCl3) % 
169.7, 166.3, 153.0, 146.1, 140.3, 135.7, 123.2, 118.5, 112.5, 110.2, 104.1, 97.1, 60.7, 
45.6, 39.1, 28.5, 28.1, 28.0, 26.2, 26.1, 22.7; enriched 13C = 169.7 and 166.3; IR (neat) 
3353, 2925, 1664, 1457 cm-1;  HRMS (ESI/APCI) calcd for C19[13C]2H26N2[15N]O3 


















271, Trans: 1H NMR (300 MHz, (CD3)2CO) % 7.91 (bs, 1H), 7.32 (d, J = 8.4 Hz, 1H), 
6.81 (d, J = 2.4 Hz, 1H), 6.64 (dd, J = 8.4, 2.1 Hz, 1H), 6.22 (dd, J = 17.4, 10.5 Hz, 1H), 
5.67-5.63 (m, 1H), 5.14-5.03 (m, 2H), 4.42-4.38 (m, 1H), 4.20-4.17 (m, 1H), 3.64-3.42 
(m, 4H), 3.07-2.98 (m, 1H), 2.00-1.82 (m, 3H), 1.56 (s, 3H), 1.54 (s, 3H); 13C NMR (75 
MHz, CDCl3) % 169.7, 166.3, 166.1, 152.8, 146.0, 140.2, 135.7, 123.2, 118.4, 112.3, 
110.2, 104.1, 97.1, 65.1, 64.9, 60.5, 45.7, 39.1, 29.9, 28.1, 26.2, 22.7, 14.4; enriched 13C 
= 169.7, 166.3, 166.1; IR (neat) 3358, 2920, 1662, 1456 cm-1;  HRMS (ESI/APCI) calcd 
























281 282  
Acetic acid (60 mL) and 37% aqueous formaldehyde (2.08 mL 25.6 mmol) were stirred 
together at room temperature.  To this solution 40% aqueous dimethylamine (11 mL, 96.5 
mmol) was added and the reaction stirred for 7 minutes.  A solution of 6-OBoc indole 
281 (5.29 g, 22.7 mmol) in 10 mL of acetic acid was slowly added to the above solution 
and the reaction stirred for 15 hours at room temperature.  The reaction mixture was 
basified to pH 10 with 2M NaOH and extracted with diethyl ether (3 x 100 mL).  The 
combined organic layer was dried over Na2SO4 and concentrated under vacuum.  Crude 
yield: 6.59 g, 22.7 mmol. 
 
1H NMR (300 MHz, CDCl3) % 9.21 (bs, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 2.1 
Hz, 1H), 6.92-6.88 (m, 2H), 2.23 (s, 6H), 1.56 (s, 9H); 13C NMR (75 MHz, CDCl3) 
% 153.1, 146.8, 136.1, 126.2, 125.3, 119.5, 113.6, 112.2, 104.2, 83.5, 66.1, 58.2, 54.4, 


































Gramine 282 (230 mg, 0.792 mmol), glycine 122 (211 mg, 0.792 mmol) and DABCO 
(88 mg, 0.792 mmol) were stirred together in MeCN (4 mL) at reflux for 18 hours.  The 
reaction mixture was concentrated under vacuum and purified via flash column 
chromatography.  The desired product eluted in 3:1 hexanes-ethyl acetate as a white 
amorphous solid.  Yield: 353 mg, 0.689 mmol, 87%.   
 
1H NMR (300 MHz, CDCl3) % 8.26 (bs, 1H), 7.59-6.59 (m, 14H), 4.37 (dd, J = 8.7, 13.5 
Hz, 1H) 4.20-4.12 (m, 2H), 3.42 (dd, J = 14.4, 5.1 Hz, 1H), 3.20 (dd, J = 14.1, 8.7 Hz, 
1H), 1.58 (s, 9H), 1.22 (t, 3H); 13C NMR (75 MHz, CDCl3) % 172.5, 171.0, 152.8, 147.0, 
139.6, 136.0, 135.9, 130.5, 129.0, 128.5, 128.4, 128.2, 127.7, 125.9, 124.3, 119.3, 113.4, 
111.9, 104.0, 83.4, 66.1, 61.2, 29.5, 28.0, 14.4; HRMS (ESI/APCI) calcd for C31H33N2O5  





























To a solution of imine 283 (340 mg, 0.663 mmol) in THF (5 mL) was added 1M HCl 
(1.65 mL).  The reaction mixture stirred for 20 minutes at room temperature and the THF 
was removed under vacuum.  The resulting slurry was basified with saturated aqueous 
NaHCO3 (20 mL) and extracted with CH2Cl2 (3 x 30 mL).  The combined organic layer 
was dried over Na2SO4 and concentrated under vacuum.  The crude material was purified 
via flash column chromatography in 3:1 hexanes-ethyl acetate with the desired product 
eluting with a 5% MeOH in CH2Cl2 flush of the column.  Yield:  228 mg, 0.656 mmol, 
99%.  The free amine (212 mg, 0.473 mmol) was dissolved in dioxane (2.36 mL) and 
cooled to 0ºC. Di-tert-butyl dicarbonate (108 mg, 0.496 mmol) and 1M NaOH (0.4 mL) 
were added to the stirring reaction mixture.  The reaction was allowed to warm to room 
temperature over 18 hours, after which the reaction was concentrated and the residue was 
dissolved in water (5 mL).  The slurry was acidified to pH 2 with saturated aqueous 
KHSO4 and extracted with ethyl acetate.  The combined organic layer was dried over 
Na2SO4 and concentrated under vacuum.  Yield:  167 mg, 0.374 mmol, 79%. 
  
1H NMR (300 MHz, CDCl3) % 8.42 (bs, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.14 (s, 1H), 6.92-
6.90 (m, 2H), 5.08 (d, J = 8.1 Hz, 1H), 4.61-4.56 (m, 1H), 4.14-4.09 (m, 2H), 3.70 (s, 
2H), 3.24-3.22 (m, 2H), 1.57 (s, 9H), 1.41 (s, 9H), 1.18 (t, 3H); 13C NMR (75 MHz, 
 295 
CDCl3) % 172.5, 155.5, 152.8, 147.1, 136.0, 126.0, 123.8, 119.3, 113.8, 110.4, 104.2, 
83.5, 80.1,67.3, 61.6, 54.5, 28.5, 28.0, 14.3; HRMS (ESI/APCI) calcd for C23H32N2O7Na  

























Indole 284 (240 mg, 0.535 mmol) was dissolved in THF (1.78 mL) and water (3.57 mL).  
To the solution, LiOH (128.2 mg, 5.35 mmol) was added and the reaction stirred at room 
temperature for 16 hours.  The mixture was concentrated under vacuum and the residue 
was diluted with water (10 mL) and acidified to pH 2 with 1M KHSO4.  The crude 
material was extracted with ethyl acetate (2 x 20 mL) and CH2Cl2 (2 x 20 mL).  The 
combined organic layer was dried over Na2SO4 and concentrated under vacuum.  The 
crude acid (129 mg, 0.307 mmol) was dissolved in MeCN (3.1 mL) and L-proline ethyl 
ester (43 mg, 0.307 mmol) was added to the solution.  HATU (175 mg, 0.461 mmol) and 
DIPEA (0.213 mL, 1.23 mmol) were added to the reaction mixture, and the solution 
stirred for 17 hours at room temperature.  The reaction was quenched with 1M HCl (20 
mL) and extracted with CH2Cl2 (3 x 30 mL).  The combined organic layer was dried over 
Na2SO4 and concentrated.  The crude material was purified via flash column 
chromatography using 1:1 hexanes-ethyl acetate.  Yield:  251 mg, 0.46 mmol, 86%. 
 
Mixture of rotamers: 1H NMR (400 MHz, CDCl3) % 7.58 (d, J = 8.8 Hz, 1H), 7.51-7.47 
(m, 1H), 7.13-7.11 (m, 3H), 6.97 (s, 2H), 6.89-6.85 (m, 3H), 5.46 (d, J = 8.4 Hz, 1H) 
5.27 (d, J = 8.4 Hz, 1H), 4.72-4.58 (m, 3H),4.46-4.43 (m, 1H), 4.15-4.07 (m, 6H), 3.65-
 297 
3.32 (m, 6H), 3.19-3.03 (m, 4H), 2.43-2.38 (m, 2H), 1.88-1.79 (m, 6H), 1.52 (s, 
18H)1.23-1.17 (m, 6H); 13C NMR (75 MHz, CDCl3) % 172.3, 172.1, 171.2, 170.9, 155.3, 
152.8, 152.7, 147.2, 147.1, 135.9, 125.8, 124.8, 124.1, 119.4, 119.2, 113.8, 113.7, 111.1, 
110.2, 104.1, 83.4, 83.3, 79.8, 61.3, 61.2, 59.3, 59.2, 53.6, 47.1, 46.9, 30.2, 29.2, 28.9, 
28.7, 28.6, 28.5, 27.9, 25.1, 24.3, 14.3; HRMS (ESI/APCI) calcd for C28H40N3O8  (M+H) 






























276, 6-hydroxybrevianamide F285  
Peptide 285 (58.4 mg, 0.107 mmol) was dissolved in 1 mL CH2Cl2 and cooled to 0ºC.  
TFA (1 mL) was slowly added to the solution and the ice bath was removed.  The 
reaction mixture stirred for 2 hours, and was quenched with saturated aqueous NaHCO3 
to pH 10.  The material was extracted with ethyl acetate (2 x 50 mL) and the combined 
organic layer was dried over Na2SO4 and concentrated.  The crude amine (33 mg, 0.095) 
was dissolved in MeCN (1 mL) and NEt3 (9.7 µL, 0.095 mmol) was added.  The reaction 
mixture stirred at reflux for 6 hours.  The solution cooled to room temperature, 1M HCl  
(5 mL) was added, and extracted with ethyl acetate (1 x 15 mL) and CH2Cl2 (1 x 15 mL).  
The organic layer was dried over Na2SO4 and concentrated under vacuum.  The mixture 
of diketopiperazine diastereomers was purified via flash column chromatography with a 
gradient elution of 5-7% MeOH in DCM.   
 
276, Cis: 1H NMR (300 MHz, CO(CD3)2) % 7.94 (bs, 1H), 7.41 (d, J = 8.7 Hz, 1H), 7.13 
(s, 1H), 6.84 (s, 1H), 6.66-6.63 (m, 1H), 6.28 (bs, 1H), 5.63 (s, 1H), 4.37-4.33 (m, 1H), 
4.17-4.11 (m, 1H), 3.58-3.35 (m, 4H), 3.01-2.93 (m, 4H) 2.32 (s, 3H), 1.82 (s, 3H), 1.78-
1.71 (m, 3H), 1.66 (s, 3H); 13C NMR (75 MHz, 20:1-CDCl3/CD3OD) % 170.4, 153.0, 
 300 
137.4, 123.3, 121.1, 119.2, 109.8, 96.7, 58.2, 57.9, 45.0, 30.6, 29.7, 28.7, 21.4; HRMS 

















Trans: 1H NMR (300 MHz, CDCl3) % 7.26 (d, J = 8.7 Hz, 1H), 6.77 (s, 1H), 6.69 (d, J = 
2.1 Hz, 1H), 6.58 (dd, J = 8.7, 2.7 Hz, 1H), 4.13-4.10 (m, 1H), 3.31-3.29 (m, 3H), 3.02-
2.93 (m, 3H) 2.39-2.34 (m, 2H), 1.94-1.85 (m, 2H), 1.76-1.66 (m, 2H), 1.56-1.48 (m, 




















118 286  
Indole 118 (2.34 g, 20.0 mmol) was dissolved in 100 mL THF and powdered KOH (5.61 
g, 100.0 mmol) was added.  The reaction stirred at room temperature for 10 minutes.  To 
the solution, TsCl (4.20 g, 22.0 mmol) was added and the reaction stirred for 20 hours at 
room temperature.  The solid was filtered and washed with CH2Cl2 (100 mL).  The 
filtrate was concentrated and taken on to the next reaction.  The Ts-protected indole (1.0 
g, 3.68 mmol) was dissolved in 7.3 mL THF and cooled to -78ºC.  To the mixture, a 
1.6M solution of n-BuLi in hexanes (2.76 mL, 4.42 mmol) was slowly added and the 
reaction stirred for 45 minutes at -78ºC.  Prenyl bromide (1.27 mL, 11.0 mmol) was 
quickly added and the reaction mixture stirred for 15 minutes at -78ºC.  The reaction was 
then allowed to warm to room temperature while stirring for 17 hours.  The mixture was 
quenched with saturated aqueous NH4Cl (25 mL) and extracted with CH2Cl2 (3 x 25 mL).  
The organic layer was washed with brine (2 x 50 mL), dried over Na2SO4, and 
concentrated under vacuum.  The crude mixture was placed under high pressure vacuum 
in a 45ºC oil bath to remove volatiles (4 hours).  Yield: 850 mg, 2.50 mmol, 68%. 
 
1H NMR (300 MHz, CDCl3) % 8.22 (d, J = 9.0 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.42 (d, 
J = 8.1 Hz, 1H), 7.30-7.16 (m, 4H), 6.39 (s, 1H), 3.61 (s, 2H), 3.42 (m, 1H), 3.72 (d, J = 
7.2 Hz, 2H), 2.32 (s, 3H), 1.82 (s, 3H), 1.78-1.71 (m, 3H), 1.66 (s, 3H); 13C NMR (75 
MHz, CDCl3) % 144.9, 141.4, 137.6, 136.5, 135.1, 130.1, 130.0, 126.5, 124.0, 123.7, 
 303 
120.4, 120.0, 114.9, 109.2, 28.2, 26.0, 21.8, 18.0; HRMS (ESI/APCI) calcd for 















286 287  
To a solution of indole 286 (850 mg, 2.50 mmol) in MeOH (17 mL) was added Mg 
powder (243 mg, 10.0 mmol).  The mixture was sonicated for 15 minutes at room 
temperature.  The reaction was quenched with saturated aqueous NH4Cl (30 mL), 
concentrated, and extracted with CH2Cl2 (3 x 25 mL).  The organic layer was washed 
with saturated aqueous NaHCO3 (50 mL) and brine (50 mL).  The organic layer was 
dried over Na2SO4 and concentrated under vacuum.  The crude material was purified via 
flash column chromatography in 40:1 Pet ether-ethyl acetate.  Yield:  200 mg, 1.08 
mmol, 43%. 
 
1H NMR (300 MHz, CDCl3) % 7.83 (bs, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.7 
Hz, 1H), 7.21-7.14 (m, 2H), 6.31 (s, 1H), 3.61 (s, 2H), 5.45 (m, 1H), 3.52 (d, J = 7.2 Hz, 
2H), 1.87 (s, 3H), 1.81 (s, 3H); 13C NMR (75 MHz, CDCl3) % 139.0, 136.2, 134.8, 129.2, 
121.2, 120.5, 120.1, 119.9, 110.7, 99.7, 27.4, 26.1, 18.2; HRMS (ESI/APCI) calcd for 

























Acetic acid (2 mL) and 37% aqueous formaldehyde (0.100 mL 1.22 mmol) were stirred 
together at room temperature.  To this solution 40% aqueous dimethylamine (0.517 mL, 
4.59 mmol) was added and the reaction stirred for 7 minutes.  A solution of indole 287 
(200 mg, 1.08 mmol) in 1.27 mL of acetic acid was slowly added to the above solution 
and the reaction stirred for 15 hours at room temperature.  The reaction mixture was 
basified to pH 10 with 2M NaOH and extracted with diethyl ether (3 x 25 mL).  The 
combined organic layer was dried over Na2SO4 and concentrated under vacuum.  Crude 
yield: 261 mg, 1.08 mmol 
 
1H NMR (300 MHz, CDCl3) % 8.06 (bs, 1H), 7.68-7.65 (m, 1H), 7.29-7.26 (m, 1H), 7.14-
7.11 (m, 2H), 3.61 (s, 2H), 3.54 (d, J = 7.2 Hz, 2H), 2.31 (s, 6H), 1.81 (s, 3H), 1.78 (s, 
3H); 13C NMR (75 MHz, CDCl3) % 136.8, 135.3, 134.8, 129.7, 121.2, 120.6, 119.6, 
118.9, 110.5, 108.4, 53.6, 45.7, 26.1, 25.4, 18.2; HRMS (ESI/APCI) calcd for C14H16N  



































Gramine 288 (260 mg, 1.08 mmol), glycine 122 (317 mg, 1.18 mmol) and 
tributylphosphine (0.159 mL, 0.648 mmol) were stirred together in MeCN (5.4 mL) at 
110ºC for 18 hours.  The reaction mixture was cooled to room temperature, concentrated 
under vacuum and purified via flash column chromatography.  The desired product eluted 
in 9:1 hexanes-ethyl acetate as an orange amorphous solid.  Yield: 361 mg, 0.778 mmol, 
72%. 
 
1H NMR (300 MHz, CDCl3) % 7.61-7.05 (m, 14H), 6.91-6.86 (m, 1H), 5.08 (bs, 1H), 4.37 
(dd, J = 9.3, 4.2 Hz, 1H) 4.24-4.13 (m, 2H), 3.46-3.21 (m, 4H), 1.68 (s, 3H), 1.64 (s, 3H), 
1.25 (t, 3H); 13C NMR (75 MHz, CDCl3) %172.6, 170.3, 139.5, 136.0, 135.1, 134.7, 
130.3, 129.3, 129.1, 128.1, 127.8, 121.0, 120.7, 119.3, 118.5, 110.2, 107.1, 66.2, 61.1, 
28.3, 25.9, 25.3, 18.0, 14.4; HRMS (ESI/APCI) calcd for C31H33N2O2 (M+H) 465.2537, 







































Imine 289 (501 mg, 1.08 mmol) was dissolved in 8 mL THF and 2.7 mL 1M HCl.  The 
reaction stirred for 30 minutes at room temperature.  The THF was removed in vacuo and 
the resulting slurry was basified with saturated aqueous NaHCO3.  The crude product was 
extracted with CH2Cl2 (3 x 30 mL), dried over Na2SO4 and concentrated under vacuum.  
The crude material was purified via flash column chromatography using 3:1 hexanes-
ethyl acetate and the product eluted with a 10% MeOH in DCM flush of the column as an 
orange oil.  The free amine (165 mg, 0.550 mmol) and N-Boc-L-proline (118 mg, 0.550 
mmol) were stirred together in 5.5 mL MeCN.  To the solution was added HATU (313 
mg, 0.825 mmol) and DIPEA (0.383 mL, 2.2 mmol) and the reaction stirred at room 
temperature for 3 hours.  The reaction mixture was quenched with 1M HCl (15 mL) and 
extracted with CH2Cl2 (3 x 30 mL).  The combined organic layer was dried over Na2SO4 
and concentrated.  The crude material was purified via flash column chromatography in 
1:1 hexanes-ethyl acetate.  Yield: 240 mg, 0.482 mmol, 88%. 
 
1H NMR (300 MHz, CDCl3) % 7.48-7.39 (m, 2H), 7.08-7.04 (m, 2H), 5.27 (bs, 1H), 4.73 
(dd, J = 8.4, 4.5 Hz, 2H) 4.13-3.93 (m, 3H), 3.69-3.52 (m, 2H), 3.48 (d, J = 6.9, 3H), 
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3.21-3.19 (m, 3H), 2.56-2.43 (m, 2H), 2.17-1.98 (m, 4H), 1.75 (s, 3H), 1.73 (s, 3H), 1.54 
(s, 9H); 13C NMR (100 MHz, CDCl3) % 172.3, 136.1, 135.3, 135.1, 121.5, 121.4, 120.3, 
118.1, 117.8, 110.7, 80.8, 80.6, 61.5, 53.7, 53.6, 53.5, 47.2, 31.0, 28.5, 27.4, 26.0, 25.3, 
































Peptide 291 (240 mg, 0.482 mmol) was dissolved in CH2Cl2 (1.6 mL) and cooled to 0ºC.  
TFA (1.6 mL) was slowly added to the cooled solution, and the reaction stirred at room 
temperature for 3 hours.  The reaction was quenched with saturated aqueous NaHCO3 to 
pH 10 and extracted with ethyl acetate (5 x 100 mL).  The organic layer was dried over 
Na2SO4 and concentrated.  The crude free amine (169 mg, 0.459 mmol) was dissolved in 
4.5 mL toluene and 2-hydroxypyridine (8.75 mg, 0.092 mmol) was added.  The reaction 
mixture stirred at reflux for 16 hours, which was then cooled to room temperature and 
concentrated.  The residue was diluted with CH2Cl2 (10 mL) and washed with 10 mL 1M 
HCl.  The organic layer was dried over Na2SO4 and concentrated.  The crude material 
was purified via flash column chromatography with 3% MeOH in DCM to afford a 1:1 
mixture of tryprostatin B (278) and trans-tryprostatin B in 59% yield (278: 50 mg, 0.142 
mmol) 
 
1H NMR (300 MHz, CDCl3) % 8.08 (bs, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 8.1 
Hz, 1H), 7.18-7.06 (m, 2H), 5.64 (bs, 1H), 5.33-5.28 (m, 1H), 4.42-4.34 (m, 1H), 4.08-
4.03 (m, 1H), 3.71-3.59 (m, 3H), 3.48-3.44 (m, 1H), 2.99-2.83 (m, 1H), 2.39-2.29 (m, 
1H), 2.03-1.88 (m, 3H), 1.77 (s, 3H), 1.74 (s, 3H); 13C NMR (100 MHz, CDCl3) % 169.6, 
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166.7, 136.7, 135.7, 135.6, 128.2, 122.0, 120.1, 119.9, 117.9, 111.0, 104.8, 59.5, 54.8, 
45.6, 28.5, 25.9, 25.8, 25.3, 22.8, 18.2; IR (neat) 3303, 2969, 1672, 1664 cm-1;  HRMS 





Trans: 1H NMR (300 MHz, CDCl3) % 8.02 (bs, 1H), 7.51 (d, J = 7.2 Hz, 1H), 7.25 (d, J = 
8.7 Hz, 1H), 7.13-7.04 (m, 2H), 6.40-6.35 (m, 1H), 5.31-5.26 (m, 1H), 4.78 (d, J = 8.7 
Hz, 1H) 4.27-4.21 (m, 1H), 3.56-3.35 (m, 4H), 3.16-3.09 (m, 1H), 2.42-2.26 (m, 1H), 
2.05-1.91 (m, 3H), 1.64 (s, 3H), 1.55 (s, 3H); HRMS (ESI/APCI) calcd for 
C21H25N3O2Na (M+Na) 374.1839, found 374.1841. 
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7.2.3 Chapter 6 Experimentals 
2-Methyl-7-amino-1,8-naphthyridine (293): 





291 292 293  
Concentrated phosphoric acid (18 mL) was cooled to 0ºC.  Commercially available 2,6-
diaminopyridine 291 (2.0 g, 18.3 mmol) was added and the reaction was heated to 60ºC.  
Commercially available 3-ketobutanal dimethyl acetal 292 (2.38 mL, 17.9 mmol) was 
added to the reaction mixture dropwise via a syringe pump over 30 minutes.  The reaction 
was heated to 115ºC for 3.5 hours.  The reaction mixture was cooled to 0ºC and ice cold 
15% NH4OH was quickly added in portions until pH 12.  The product was extracted 5 
times with CHCl3, dried over Na2SO4 and concentrated.  Yield: 2.53 g, 15.9 mmol, 89%. 
 
1H NMR (300 MHz, CDCl3) % 7.72 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 8.7 Hz, 1H), 6.94 (d, 
J = 8.1 Hz, 1H), 6.63 (d, J = 9.0 Hz, 1H), 4.00 (bs, 2H), 2.53 (s, 3H). 13C NMR (75 MHz, 
CDCl3) % 162.2, 159.9, 156.4, 138.1, 136.4, 119.0, 115.5, 111.8, 25.6; HRMS 














294 299  
Commercially available suberic acid 294 (5.0 g, 28.7 mmol) was dissolved in acetic 
anhydride (10 mL) and heated to reflux for one hour.  The reaction cooled to room 
temperature and the solvent was removed in vaccuo.  The resulting solid was 
recrystallized from acetonitrile.  Yield: 4.39 g, 28.1 mmol, 98%. 
 
1H NMR (300 MHz, CDCl3) % 2.45 (t, J = 7.2 Hz, 4H), 1.72-1.62 (m, 4H), 1.41-1.37 (m, 







 Naphthyrdine suberic acid (300): 








Suberoyl anhydride 299 (294 mg, 1.88 mmol) was dissolved in THF (9 mL).  2-Methyl-
7-amino-1,8-naphthyridine 293 (300 mg, 1.88 mmol) was added to the reaction mixture 
and the reaction was heated to reflux for 1.5 hours.  The reaction cooled to room 
temperature and water (40 mL) was added.  The solid was filtered and the crude mixture 
was purified via flash column chromatography (5% MeOH in DCM).  Yield: 320 mg, 
1.02 mmol, 54% 
 
1H NMR (300 MHz, CDCl3) % 8.45 (d, J = 8.7 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.98 (d, 
J = 8.1 Hz, 1H), 7.24 (d, J = 11.1 Hz, 1H), 2.70 (s, 3H), 2.46 (t, J = 7.2 Hz, 2H), 2.32 (t, J 
= 7.2 Hz, 2H), 1.75-1.61 (m, 4H), 1.40-1.38 (m, 4H). 13C NMR (75 MHz, 20:1 

























300 289  
Naphthyridine suberic acid 300 (200 mg, 0.634 mmol) was dissolved in THF (3 mL) and 
cooled to 0oC.  Ethyl chloroformate (0.078 mL, 0.824 mmol) and triethylamine (0.123 
mL, 0.888 mmol) were added and the reaction mixture was stirred at room temperature of 
10 minutes.  The solid was filtered and the filtrate was added to hydroxylamine in water 
(2.10 mL, 1.05 mmol).  The reaction stirred at room temperature for 45 minutes.  The 
reaction was separated and extracted with ethyl acetate (3 x 20 mL).  The organic layer 
was dried over Na2SO4 and concentrated.  The crude mixture was purified via flash 
column chromatography (5% MeOH in DCM to 15% MeOH in DCM).  Yield: 79.6 mg, 
0.241 mmol, 38%. 
 
1H NMR (300 MHz, CDCl3) % 8.24 (d, J = 9.3 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.89 (d, 
J = 8.1 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 4.21 (s, 6H), 3.14 (s, 3H), 2.55 (s, 3H). 13C 
NMR (75 MHz, 20:1 CDCl3/CD3OD) % 173.6, 162.7, 154.3, 138.9, 137.2, 121.5, 118.5, 
114.8, 37.6, 32.8, 29.1, 28.5, 25.3, 25.2, 25.1; HRMS (ESI/APCI) calcd for C17H23N4O3 






















303 304  
A solution of "-alanine 303 (2.67 g, 30 mmol) in a mixture of dioxane (60 mL), water (30 
mL) and 1N NaOH (30 mL) was stirred and cooled in an ice-water bath.  Ditert-
butylpyrocarbonate (7.2 g, 33 mmol) was added, and stirring was continued at room 
temperature for 6 hours.  The solution was then concentrated in a vacuum to about 30 
mL, cooled in an ice-water bath and acidified to pH 2 with 1 M KHSO4.  The aqueous 
layer was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were 
dried over Na2SO4 and concentrated.  Yield: 5.22 g, 27.6 mmol, 92% 
 
1H NMR (300 MHz, CDCl3) % 10.56 (bs, 1H), 3.37 (m, 2H), 2.56 (m, 2H), 1.42 (s, 9H). 


















304 305  
To a solution of N-Boc-"-alanine 304 (3.0 g, 15.7 mmol) in DMF (10 mL) was added 
pentafluorophenol (2.2 g, 12.0 mmol) and EDCI (2.8 g, 14.6 mmol)  The mixture was 
stirred at room temperature for 24 hours.  The solvent was evaporated and the crude 
product was taken up in CHCl3 (30 mL).  The organic layer was washed with H2O and 
dried over MgSO4.  The solvent was evaporated in vacuo and the crude residue was 
purified via silica gel flash column chromatography (1:1 CHCl3/hexanes) to afford 17 as 
a white solid.  Yield: 2.95 g, 8.32 mmol, 53% 
 
1H NMR (300 MHz, CDCl3) % 5.02 (bs, 1H), 3.50 (q, J = 6.0, 6.3 Hz, 2H), 2.91 (t, J = 6.0 





































To a solution of the activated ester 305 (449 mg, 1.26 mmol) in dry DMF (4 mL) was 
added 2-amino-7-methyl-1,8-naphthyridine 293 (200 mg, 1.26 mmol) and DIPEA (162 
mg, 1.26 mmol).  The mixture was stirred at 40oC for 24 hours.  The solvent was 
evaporated to dryness and the crude residue was purified via silica gel flash column 
chromatography (50:1 CHCl3/MeOH).  Yield: 400 mg, 1.21 mmol, 96%. 
 
1H NMR (300 MHz, CDCl3) % 9.82 (bs, 1H), 8.43 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 8.7 
Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 5.36 (bs, 1H), 2.94 (d, J = 1.2 
Hz, 2H), 2.86 (d, J = 1.5 Hz, 2H), 2.71 (s, 3H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) 
% 163.4, 162.3, 154.3, 154.0, 139.3, 136.9, 121.9, 118.7, 114.9, 79.5, 37.5, 36.8, 36.4, 




























306 307  
To a solution of 306 (191 mg, 0.58 mmol) in dry CHCl3 (3 mL) at 0oC was added ethyl 
acetate containing 4M HCl (1.5 mL) and the mixture was stirred at room temperature for 
30 minutes.  The solvent was evaporated to dryness to give the hydrochloride salt of 19.  
The hydrochloride salt of 307 was dissolved in H2O (10 mL) and extracted into CHCl3 by 
the addition of 28% aqueous ammonia solution.  The organic layer was dried over 
MgSO4 and the solvent was evaporated in vacuo to give 307.  Yield: 42.7 mg, 0.186 
mmol, 32%. 
 
1H NMR (300 MHz, CDCl3) % 8.39 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 9.0 Hz, 1H), 7.97 (d, 



























N-Boc-melphalan (90 mg, 0.22 mmol) and naphthyridine 307 (51 mg, 0.22 mmol) were 
dissolved in DCM (3.7 mL) followed by the addition of NMM (0.082 mL, 0.75 mmol).  
The reaction mixture stirred for 40 minutes at 0oC.  EDCI (34 mg, 0.22 mmol) was added 
and the reaction mixture stirred for another 40 minutes at 0oC and then was allowed to 
warm to room temperature over 18 hours.  The reaction mixture was diluted with DCM 
(15 mL) and washed with 10% aqueous citric acid (15 mL).  The organic layer was dried 
over Na2SO4 and concentrated.  The crude material was purified via silica gel flash 
column chromatography (50:1 CHCl3/MeOH).  Yield: 23 mg, 0.037 mmol, 17%. The 
Boc-protected N-melphalan (26 mg, 0.042 mmol) was dissolved in HCl saturated ethyl 
acetate (4.2 mL) and stirred for 2 hours at room temperature.  The reaction was 
concentrated and purified via recrystallization (EtOH and diethyl ether).  Yield:  9.13 mg, 
0.176 mmol, 42%.  
 
 1H NMR (300 MHz, CDCl3) % 8.60 (d, J = 7.8 Hz, 1H), 8.53 (d, J = 9.0 Hz, 1H), 8.33 (d, 
J = 9.3 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 7.8 Hz, 2H), 6.51 (d, J = 7.8 Hz, 
2H), 3.58-3.53 (m, 4H), 3.49-3.44 (m, 4H), 3.40-3.31 (m, 1H), 3.21-3.20 (m, 6H), 2.66 
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7.3 General Biosynthetic Considerations 
 [13C]2-[15N]2-L-Proline and [13C]- L-glycine were obtained from the NIH Stable 
Isotopes Resource at Los Alamos National Laboratory.  Cultures of Aspergillus 
versicolor NRRL 35600 were obtained from the Department of Agriculture in Peoria, 
Illinois. 1H-NMR spectra and 13C-NMR spectra were obtained on Varian 300, 400, 400 
MR or 500 MHz NMR spectrometers.  NMR spectra were taken in CDCl3 (1H, 7.26 ppm; 
13C, 77.0 ppm), CD3OD (1H, 3.31 ppm, 49.15 ppm), d6-DMSO (1H, 2.50 ppm, 13C, 39.51 
ppm) and D2O (1H, 4.79 ppm) obtained from Cambridge Isotope Labs.  Mass spectra 
were obtained on Fisions VG Autospec using a high/low resolution magnetic sector.  
7.4 Biosynthesis Experimentals 
7.4.1 Procedure for Completing Feeding Studies 
Terrestrial-derived Aspergillus versicolor NRRL 35600 was suspended in a sterile 
10% glycerol solution.  Spores from this culture were transferred to sterile malt extract 
agar slants (prepared from 25 g malt agar and 500 mL distilled H2O); 20 µL of the 
suspension was used per slant.  The slants were placed in an incubator at 25 ºC for 14 
days.  Potato Dextrose Broth (PDB) was prepared by dissolving 48 g of the medium and 
6 g tryptose in 2L of doubly distilled H2O (DDH2O). The solution was heated to aid in 
dissolving the medium, which was then transferred to fernbach flasks (4 x 500 mL) and 
autoclaved.   
Spores of A. versicolor from eight slants were shaken into the four fernbach flasks 
containing sterile PDB. The fernbach flasks were covered and gently placed in the 
incubator for 14 days at 25 ºC for the notoamide E, 6-hydroxydeoxybrevianamide E, and 
stephacidin A incorporation studies.  The inoculated flasks used for the notoamide S 
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feeding study were allowed to incubate for 9 days.  The PDB was removed leaving a disk 
of the fungus.  The undersides of the disks, the mycelia cells, were rinsed with 100 mL of 
sterile water. 
Sterile trace element solution (35 mM NaNO3, 5.7 mM K2HPO4, 4.2 mM 
MgSO4&7H2O, 1.3 mM KCl, 36 mM FeSO4&7H2O, 25 mM MnSO4&H2O, 7 mM 
ZnSO4&7H2O, and 1.5 mM CuCl2&2H2O) containing the labeled precursor was placed into 
each of the flasks using a syringe and needle (Table 10).  The fungal cells were incubated 
at 25°C for 14-21 days and each flask was swirled daily to ensure even distribution of the 
labeled compound.  
Table 10. Details of each precursor incorporation experiment with A. versicolor.  
Proposed 
Precursor 
Mmol Precursor Additive Used Days Incubated 




0.159 DMSO 14 days 
Stephacidin A 0.140 DMSO 21 days 
Notoamide S 0.068 N/A 14 days 
 
A detergent had to be used to dissolve the water-insoluble proposed precursors.  
The water-insoluble compounds were dissolved in 0.5 mL DMSO.  TWEEN 80 (1% 
solution) was added to the dissolved precursor.  Sterile trace element solution was added 
to each precursor/TWEEN 80 solution and the mixture was sonicated for 15 minutes to 
aid in micelle formation.   
The aqueous solution was decanted and stored at 4°C with 1-2 mL of chloroform. 
The mycelia cells from each flask were harvested, combined with the cells from duplicate 
experiments and pureed in an Oster blender with 1:1 MeOH-CHCl3. The puree was 
transferred to a 2 L Erlenmeyer flask, diluted to 1.2 L with 1:1 MeOH-CHCl3, and placed 
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in the shaker for 24 hours.  Celite (30 g) was added to the flask and allowed to shake for 
an extra 10 minutes. The suspension was filtered through Whatman #2 paper and the 
filtrate was stored at 4°C. The mycelia “cake” was diluted with 600 mL 1:1 MeOH-
CHCl3 and placed on the shaker for an additional 48 hours.  The suspension was filtered 
through Whatman #2 paper, and the combined filtrates were concentrated under vacuum.  
The residue was dissolved in 250 mL H2O and extracted with EtOAc (3 x 300 mL). The 
organic layer was concentrated and partitioned between MeCN and hexanes. The layers 
were separated, and the MeCN layer was concentrated under vacuum.   
The crude material was purified via silica gel flash column chromatography (1% 
MeOH in DCM – 3% MeOH in DCM) to afford three fractions that were each analyzed 
by 13C NMR spectroscopy. Fractions containing enrichment of 13C were further purified 
via preparative thin layer chromatography (1000 mm, 3% MeOH in DCM x5). 
7.4.2 Calculations of the Percentage of 13C-incorporation 
 The percentage of 13C-enrichment in the fungal metabolites from isotopically 
labeled biosynthetic precursors was calculated according to the method Lambert et al.7.3  
These calculations are based on the comparison of the mass spectrum of the labeled 
material to the mass spectrum of the unlabeled material.  For these experiments, 
electrospray mass spectroscopy was used, thus the base peak in the mass spectrum was 
the M+H peak.  For feeding studies using 15N-labels, the additional 15N was fixed. For 
these experiments the base peak was the M(15N)+H for 6-hydroxydeoxybrevianamide E 
or M(15N)2+H for notoamide S. 
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Percent Incorporation of notoamide E into notoamide D: 
Native Notoamide D (C26H31N3O3) 
[M+H] (450.23): 73.78% 
[M+H+1] (451.24): 21.94% 
[M+H+2] (452.25): 3.76% 
[M+H+3] (453.25): 0.47% 
[M+H+4] (454.25): 0.05% 
 
13C Notoamide D from incorporation experiments: 
[M+H] (450.23): 2.4% 
[M+H+1] (451.24): 9.9% 
[M+H+2] (452.25): 85.9% 
 
[M+H+3] (453.25): 1.5% 
[M+H+4] (454.25): 0.3% 
 
Calculation of Native Notoamide D:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.78 = 1918.28 
[M+H+1]:  12C: 25 x 21.94 = 548.5  13C: 1 x 21.94 = 21.94 
[M+H+2]:  12C: 24 x 3.76 = 90.24    13C: 2 x 3.76 = 7.52 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.93     total 13C: 31.07 
 
Native Notoamide D 13C content: 31.07/(2568.93 +31.07) x 100% = 1.2% 
 
Calculation for 13C Notoamide D from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 2.4 = 62.7  
[M+H+1]:  12C: 25 x 9.9 = 247.5  13C: 1 x 9.9 = 9.9 
[M+H+2]:  12C: 24 x 85.9 = 2061.6    13C: 2 x 85.9 = 171.8 
[M+H+3]:  12C: 23 x 1.5 = 34.5  13C: 3 x 1.5 = 4.5 
[M+H+4]:  12C: 22 x 0.3 = 6.6  13C: 4 x 0.3 = 1.2 
 
total 12C: 2412.9     total 13C: 187.4 
 
Notoamide D from incorporation experiments 13C content: 187.4/(2412.9 + 187.4) x 
100% = 7.2% 
 





Percent Incorporation of notoamide E into notoamide C: 
Native Notoamide C (C26H31N3O3) 
[M+H] (450.23): 73.78% 
[M+H+1] (451.24): 21.94% 
[M+H+2] (452.25): 3.76% 
[M+H+3] (453.25): 0.47% 
[M+H+4] (454.25): 0.05% 
 
13C Notoamide C from incorporation experiments: 
[M+H] (450.23): 0.0% 
[M+H+1] (451.24): 10.8% 
[M+H+2] (452.25): 87.4% 
[M+H+3] (453.25): 1.7% 
[M+H+4] (454.25): 0.1% 
 
Calculation of Native Notoamide C:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.78 = 1918.28 
[M+H+1]:  12C: 25 x 21.94 = 548.5  13C: 1 x 21.94 = 21.94 
[M+H+2]:  12C: 24 x 3.76 = 90.24    13C: 2 x 3.76 = 7.52 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.93     total 13C: 31.07 
 
Native Notoamide C 13C content: 31.07/(2568.93 + 31.07) x 100% =  1.2% 
 
Calculation for 13C Notoamide C from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 0.0 = 0.0 
[M+H+1]:  12C: 25 x 10.8 = 270  13C: 1 x 10.8 = 10.8 
[M+H+2]:  12C: 24 x 87.4 = 2097.6  13C: 2 x 87.4 = 174.8 
[M+H+3]:  12C: 23 x 1.7 = 39.1  13C: 3 x 1.7 = 5.1 
[M+H+4]:  12C: 22 x 0.1 = 2.2  13C: 4 x 0.1 = 0.4 
 
total 12C: 2408.9    total 13C: 191.1  
 
Notoamide C from incorporation experiments 13C content: 191.1/(2408.9 + 191.1) x 
100% = 7.4% 
 




Percent Incorporation of 6-hydroxydeoxybrevianamide E into notoamide J: 
Native Notoamide J (C21H25N3O4) 
[M+H] (384.18): 77.9% 
[M+H+1] (385.19): 18.9% 
[M+H+2] (386.20): 2.84% 
[M+H+3] (387.20): 0.32% 
[M+H+4] (388.21): 0.03% 
 
13C Notoamide J from incorporation experiments: 
[M+H] (384.18): 0% 
[M+H+1] (385.19): 0% 
[M+H+2] (386.20): 99.5% 
[M+H+3] (387.20): 0% 
[M+H+4] (388.20): 0.5% 
 
Calculation of Native Notoamide J:  (assume 100 molecules) 
[M+H]:  12C: 21 x 77.9 = 1635.9 
[M+H+1]:  12C: 20 x 18.9 = 378  13C: 1 x 18.9 = 18.9 
[M+H+2]:  12C: 19 x 2.84 = 53.96    13C: 2 x 2.84 = 5.68 
[M+H+3]:  12C: 18 x 0.32 = 5.76  13C: 3 x 0.32 = 0.96 
[M+H+4]:  12C: 17 x 0.03 = 0.51  13C: 4 x 0.03 = 0.12 
 
total 12C: 2074.13     total 13C: 25.66 
Native Notoamide J 13C content: 25.66/(2074.13 +25.66) x 100% = 1.2% 
 
Calculation for 13C Notoamide J from incorporation experiments: (assume 100 
molecules)  15N-fixed at 1 
 [M+H]:  12C: 21 x 0 = 0  
[M+H+1]:  12C: 20 x 0 = 0   13C: 1 x 0.0 = 0.0 
[M+H+2]:  12C: 19 x 99.5 = 1890.5    13C: 2 x 99.5 = 199 
[M+H+3]:  12C: 18 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 17 x 0.5 = 8.5  13C: 4 x 0.5 = 2 
 
total 12C:  1899     total 13C: 201 
Notoamide J from incorporation experiments 13C content: 201/(1899 + 201) x 100% = 
9.6% 
 





Percent Incorporation of stephacidin A into notoamide B: 
Native Notoamide B (C26H31N3O3) 
[M+H] (448.22.): 73.8% 
[M+H+1] (449.22): 21.93% 
[M+H+2] (450.21): 3.75% 
[M+H+3] (451.21): 0.47% 
[M+H+4] (452.20): 0.05% 
 
13C Notoamide B from incorporation experiments: 
[M+H] (450.20): 49.2% 
[M+H+1] (451.20): 0.1% 
[M+H+2] (452.19): 50.5% 
[M+H+3] (453.19): 0.0% 
[M+H+4] (454.18): 0.0% 
 
Calculation of Native Notoamide B:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.8 = 1918.8 
[M+H+1]:  12C: 25 x 21.93 = 548.25  13C: 1 x 21.93 = 21.93 
[M+H+2]:  12C: 24 x 3.75 = 90.0    13C: 2 x 3.75 = 7.5 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.96     total 13C: 31.04 
 
Native Notoamide B 13C content: 31.04/(2568.96 +31.04) x 100% = 1.2% 
 
Calculation for 13C Notoamide B from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 49.2 = 1279.2  
[M+H+1]:  12C: 25 x 0.1 = 2.5  13C: 1 x 0.1 = 0.1 
[M+H+2]:  12C: 24 x 50.5 = 1212    13C: 2 x 50.5 = 101 
[M+H+3]:  12C: 23 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 22 x 0.0 = 0   13C: 4 x 0.0 = 0 
 
total 12C:  2493.7     total 13C: 101.1 
 
Notoamide B from incorporation experiments 13C content: 101.1/(2493.7 + 101.1) x 
100% = 3.9% 
 




Percent Incorporation of notoamide S into notoamide D: 
Native Notoamide D (C26H31N3O3) 
[M+H] (450.23): 73.78% 
[M+H+1] (451.23): 21.94% 
[M+H+2] (452.24): 3.76% 
[M+H+3] (453.25): 0.47% 
[M+H+4] (454.25): 0.05% 
 
13C Notoamide D from incorporation experiments: 
[M+H] (450.23): 1.3% 
[M+H+1] (451.23): 3.9% 
[M+H+2] (452.24): 94.8% 
[M+H+3] (453.25): 0.0% 
[M+H+4] (454.25): 0.0% 
 
Calculation of Native Notoamide D:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.78 = 1918.28 
[M+H+1]:  12C: 25 x 21.94 = 548.5  13C: 1 x 21.94 = 21.94 
[M+H+2]:  12C: 24 x 3.76 = 90.24    13C: 2 x 3.76 = 7.52 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.93     total 13C: 31.07 
 
Native Notoamide D 13C content: 31.07/(2568.93 +31.07) x 100% =  1.2% 
 
Calculation for 13C Notoamide D from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 1.3 = 33.8  
[M+H+1]:  12C: 25 x 3.9 = 97.5  13C: 1 x 3.9 = 3.9 
[M+H+2]:  12C: 24 x 94.8 = 2275.2    13C: 2 x 94.8 = 189.6 
[M+H+3]:  12C: 23 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 22 x 0.0 = 0   13C: 4 x 0.0 = 0 
 
total 12C: 2406.5    total 13C: 193.5 
 
Notoamide D from incorporation experiments 13C content: 194.4/(2413.4 + 194.4) x 
100% = 7.4% 
 





Percent Incorporation of notoamide S into notoamide C: 
Native Notoamide C (C26H31N3O3) 
[M+H] (450.23): 73.78% 
[M+H+1] (451.23): 21.94% 
[M+H+2] (452.24): 3.76% 
[M+H+3] (453.25): 0.47% 
[M+H+4] (454.25): 0.05% 
 
13C Notoamide C from incorporation experiments: 
[M+H] (450.25): 0.0% 
[M+H+1] (451.): 4.7% 
[M+H+2] (452.25): 94.5% 
[M+H+3] (453.): 0.0% 
[M+H+4] (454.): 0.8% 
 
Calculation of Native Notoamide C:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.78 = 1918.28 
[M+H+1]:  12C: 25 x 21.94 = 548.5  13C: 1 x 21.94 = 21.94 
[M+H+2]:  12C: 24 x 3.76 = 90.24    13C: 2 x 3.76 = 7.52 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.93     total 13C: 31.07 
 
Native Notoamide C 13C content: 31.07/(2568.93 + 31.07) x 100% =  1.2% 
 
Calculation for 13C Notoamide C from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 0.0 = 0.0 
[M+H+1]:  12C: 25 x 4.7 =117.5  13C: 1 x 4.7 = 4.7 
[M+H+2]:  12C: 24 x 94.5 = 2268.0  13C: 2 x 94.5 = 189.0 
[M+H+3]:  12C: 23 x 0.0 = 0.0  13C: 3 x 0.0 = 0.0 
[M+H+4]:  12C: 22 x 0.8 = 17.6  13C: 4 x 0.8 = 3.2 
 
total 12C: 2403.1    total 13C: 196.9 
 
Notoamide C from incorporation experiments 13C content: 196.9/(2403.1 + 196.9) x 
100% = 7.6% 
 
Percent incorporation of intact doubly 13C-labeled Notoamide S = 7.6%- 1.2% = 6.4 
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Percent Incorporation of notoamide S into notoamide B: 
Native Notoamide B (C26H29N3O4) 
[M+H] (448.22.): 73.8% 
[M+H+1] (449.22): 21.93% 
[M+H+2] (450.21): 3.75% 
[M+H+3] (451.21): 0.47% 
[M+H+4] (452.20): 0.05% 
 
13C Notoamide B from incorporation experiments: 
[M+H] (450.20): 0.0% 
[M+H+1] (451.20): 3.4% 
[M+H+2] (452.19): 96.9% 
[M+H+3] (453.19): 0.0% 
[M+H+4] (454.18): 0.0% 
 
Calculation of Native Notoamide B:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.8 = 1918.8 
[M+H+1]:  12C: 25 x 21.93 = 548.25  13C: 1 x 21.93 = 21.93 
[M+H+2]:  12C: 24 x 3.75 = 90.0    13C: 2 x 3.75 = 7.5 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.96     total 13C: 31.04 
 
Native Notoamide B 13C content: 31.04/(2568.96 +31.04) x 100% = 1.2% 
 
Calculation for 13C Notoamide B from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 0.0 = 0.0  
[M+H+1]:  12C: 25 x 3.4 = 85 .0  13C: 1 x 3.4 = 3.4 
[M+H+2]:  12C: 24 x 96.9 = 2325.6    13C: 2 x 96.9 = 193.8 
[M+H+3]:  12C: 23 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 22 x 0.0 = 0   13C: 4 x 0.0 = 0 
 
total 12C: 2410.6    total 13C: 197.2 
 
Notoamide B from incorporation experiments 13C content: 197.2/(2410.6 + 197.2) x 
100% = 7.6% 
 




Percent Incorporation of notoamide S into stephacidin A: 
Native Stephacidin A (C26H29N3O3) 
[M+H] (432.22): 73.8% 
[M+H+1] (433.22): 21.93% 
[M+H+2] (434.23): 3.75% 
[M+H+3] (435.23): 0.47% 
[M+H+4] (436.24): 0.05% 
 
13C Stephacidin A from incorporation experiments: 
[M+H] (432.22): 0.0% 
[M+H+1] (433.22): 10.0% 
[M+H+2] (434.23): 88.3% 
[M+H+3] (435.23): 0.0% 
[M+H+4] (436.24): 1.7% 
 
Calculation of Native Stephacidin A:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.8 = 1918.8 
[M+H+1]:  12C: 25 x 21.93 = 548.25  13C: 1 x 21.93 = 21.93 
[M+H+2]:  12C: 24 x 3.75 = 90.0    13C: 2 x 3.75 = 7.5 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.96     total 13C: 31.04 
 
Native Stephacidin A 13C content: 31.04/(2568.96 +31.04) x 100% = 1.2% 
 
Calculation for 13C Stephacidin A from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 0.0 = 0.0  
[M+H+1]:  12C: 25 x 10.0 = 250  13C: 1 x 10.0 = 10.0 
[M+H+2]:  12C: 24 x 88.3 = 2119.2    13C: 2 x 88.3 = 176.6 
[M+H+3]:  12C: 23 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 22 x 1.7 = 37.4  13C: 4 x 1.7 = 6.8 
 
total 12C: 2406.6    total 13C: 193.4 
 
Stephacidin A from incorporation experiments 13C content: 193.4/(2406.6 + 193.4) x 
100% = 7.4% 
 
Percent incorporation of intact doubly 13C-labeled Notoamide S = 7.4% - 1.2% = 
6.2%  
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Percent Incorporation of notoamide S into versicolamide B: 
Native Versicolamide B (C26H29N3O4) 
[M+H] (448.22.): 73.8% 
[M+H+1] (449.22): 21.93% 
[M+H+2] (450.21): 3.75% 
[M+H+3] (451.21): 0.47% 
[M+H+4] (452.20): 0.05% 
 
13C Versicolamide B from incorporation experiments: 
[M+H] (450.20): 0.0% 
[M+H+1] (451.20): 0.0% 
[M+H+2] (452.19): 99.7% 
[M+H+3] (453.19): 0.0% 
[M+H+4] (454.18): 0.3% 
 
Calculation of Native Versicolamide B:  (assume 100 molecules) 
[M+H]:  12C: 26 x 73.8 = 1918.8 
[M+H+1]:  12C: 25 x 21.93 = 548.25  13C: 1 x 21.93 = 21.93 
[M+H+2]:  12C: 24 x 3.75 = 90.0    13C: 2 x 3.75 = 7.5 
[M+H+3]:  12C: 23 x 0.47 = 10.81  13C: 3 x 0.47 = 1.41 
[M+H+4]:  12C: 22 x 0.05 = 1.1  13C: 4 x 0.05 = 0.2 
 
total 12C: 2568.96     total 13C: 31.04 
 
Native Versicolamide B 13C content: 31.04/(2568.96 +31.04) x 100% = 1.2% 
 
Calculation for 13C Versicolamide B from incorporation experiments: (assume 100 
molecules) 
 
[M+H]:  12C: 26 x 0.0 = 0.0  
[M+H+1]:  12C: 25 x 0.0 = 0.0  13C: 1 x 0.0 = 0.0 
[M+H+2]:  12C: 24 x 99.7 = 2392.8    13C: 2 x 99.7 = 199.4 
[M+H+3]:  12C: 23 x 0.0 = 0   13C: 3 x 0.0 = 0 
[M+H+4]:  12C: 22 x 0.3 = 6.6  13C: 4 x 0.3 = 1.2 
 
total 12C: 2399.4    total 13C: 200.6 
 
Versicolamide B from incorporation experiments 13C content: 200.6/(2399.4 + 200.6) x 
100% = 7.7% 
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Appendix 2:  Research Proposal 
 
 
Drug Delivery:  Design and Synthesis of a Novel Prodrug for the Targeted 




The aim of this proposal is to develop a novel method of drug delivery targeted 
toward the treatment of brain tumors.  Several important factors need to be considered 
when developing treatments for brain tumors, such as how to effectively transport the 
therapeutic agent across the blood brain barrier (BBB) and how to actively target the 
tumor.  Glucose is an essential nutrient for both the brain and tumors, and as such, 
glucose crosses the BBB and enters tumor cells via a specific transporter protein, GLUT-
1.  By utilizing the glucose transporter protein, several prodrugs (1-4, Figure 1) could be 
synthesized that employ a glucose derivative (2-deoxy-glucose) acting as a carrier across 
the BBB and into the tumor.  Through an acid-labile linker, the glucose derivative could 
be cleaved from the active chemotherapeutic agent once in the acidic microenvironment 
of the tumor.  Given that prodrugs 1-4 contain 2-deoxy-glucose (2-DG) as the carrier, as 
opposed to D-glucose, once the ester bond is hydrolyzed, 2-DG could also act as a 












































Figure 1.  Proposed prodrug compounds. 
 
Specific Aims for this Proposal: 
1. To develop a method of drug delivery that will allow the drug to cross the blood 
brain barrier (BBB). 
2. To develop a strategy that allows the drug to specifically target the brain tumor 
while minimizing the effect of the drug on normal healthy cells. 
3. To form an efficient prodrug that is only activated within the brain tumor. 
 
Background and Significance: 
The efficiency of currently available chemotherapeutics used in the treatment of 
cancer is greatly limited by the inability of these drugs to differentiate between cancer 
cells and normal healthy cells.1  The poor biodistribution (BD) of conventional treatments 
 384 
limits the amount of the anti-cancer drug that can be administered safely, thereby 
reducing their efficacy in eliminating malignant cells.2  The use of a drug delivery system 
can aid in the BD of traditional drugs by selectively targeting tumors and treating the 
cancerous cells, while minimizing exposure of healthy cells to the drug.  Thus, targeted 
drug delivery can not only lower the dose of the drug, but also reduce the side effects.  
Several methods of targeted drug delivery have been explored over the years, but only a 
few of these therapeutic agents have been approved for treatment. 
The treatment of central nervous system (CNS) disorders are often complicated 
by the presence of protective barriers that restricts the passage of foreign particles into the 
brain.3  As shown in Figure 2, there are two vascular barriers in the brain, the endothelial 
blood-brain barrier (BBB) and the epithelial blood-cerebrospinal fluid barrier (BCSFB).  
In order for any therapeutic agents to reach the brain, they must cross one of these two 
physiological barriers.  In terms of drug delivery, the BBB is the most relevant barrier 
since the area of the BBB is about 1000 times larger than that of the BSDFB.4  
Unfortunately, many neurotherapeutics are unsuccessful in treating CNS disorders 




Figure 2.  Overview of the two main barriers in the CNS.3 
 
Due to the presence of tight junctions between adjacent cells, molecules are 
inhibited from penetrating the BBB between gaps of cells within the plane of the 
membrane.  However, there are four main transport systems for the passage of substances 
across the BBB (Figure 3).6,8  First, there is passive diffusion, which allows for fat-
soluble substances to dissolve in the cell membrane and cross the barrier.  Examples of 
substances that pass the BBB through passive diffusion are alcohol, nicotine, and 
caffeine.  The second method is active transport, which works by carrying essential 
substances that the brain needs, such as glucose or amino acids, by way of special 
transport proteins embedded in the membrane of the barrier.  The third method of passage 
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is receptor-mediated transport.  Specific molecules, such as insulin, can link to receptors 
on the surface of the brain and be escorted through the barrier.  Finally, native plasma 
proteins such as albumin, which are poorly transported, can be cationized to increase 
their uptake by adsorptive-mediated endocytosis and transcytosis.8  These transport 
systems have become increasingly important in the development of drug delivery across 
the BBB.7  By linking the desired therapeutic agent to molecules such as glucose or 
insulin, the drug can be transported into the brain. 
 
Figure 3.  Pathways across the blood brain barrier.8 
 
Glucose transport is one of the most essential and well-studied transport systems 
across the BBB.9  Glucose is the main nutrient of the brain, and about 20% of glucose in 
the bloodstream is metabolized in the brain.  Thus, glucose is actively transported across 
the BBB by the passive glucose transporter, GLUT-1.10  The conjugation of glucose to a 
desired therapeutic agent could allow for transportation of the drug across the BBB.  In 
fact, this method was recently attempted in the treatment of Parkinson’s disease (Figure 
4).11 L-Dopa is the most widely used treatment for Parkinson’s disease; however, only a 
small percentage of L-dopa actually makes it into the brain since L-dopa is also converted 
to dopamine in peripheral tissues.  This premature conversion of L-dopa also causes 
unwanted side effects in patients, and unfortunately, once dopamine is formed outside the 
brain it cannot cross the BBB.  One way to direct treatment to the brain, while reducing 
the side effects from dopamine, is by conjugating dopamine to glucose.  Preliminary 
results showed that the drug-glucose system was transported across the BBB via the 
























Figure 4.  Structures of dopamine precursor (L-dopa), dopamine, and the glucose-
dopamine prodrug (glu-dopamine). 
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It has been known for some time that glucose serves as an energy source for both 
healthy and cancerous cells.10,12  As shown in Figure 5, glycolysis is responsible for the 
conversion of glucose to pyruvate, which results in the net production of two molecules 
of ATP per glucose molecule.13  However, cancer cells contain a higher number of 
glucose transporters (GLUT-1) than healthy cells, which results in a faster rate of glucose 
metabolism in cancer cells.10  This increased uptake of glucose contributes to the rapid 
growth of malignant cells and tumors.  Furthermore, the elevated rates of glucose uptake, 
in conjunction with the reduced rates of oxidative phosphorylation, result in the 
accumulation of lactic acid and an overall acidic pH state of the tumor.14  The acidic 
microenvironment of the tumor is also brought about by insufficient blood supply and 






















Figure 5.  Metabolism of glucose. 
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It has been well established that glucose is a necessary nutrient for the brain, and 
as such, the capacity of the glucose transporter at the BBB is significantly higher than 
those of other nutrient transporters.7  Likewise, glucose is also a necessary nutrient for 
brain tumors to survive. As a result, cancer cells have increased rates of glucose 
metabolism when compared with healthy cells, due to an increased expression of GLUT-
1.  However, the use of glucose as a targeted delivery system for the treatment of brain 
tumors has not been deeply explored.   
In 1996, the known antitumor agent chlorambucil was conjugated to several 
glucose derivatives (Figure 6, 5-8), and research showed that these conjugates recognized 
the human GLUT-1 glucose transporter.15  Inhibition studies determined that all four 
compounds reacted with the GLUT-1 transporter, albeit with varying degrees of affinity.  
Unfortunately, further investigations revealed that the glu-chlorambucil derivatives 
reacted with the glucose transporters in a non-penetrating way, which was attributed to 












5, X = O, R = CH3
6, X = O, R = H
7, X = N, R = CH3
8, X = N, R = H  
Figure 6.  Glucose-chlorambucil derivatives 5-8.   
 
In order to restrict the bulkiness of the alkylating moiety, research was directed 
toward the synthesis of glucose-busulfan derivatives.  To mimic the mode of action of 
busulfan, mesylated glucose derivatives (9-12) were synthesized (Figure 7) and tested 
with the human GLUT-1 transporter.16  Results showed that mesylation of OH-4 and OH-
6 displayed a slightly diminished affinity for the GLUT-1 glucose transporter, while 
mesylation of OH-3 led to complete loss of affinity. These findings suggest that certain 
structural requirements are necessary for binding of D-glucose derivatives to the GLUT-1 
transporter protein.  Additionally, involvement of the OH-1, OH-3, and OH-6 in binding 
to the transporter has also been demonstrated.16  Thus, small structural changes in the 








9, R1 = H, R2 = H, R3 = Ms
10, R1 = Ms, R2 = H, R3 = H
11, R1 = Ms, R2 = H, R3 = Ms
12, R1 = H, R2 = Ms, R3 = H  
Figure 7. Methylsulfonyl derivatives. 
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It may seem counterintuitive to conjugate a drug to glucose, since this sugar 
essentially feeds the brain tumor.  It should also be remembered, however, that glycolysis 
is enhanced in transformed cells and provides at least some, if not all, of the energy for 
cell proliferation.  Thus, antiglycolytic strategies stand as promising new leads for anti-
cancer therapeutics.17  One way to achieve inhibition of glycolysis is through the use of 
2-deoxy-D-glucose (2-DG), a glucose analogue that is preferentially captured by cancer 
cells.  As shown in Figure 8, 2-DG is taken up by the cancer cell, where it undergoes 
phosphorylation, similar to D-glucose.  However, phosporylated-2-DG cannot be 





















Figure 8.  Metabolism of 2-DG.13 
 
Previous studies have shown that when cancer cells are treated with 2-DG, four 
different responses have been observed: (1) proliferation slow down; (2) proliferation 
arrest without signs of apoptosis; (3) strong cell cycle arrest accompanied by moderate 
apoptosis induction; and (4) massive apoptosis.17  In addition, the GLUT-1 transporter 
cannot differentiate between D-glucose and 2-deoxy- D-glucose, so 2-DG is efficiently 
transported across the BBB.  In the past few years, 2-DG has entered clinical trials for the 
treatment of patients with malignant glioma, the most common and lethal form of brain 
cancer.18  Preliminary results have shown that patients display excellent tolerance to a 
combined treatment of orally administered 2-DG and hypofractionated radiotherapy.  
Phase III efficacy trials are currently at an advanced stage, and results have shown that 
patients display extensive tumor necrosis with well-preserved normal brain tissue 
adjoining the tumor.  These promising results indicate that 2-DG treatment differentiates 
between tumor and normal tissue.  
Described herein is the synthesis of a novel prodrug utilizing 2-DG as a carrier to 
transport a modified alkylating agent across the BBB.  Once inside the acidic 
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microenvironment of the tumor, the drug will be cleaved from the carrier, allowing for 
two methods of chemotherapeutic treatment to work individually.  The alkylating drug 
will work by cross-linking DNA, thereby blocking fundamental metabolic processes such 
as replication and transcription, while the 2-DG carrier inhibits glycolysis within 
cancerous cells.   
 
Research Design and Methods: 
 We envision the development of a carrier-linker-drug system that will accomplish 
three things: (1) transportation of the drug across the blood brain barrier; (2) targeted 
drug delivery to the brain tumor; and (3) activation of the drug specifically within the 
tumor.  To achieve these goals, four 2-DG derivatives (1-4, Figure 9) will be synthesized 
and tested, in order to evaluate the positions of the sugar molecule that can be substituted 
without altering the affinity to the GLUT-1 transporter protein.  Additionally, each 
derivative will be equipped with an acid-labile linker for pH-responsive drug release 









































Figure 9.  2-deoxy-glucose derivatives 
 
 Retrosynthetically, the 2-DG derivatives (1-4) could arise from the benzyl 
deprotection of 13-16 (Scheme 1).  Coupling of 21, which is derived from glycine 22 and 
ethylene oxide 23, with the 2-DG free hydroxyl moiety (17-20) affords the carrier-linker-






1, R1 = C(O)CH2N(CH2CH2Cl)2, R2 = R3 = R4 = H
2, R2 = C(O)CH2N(CH2CH2Cl)2, R1 = R3 = R4 = H
3, R3 = C(O)CH2N(CH2CH2Cl)2, R1 = R2 = R4 = H





13, R1 = C(O)CH2N(CH2CH2Cl)2, R2 = R3 = R4 = Bn
14, R2 = C(O)CH2N(CH2CH2Cl)2, R1 = R3 = R4 = Bn
15, R3 = C(O)CH2N(CH2CH2Cl)2, R1 = R2 = R4 = Bn





17, R1 = H, R2 = R3 = R4 = Bn
18, R2 = H, R1 = R3 = R4 = Bn
19, R3 = H, R1 = R2 = R4 = Bn












Scheme 1.  Retrosynthetic analysis of the carrier-linker-drug skeleton. 
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 The formation of the 2-DG carriers (17-20) would require individual syntheses in 
order to ensure that one of the hydroxyl groups remains unprotected.  As shown in 
Scheme 2, the synthesis of 17 would begin by treating commercially available 24 with 
48% HBr and PPh3 in CH2Cl2 to yield the corresponding 2-deoxysugar in a one-pot 












24 17  
Scheme 2. One-pot synthesis of 17. 
 
 As shown in Scheme 3, compound 18 is envisioned from commercially available 
25, which upon treatment with benzyl alcohol in the presence of toluenesulfonic acid will 
afford the 2-benzyloxy protected 2-DG derivative 26.  According to literature 
precedence, the reaction of 26 in the presence of dibutyltin oxide in benzene, 
tetrabutylammonium iodide, and allyl bromide (27) should afford OH-3 allylated product 
28.20      Bis-benzyl protection of 28 using standard conditions would yield 29, and 
subsequent deallylation by treatment with Pd(PPh3)4, acetic acid, and p-toluenesulfinate 










































Scheme 3.  Synthesis of 18. 
 
 Compound 19 is devised from commercially available 2-deoxy-glucose (Scheme 
4). Condensation of 25 with benzyl alcohol in the presence of toluenesulfonic acid should 
afford the benzyl glycoside of 2-deoxy-glucose (26, shown above).  In situ diol protection 
under standard conditions will then afford 4,6-O-benzylidene derivative 30.22  Protection 
of the free alcohol moiety with benzyl chloride and potassium hydroxide in DMF should 
furnish 31, which will undergo subsequent reductive ring opening with sodium 






1.  p-TsOH, BnOH



















31 19  
Scheme 4.  Synthesis of 2-DG derivative 19. 
 
 The final 2-DG derivative 20 is planned from 25 via selective tritylation of the 6-
hydroxyl moiety to afford 32.  Global benzyl protection will yield 33, which will then be 



























Scheme 5.  Synthesis of derivative 20.  
 
 As Scheme 6 shows, the linker-drug portions of targets 1-4 are envisioned from 
initial condensation of commercially available glycine ethyl ester 22 with ethylene oxide 
23 to give 34.  Protection of the primary alcohols using TBSCl, followed by 











1.  TBSCl, imidazole, DMF





Scheme 6.  Formation of the linker-drug derivative 21. 
 
 At this stage, the linker-drug side chains will be appended to the 2-DG derivatives 
via treatment with DCC and DMAP, thereby affording esters 35-38 (Scheme 7).25  
Cleavage of the TBS protecting groups, followed by conversion of the primary alcohols 
to the corresponding chlorides will yield the benzyl-protected derivatives 13-16.  Global 
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deprotection using standard hydrogenation conditions should then give the desired 





17, R1 = H, R2 = R3 = R4 = Bn
18, R2 = H, R1 = R3 = R4 = Bn
19, R3 = H, R1 = R2 = R4 = Bn













35, R1 = C(O)CH2N(CH2CH2OTBS)2, R2 = R3 = R4 = Bn
36, R2 = C(O)CH2N(CH2CH2OTBS)2, R1 = R3 = R4 = Bn
37, R3 = C(O)CH2N(CH2CH2OTBS)2, R1 = R2 = R4 = Bn
38, R4 = C(O)CH2N(CH2CH2OTBS)2, R1 = R2 = R3 = Bn
1.  TBAF, THF





13, R1 = C(O)CH2N(CH2CH2Cl)2, R2 = R3 = R4 = Bn
14, R2 = C(O)CH2N(CH2CH2Cl)2, R1 = R3 = R4 = Bn
15, R3 = C(O)CH2N(CH2CH2Cl)2, R1 = R2 = R4 = Bn







1, R1 = C(O)CH2N(CH2CH2Cl)2, R2 = R3 = R4 = H
2, R2 = C(O)CH2N(CH2CH2Cl)2, R1 = R3 = R4 = H
3, R3 = C(O)CH2N(CH2CH2Cl)2, R1 = R2 = R4 = H
4, R4 = C(O)CH2N(CH2CH2Cl)2, R1 = R2 = R3 = H  
 
Scheme 7.  Synthesis of the carrier-linker-drug derivatives 1-4. 
 
 With prodrugs 1-4 prepared, several tests will be necessary to evaluate their 
therapeutic effects.  Initially, the two most important aspects to study will be uptake of 
the prodrugs by the GLUT-1 transporter protein, as well as their cytotoxicity.  An 
additional experiment will include testing the rate of hydrolysis of the ester bond. 
In vitro models of the BBB have been developed to better understand the 
underlying cell biology, to predict drug permeability prior to animal studies, and to 
overcome the inherent difficulty in performing BBB molecular level studies in vivo.26  
One established method that evaluates the ability of glucose-drug derivatives to interact 
with the glucose transporter GLUT-1 is the use of human erythrocytes, since these cells 
express the same GLUT-1 transporter as that of the BBB.10  The interaction of prodrugs 
1-4 with GLUT-1 can be determined via literature methods previously established to 
measure the efficiency of these compounds to prevent the uptake of 14C-glucose (IC50) in 
human erythrocytes.15,16  A more recently established in vitro model utilizes murine brain 
microvascular endothelial cells co-cultured with rat primary astrocytes in the presence of 
biochemical inducing agents.26  This model expresses functional GLUT-1 transporter 
proteins and could serve as an excellent experiment to test the binding and uptake of 
compounds 1-4.   
Once it has been established which prodrugs react with the GLUT-1 transporter, 
additional studies will be carried out.  In order to test the cytotoxicity of the prodrug 
derivatives, various brain tumor cell lines will be inoculated with the derivatives, and cell 
viability will be evaluated at regular time intervals.   
Another important aspect to study is hydrolysis of the prodrugs’ ester bond.  Since 
the alkylating agent needs to be delivered to the brain tumor, it is important that the ester 
bond does not cleave prior to passing the BBB and entering the tumor.  Since tumors 
exhibit a slightly acidic environment, the stability of the prodrug ester bond will be tested 
with phosphate buffer solutions of varying pH levels in parallel experiments.  The 
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prodrug will be tested further in human plasma to ensure that the ester linkage does not 
cleave under normal physiological conditions.  
Pending the results of the above experiments, additional in vitro and in vivo 
testing of the prodrugs will be required.  It will be important to determine if the prodrug 
is actually delivered to the brain tumor, which can be accomplished through in vivo 
studies using mice (or rats) implanted with specific brain tumors.  Radiolabeled 18F-DG 
prodrug derivatives will be synthesized and injected into the mouse.17  Positron emission 
tomography (PET scans) will then enable visualization of the tagged prodrug compound 
in order to check for its presence within the malignant tumor.   
 
Potential Difficulties and Limitations: 
 While not all of the difficulties or limitations can be anticipated, a few of the 
potential shortcomings of this proposal are listed here, along with how these issues might 
be addressed.    
1. It is possible that the 2-DG prodrugs are too bulky or hydrophobic to cross the 
BBB via the GLUT-1 transporter.  If this is the case, there are a number of other 
carrier-mediated transport systems that could allow passage of a prodrug across 
the BBB.  One such method would be to couple the alkylating agent to an amino 
acid, such as phenylalanine, or to a nucleoside such as adenosine.27   
2. There is a possibility that the ester bond could be cleaved prematurely by an 
esterase, thus releasing the alkylating agent prior to passage across the BBB.  One 
way to address this issue is to slightly alter the synthesis of the prodrug in order to 
include different pH-labile cross-linkers, such as a hydrazone moiety or a 
phosphoramidate.14  
3. Another dimension of the BBB that has not been discussed is the presence of 
efflux proteins.  These proteins are responsible for pushing unwanted substances 
from the brain into the blood.  There is a possibility that once the prodrug enters 
the brain, the active efflux transport (AET) protein will expel the drug from the 
central nervous system.  One way to counteract the AET system is to develop a 
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